Logo Reference Ranges Report
Sorted by refranges    {click on appropriate heading to sort}
Test NameBilling CodeTest CodeMethodReference Ranges
HCV RNA QUANTITATION (PCR)HCVRQTHCVRQTPCR: Ampliprep/TaqMan HCV Test
TitleRangesUnits
Hepatitis C Viral RNA Viral Load ResultNot detectedLog IU/mL
Hepatitis C Viral RNA Viral Load ResultNot detectedIU/mL
Reportable range HCV RNA 1.2 to 8.0 Log IU/mL (15-100,000,000 IU/mL)
The test is intended for use as an aid in the management of HCV-infected individuals undergoing anti-viral therapy. The COBAS Ampliprep/COBAS Taqman test is not intended for use as a screening test for the presence of HCV in blood or blood products.
EZOGABINE AND METABOLITEEZOMETEZOMETHigh Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
The optimized effective dose is 600 to 1200 mg daily.
Ezogabine exhibits a linear pharmacokinetic profile between 600 - 1200 mg. Ezogabine is rapidly absorbed with a median time to maximum blood levels between 30 minutes to 2 hours. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations (Cmax +/- SD) of 1593 +/- 198 ng/mL.
Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.
Formed by N-acetylation of ezogabine and is pharmacologically less active as compared to ezogabine. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations of (Cmax +/- SD) 874 +/- 75 ng/mL. Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.
1,3 BETA-D-GLUCAN13BGA13BGASemi-Quantitative Colorimetry
TitleDescriptorRangesUnits
1,3 Beta-D-GlucanNegativeLT 31pg/mL
Negative31-59
Indeterminate60-79
Positive80 or greater
1,3 Beta-D-Glucan
Interpretation
ASPIRIN WORKS (TM)ASAWKASAWKELISA
TitleDescriptorRangesUnits
11-Dehydro Thromboxane B2Normalized levels of 11-Dehydro Thromboxane B2 indicates an aspirin effect1500 or lesspg/mg
Normalized levels of 11-Dehydro Thromobxane B2 indicates a lack of an aspirin effectGT 1500
SEXUAL HEALTH PANEL MALE RFLXSHPANMSHPANM
12HIVR
HSVG
HCVAB
HBSAG
TREP
APTCG
SEXUAL HEALTH PANEL FEMALE RFLXSHPANFSHPANF
12HIVR
HSVG
HCVAB
HBSAG
TREP
APTCGT
14,3,3 PROTEIN, CSF (PRION) RFLXPRIONPRIONImmunoassay
14-3-3 Protein, CSF   
See separate report
OXCARBAZEPINE METABOLITEOXCAROXCARHPLC/DAD
15-35 micrograms per milliter (ug/ml)
18-HYDROXYCORTICOSTERONE18OHCC18OHCCHPLC/MS
TitleDescriptorRangesUnits
18-Hydroxycorticosteroneng/dL
Premature infant(26-28 weeks) Day 410-670
Premature infant(31-35 weeks) Day 457-410
Full-term infant3 days31-546
1-12 months5-220
Children1-2 years18-155
2-10 years6-85
10-15 years10-72
Adults9-58
Normal Na intake 8 am supine4-21
8 am upright5-46
Low Na intake8 am supine11-75
8 am upright19-96
VIT D, 25 HYDROXY D23 (LCMSMS)VITD23VITD23Liquid Chromatography-Tandem Mass Spectrometry LCMSMS
TitleDescriptorRangesUnits
25-OH Vitamin D2ng/mL
25-OH Vitamin D3ng/mL
25-OH Vitamin D, TotalSevere DeficiencyLT 10.0ng/mL
Mild to Moderate Deficiency10.0-23.9
Optimum Levels24.0-80.0
Toxicity Possible, Pediatrics (0-18 yrs)80.0 or greater
Toxicity Possible, Adults (19+ yrs)150.0 or greater
BLASTOMYCES DERMATITIDIS AGBLAGDBLAGDEnzyme Immunoassay
TitleDescriptorRangesUnits
316 MVista® Blastomyces AgNone Detectedng/mL
Reference intervalNone Detected
Results reported as ng/mL in 0.2-14.7 ng/mL range
Results above the limit of detection but below 0.2 ng/mL are reported as 'Positive, Below the Limit of Quantification.'
Results above 14.7 ng/mL are reported as 'Positive Above the Limit of Quantification.'
PAIN MANAGEMENT CLONAZEPAMPMCLONPMCLONLiquid Chromatography - Tandom Mass Spectrometry
7 Amino-Clonazepam by LC-MS/MS   Cutoff 25 ng/mL
AMINO ACIDS QNT URINEAAQUAAAQUAQuantitative Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
a-Aminoadipic acid0-2 months6-522umol/g
3-8 months34-353
9 months-2 years34-425
3-12 years15-271
13+ years7-57
a-Amino-n-butyric acid0-2 months0-84umol/g
3-8 months0-70
9 months-2 years1-96
3-12 years0-51
13+ years0-20
Alanine0-2 months658-3424umol/g
3-8 months601-2918
9 months-2 years224-2210
3-12 years176-1255
13+ years78-587
Anserine0-2 months0-109umol/g
3-8 months0-218
9 months-2 years0-635
3-12 years0-600
13+ years0-67
Arginine0-2 months0-313umol/g
3-8 months0-307
9 months-2 years0-424
3-12 years0-150
13+ years5-34
Argininosuccinic acid0-2 months0-102umol/g
3-8 months0-139
9 months-2 years0-129
3-12 years0-64
13+ years0-68
Asparagine0-2 months0-1260umol/g
3-8 months0-854
9 months-2 years0-758
3-12 years49-466
13+ years22-170
Aspartic acid0-2 months0-866umol/g
3-8 months0-299
9 months-2 years2-138
3-12 years0-60
13+ years0-26
B-Alanine0-2 months28-705umol/g
3-8 months0-731
9 months-2 years0-218
3-12 years0-195
13+ years0-130
B-Aminoisobutyric acid0-2 months0-8918umol/g
3-8 months91-7140
9 months-2 years64-9100
3-12 years18-4923
13+ years2-922
Citrulline0-2 months0-165umol/g
3-8 months0-82
9 months-2 years0-76
3-12 years0-22
13+ years0-12
Cystathionine0-2 months0-227umol/g
3-8 months0-171
9 months-2 years0-131
3-12 years0-66
13+ years0-34
Cystine0-2 months14-573umol/g
3-8 months28-461
9 months-2 years34-186
3-12 years26-98
13+ years12-81
Ethanolamine0-2 months0-2362umol/g
3-8 months0-2251
9 months-2 years156-1462
3-12 years60-714
13+ years123-610
y-Amino-n-butyric acid0-2 months0-31umol/g
3-8 months0-16
9 months-2 years0-16
3-12 years0-6
13+ years0-4
Glutamic acid0-2 months17-1012umol/g
3-8 months65-1155
9 months-2 years18-186
3-12 years9-91
13+ years4-38
Glutamine0-2 months117-4086umol/g
3-8 months0-2916
9 months-2 years480-3070
3-12 years300-1896
13+ years110-609
Glycine0-2 months1970-16940umol/g
3-8 months1613-14465
9 months-2 years837-6625
3-12 years595-5432
13+ years296-4419
Histidine0-2 months405-4186umol/g
3-8 months421-3393
9 months-2 years435-3986
3-12 years259-2070
13+ years100-1004
Homocitrulline0-2 months0-308umol/g
3-8 months0-111
9 months-2 years0-141
3-12 years0-140
13+ years3-52
Hydroxylysine0-2 months0-383umol/g
3-8 months0-205
9 months-2 years0-143
3-12 years0-70
13+ years0-56
Hydroxyproline0-2 months83-5430umol/g
3-8 months0-2561
9 months-2 years0-1191
3-12 years0-54
13+ years0-15
Isoleucine0-2 months17-312umol/g
3-8 months22-159
9 months-2 years14-107
3-12 years8-87
13+ years10-32
Leucine0-2 months9-336umol/g
3-8 months37-253
9 months-2 years22-215
3-12 years20-129
13+ years7-50
Lysine0-2 months58-2246umol/g
3-8 months52-1716
9 months-2 years49-953
3-12 years31-394
13+ years16-271
Methionine0-2 months0-84umol/g
3-8 months0-69
9 months-2 years0-59
3-12 years2-34
13+ years1-22
Ornithine0-2 months0-216umol/g
3-8 months2-151
9 months-2 years1-100
3-12 years2-75
13+ years0-24
Phenylalaline0-2 months30-356umol/g
3-8 months61-357
9 months-2 years53-364
3-12 years27-187
13+ years12-92
Proline0-2 months50-2484umol/g
3-8 months12-1237
9 months-2 years10-662
3-12 years6-117
13+ years3-23
Sarcosine0-2 months11-431umol/g
3-8 months1-138
9 months-2 years1-54
3-12 years1-10
13+ years0-4
Serine0-2 months51-2910umol/g
3-8 months173-3399
9 months-2 years364-2732
3-12 years100-947
13+ years64-501
Taurine0-2 months142-9594umol/g
3-8 months100-7410
9 months-2 years62-5572
3-12 years60-2198
13+ years19-2859
Threonine0-2 months54-2334umol/g
3-8 months67-1380
9 months-2 years118-1318
3-12 years40-585
13+ years33-209
Tryptophan0-2 months40-402umol/g
3-8 months76-388
9 months-2 years60-386
3-12 years36-183
13+ years13-94
Tyrosine0-2 months70-857umol/g
3-8 months126-775
9 months-2 years76-659
3-12 years59-410
13+ years18-170
Valine0-2 months41-428umol/g
3-8 months60-280
9 months-2 years30-338
3-12 years26-191
13+ years10-73
AMINO ACIDS QNT PLASMAAAQPAAAQPAQuantitative Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
a-Aminoadipic acid0-30 days0-4umol/L
1 month-11 months0-3
1+ year0-3
a-Amino-n-butyric acid0-30 days0-40umol/L
1 month-11 months0-40
1+ year0-30
Alanine0-30 days130-560umol/L
1 month-11 months150-170
1+ year150-570
Alloisoleucine0-30 days0-5umol/L
1 month-11 months0-3
1+ year0-3
Anserine0-30 days0-2umol/L
1 month-11 months0-2
1+ year0-2
Arginine0-30 days15-160umol/L
1 month-11 months20-160
1+ year40-160
Argininosuccinic acid0-30 days0-2umol/L
1 month-11 months0-2
1+ year0-2
Asparagine0-30 days20-80umol/L
1 month-11 months30-80
1+ year30-80
Aspartic acid0-30 days5-50umol/L
1 month-11 months0-40
1+ year0-25
B-Alanine0-30 days0-20umol/L
1 month-11 months0-20
1+ year0-20
B-Aminoisobutyric acid0-30 days0-10umol/L
1 month-11 months0-10
1+ year0-5
Citrulline0-30 days5-50umol/L
1 month-11 months5-50
1+ year10-60
Cystathionine0-30 days0-10umol/L
1 month-11 months0-5
1+ year0-5
Cystine0-30 days5-50umol/L
1 month-11 months7-50
1+ year7-70
Ethanolamine0-30 days0-40umol/L
1 month-11 months0-20
1+ year0-15
y-Amino-n-butyric acid0-30 days0-2umol/L
1 month-11 months0-2
1+ year0-2
Glutamic acid0-30 days50-300umol/L
1 month-11 months25-200
1+ year10-120
Glutamine0-30 days285-950umol/L
1 month-11 months410-900
1+ year410-700
Glycine0-30 days150-500umol/L
1 month-11 months120-450
1+ year120-450
Histidine0-30 days50-110umol/L
1 month-11 months50-110
1+ year50-110
Homocitrulline0-30 days0-5umol/L
1 month-11 months0-3
1+ year0-2
Homocystine0-30 days0-2umol/L
1 month-11 months0-2
1+ year0-2
Hydroxylysine0-30 days0-5umol/L
1 month-11 months0-5
1+ year0-5
Hydroxyproline0-30 days0-100umol/L
1 month-11 months0-90
1+ year0-55
Isoleucine0-30 days20-130umol/L
1 month-11 months20-130
1+ year30-130
Leucine0-30 days50-200umol/L
1 month-11 months50-200
1+ year60-230
Lysine0-30 days60-300umol/L
1 month-11 months60-280
1+ year80-250
Methionine0-30 days10-60umol/L
1 month-11 months10-60
1+ year14-50
Ornithine0-30 days30-200umol/L
1 month-11 months20-160
1+ year20-135
Phenylalanine0-30 days30-100umol/L
1 month-11 months30-90
1+ year30-80
Proline0-30 days100-400umol/L
1 month-11 months80-400
1+ year80-400
Sarcosine0-30 days0-5umol/L
1 month-11 months0-5
1+ year0-5
Serine0-30 days90-300umol/L
1 month-11 months90-300
1+ year60-200
Taurine0-30 days25-300umol/L
1 month-11 months25-220
1+ year25-150
Threonine0-30 days50-400umol/L
1 month-11 months50-300
1+ year60-200
Tryptophan0-30 days15-90umol/L
1 month-11 months15-90
1+ year30-100
Tyrosine0-30 days30-140umol/L
1 month-11 months30-140
1+ year30-120
Valine0-30 days80-300umol/L
1 month-11 months80-300
1+ year100-300
BLOOD TYPEABO/RHMABORHHemagglutination
ABO
RH
ABO, NON-CROSSMATCHABOM1ABOHemagglutination
ABO
OBSTETRIC PANEL RFLX NO CBCOBPAN2OBPAN2Hemagglutination, ICMA, EIA, Solid Phase
TitleDescriptorRangesUnits
ABO
RH
Antibody ScreenNegative
Hepatitis B Surface AntigenNonreactive
Hepatitis B Surface Antigen
Confirmation
Treponema pallidum Ab by EIANegative
RPRNonreactive
RPR TiterLT 1:1
Treponema pallidum Ab by TP-PANonreactive
Rubella, Ab IgGPresumed Immune10 or greaterIU/mL
Equivocal5-9
Presumed Non-ImmuneLT 5
Result flagging is based on presumed immune status
OBSTETRIC PANEL 3 (REFLEX) OBPAN3OBPAN3Hemagglutination, EIA, Solid Phase
TitleDescriptorRangesUnits
ABO
RH
Antibody ScreenNegative
Treponema pallidum Ab by EIANegative
RPRNonreactive
RPR TiterLT 1:1
Treponema pallidum Ab by TP-PANonreactive
FDA DONOR PANELFDADOFDADO
ABRH
CHAG
CRIP
CHOL
CMV
CMVM
HBC
AHBS
HBS
HBSN
HCV
HCVC
HIV
IFHI
H12C
HTLV
HTIL
ULTR
DHIV
DHCV
DHBV
STS
SYPG
WNV
WNVA
MALE DONORFDAMAOFDAMAO
ABRH
CHAG
CRIP
CMV
CMVM
HBC
AHBS
HBS
HBSN
HCV
HCVC
HIV
IFHI
H12C
HTLV
HTIL
ULTR
DHIV
DHCV
DHBV
STS
SYPG
WNV
WNVA
FEMALE DONORFDAFEOFDAFEO
ABRH
CHAG
CRIP
HBC
AHBS
HBS
HBSN
HCV
HCVC
HIV
IFHI
H12C
ULTR
DHIV
DHCV
DHBV
STS
SYPG
WNV
WNVA
ABO GROUP AND RH TYPEABOOBIABOOBIBeckman Coulter PK 7200
ABRH
PAIN MANAGEMENT ACETAMINOPHEN SCREEN (REFLEX)PMACETPMACETEIA/Confirmation by GC/MS
Acetaminophen Screen             ug/mL
Acetaminophen by GC/MS           ug/mL
ACETAMINOPHENTYLENTYLEnzyme Immunoassay
TitleDescriptorRangesUnits
AcetaminophenTherapeutic10-25ug/mL
ToxicGT 150
SULFONYLUREA HYPOGLYCEMICS PNLSUHGPSUHGPHPLC -TMS
Acetohexamide               
Chlorpropamide              
Glimepiride                 
Glipizide                   
Glyburide 
Nateglinide
Repaglinide                              
Tolazamide                  
Tolbutamide
ACETYLCHOLINE REC BINDING ABACRBDAACRBDARadioimmunoassay
TitleDescriptorRangesUnits
Acetylcholine Receptor Binding Anbitody
NegativeLT or = 0.30nmol/L
Equivocal0.31-0.49nmol/L
PositiveGT or = 0.50nmol/L
ACETYLCHOLINESTERASE, AMINOAACHEAACHEEIA
Acetylcholinesterase, Amniotic Fluid
Interpretation
Reviewed by
Date
ACID MUCOPOLYSACCHARIDES, URACMPSACMPSColorimetric
TitleDescriptorRangesUnits
Acid Mucopolysaccharides, Urinemg/L
0-2 monthsLT 60
3-6 monthsLT 60
7-12 monthsLT 60
1+ yearsLT 60
Acid MPS (calc)mg/gCr
0-2 monthsLT 350
3-6 monthsLT 250
7-12 monthsLT 150
1+ yearsLT 60
MPS Interpretation
ACYLCARNITINE PROFILE, PLASMAACYLQAACYLQATandem Mass Spectrometry
TitleDescriptorRangesUnits
Acylcarnitine, Plasma Interp
LT 1 yearNormal
1-7 yearsNormal
GT 7 yearsNormal
C2, Acetylumol/L
LT 1 year2.98-27.99
1-7 years3.69-24.71
GT 7 years3.74-16.56
C3, Propionylumol/L
LT 1 year0.00-1.12
1-7 years0.00-0.97
GT 7 years0.00-0.83
C4, Isobutytylumol/L
LT 1 year0.00-0.62
1-7 years0.00-0.50
GT 7 years0.00-0.45
C5, Isovaleryl/2 Mebutyrylumol/L
LT 1 year0.00-0.30
1-7 years0.00-0.28
GT 7 years0.00-0.30
C5-DC, Glutarylumol/L
LT 1 year0.00-0.07
1-7 years0.00-0.07
GT 7 years0.00-0.09
C5-OH, 3-OH-Isovalerylumol/L
LT 1 year0.00-0.14
1-7 years0.00-0.07
GT 7 years0.00-0.07
C6, Hexanoylumol/L
LT 1 year0.00-0.16
1-7 years0.00-0.12
GT 7 years0.00-0.12
C8, Octanoylumol/L
LT 1 year0.00-0.21
1-7 years0.00-0.23
GT 7 years0.00-0.23
C8:1, Octenoylumol/L
LT 1 year0.00-0.61
1-7 years0.00-0.63
GT 7 years0.00-0.61
C10, Decanoylumol/L
LT 1 year0.00-0.26
1-7 years0.00-0.35
GT 7 years0.00-0.31
C10:1, Decenoylumol/L
LT 1 year0.00-0.24
1-7 years0.00-0.41
GT 7 years0.00-0.31
C12, Dodecanoylumol/L
LT 1 year0.00-0.17
1-7 years0.00-0.12
GT 7 years0.00-0.12
C12:1 Dodecenoylumol/L
LT 1 year0.00-0.15
1-7 years0.00-0.16
GT 7 years0.00-0.17
C12-OH, 3-OH-Dodecanoylumol/L
LT 1 year0.00-0.03
1-7 years0.00-0.02
GT 7 years0.00-0.02
C14, Tetradecanoylumol/L
LT 1 year0.00-0.12
1-7 years0.00-0.07
GT 7 years0.00-0.05
C14:1, Tetradecenoylumol/L
LT 1 year0.00-0.20
1-7 years0.00-0.23
GT 7 years0.00-0.16
C14:2, Tetradecandienoylumol/L
LT 1 year0.00-0.09
1-7 years0.00-0.12
GT 7 years0.00-0.12
C14-OH,3-OH Tetradecanoylumol/L
LT 1 year0.00-0.02
1-7 years0.00-0.02
GT 7 years0.00-0.02
C14:1-OH,3-OH-Tetradecenoylumol/L
LT 1 year0.00-0.03
1-7 years0.00-0.03
GT 7 years0.00-0.02
C18:1, Oleylumol/L
LT 1 year0.00-0.18
1-7 years0.00-0.16
GT 7 years0.00-0.17
C18:2, Linoleylumol/L
LT 1 year0.00-0.09
1-7 years0.00-0.08
GT 7 years0.00-0.10
C18-OH,3-OH-Stearoylumol/L
LT 1 year0.00-0.01
1-7 years0.00-0.01
GT 7 years0.00-0.01
C18-OH,3-OH-Oleylumol/L
LT 1 year0.00-0.01
1-7 years0.00-0.01
GT 7 years0.00-0.01
C18:2-OH, 3-OH Linoleylumol/L
LT 1 year0.00-0.01
1-7 years0.00-0.01
GT 7 years0.00-0.01
C16, Palmitoylumol/L
LT 1 year0.00-0.25
1-7 years0.00-0.10
GT 7 years0.00-0.10
C16:1, Palmitoleylumol/L
LT 1 year0.00-0.07
1-7 years0.00-0.05
GT 7 years0.00-0.04
C16-OH, 3-OH-Palmitoylumol/L
LT 1 year0.00-0.02
1-7 years0.00-0.01
GT 7 years0.00-0.01
C16:1-OH, 3-OH-Palmitoleylumol/L
LT 1 year0.00-0.05
1-7 years0.00-0.01
GT 7 years0.00-0.01
C18, Stearoylumol/L
LT 1 year0.00-0.08
1-7 years0.00-0.05
GT 7 years0.00-0.04
ADENOVIRUS AB, IGG, IGMADENGMADENGMSemi-Quantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Adenovirus Antibody, IgGIV
Negative-no significant level of adenovirus IgG antibody detected.0.89 or less
Equivocal-questionable presence of adenovirus IgG antibody detected. Repeat testing in 10-14 days may be helpful.0.90-1.10
Positive-IgG antibody to adenovirus detected, which may suggest current or past infection.1.11 or more
Adenovirus Antibody, IgMIV
Negative-no significant level of adenovirus IgM antibody detected.0.89 or less
Equivocal-questionable presence of adenovirus IgM antibody detected. Repeat testing in 10-14 days may be helpful.0.90-1.10
Positive-IgM antibody to adenovirus detected, which may suggest current or recent infection.1.11 or more
PLATELET AGGREGATION, WHOLE BLOOD RFLXWBPAGGWBPAGGLumi-Aggregation, Whole Blood
TitleDescriptorRangesUnits
ADP AggregationPatient5.1-27.3Ohms
Control5.1-27.3Ohms
ADP SecretionPatient0.2-1.9nM
Control0.2-1.9nM
Collagen Low AggregationPatient14.6-39.8Ohms
Control14.6-39.8Ohms
Collagen Low SecretionPatient0.5-2.2nM
Control0.5-2.2nM
Thrombin SecretionPatient0.8-2.5nM
Control0.8-2.5nM
Ristocetin High AggregationPatient5.1-14.9Ohms
Control5.1-14.9Ohms
Ristocetin Low AggregationPatient0Ohms
Control0Ohms
Type 1 VWD Mixing StudyRistocentinHighOhms
Type 2 VWD Mixing StudyRistocentinLowOhms
Collagen High AggregationPatient18.5-41.0Ohms
Control18.5-41.0Ohms
Collagen High SecretionPatient0.7-2.4nM
Control0.7-2.4nM
Arachidonic Acid AggregationPatient7.0-25.8Ohms
Control7.0-25.8Ohms
Arachidonic Acid SecretionPatient0.4-1.9nM
Control0.4-1.9nM
Platelet CountPatientk/uL
0-3 days250-450
3-9 days200-400
9-30 days250-450
1-6 months300-750
6 months-2 years250-600
2-8 years250-550
8-12 years200-450
12-18 years150-250
18+ years150-400
Reviewed by
Interpretation
Note
12-DRUG MICM12NJM12NJ12-Drug MIC in liquid medium for slowly growing NTM
AFB MIC 12 Drug Package   
 See separate report
ALBUMINALBALBColorimetric (BCG)
TitleDescriptorRangesUnits
Albuming/dL
0-4 days2.9-4.6
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
ALDOLASEALDOALDOQuantitative Enzymatic
TitleDescriptorRangesUnits
Aldolase0-30 days6.0-32.0U/L
1-5 months3.0-12.0
6-35 months3.5-10.0
3-6 years2.7-8.8
7-17 years3.3-9.7
18 years and older1.5-8.1
ALDOSTERONE/RENIN RATIOALDRENALDRENRIA
TitleDescriptorRangesUnits
Aldosteroneng/dL
0-6 days5.0-102.0
1-3 weeks6.0-179.0
1-11 months7.0-99.0
1-2 years7.0-93.0
3-10 years4.0-44.0
11-14 years4.0-31.0
15+ years31.0 or less
Standing4.0-31.0
Recumbent16.0 or less
Renin (with unrestricted salt intake)ng/mL/h
Random Ambulatory0.8-2.5
Random Non-ambulatory1.5-5.2
Child, supine with normal sodium intake
1-7 days15-114
7 days-12 months18-120
12 months-3 years13-36
3-5 years7.5-21.1
5-10 years3.8-19.2
10-15 years3.8-10.7
Aldosterone/Renin Ratio
An Aldosterone/Renin activity ratio of GT 25 is suggestive of hyperaldosteronism.
ALDOSTERONEALDOSTERONEALDOSRIA
TitleDescriptorRangesUnits
Aldosteroneng/dL
0-6 days5.0-102.0
1-3 weeks6.0-179.0
1-11 months7.0-99.0
1-2 years7.0-93.0
3-10 years4.0-44.0
11-14 years4.0-31.0
15+ years31.0 or less
Standing4.0-31.0
Recumbent16.0 or less
ALPHA 2 ANTIPLASMIN ACTIVITYALP2AALP2AChromogenic Assay
TitleDescriptorRangesUnits
Alpha 2 Antiplasmin Activity%
1-4 days55-115
5-29 days70-130
30-89 days76-124
90-179 days76-140
180-364 days83-139
1-5 years93-117
6 years89-110
7-9 years88-147
10-11 years90-144
12-13 years87-142
14-15 years83-136
16-17 years77-134
18+ years82-133
AFP, TUMOR MARKERAFP-NMAFPTMICMA
TitleDescriptorRangesUnits
Alpha FetoproteinMales and non-pregnant females0.6-6.6ng/mL
ALPHA SUBUNITALPSUBALPSUBRadioimmunoassay
TitleDescriptorRangesUnits
Alpha Subunitng/mL
Males0-6 or lessng/mL
Premenopausal Females1.5 or lessng/mL
Postmenopausal Females0.9-3.3m/mL
Pregnancy (1st and 2nd trimesters)1.8-360ng/mL
Hypothyroid subjects3.7 or lessng/mL
This test measures the alpha subunit that is common to LH, FSH, TSH and hCG. These hormones are comprised of identical alpha subunits and unique beta subunits that confer biological specificity.
ALPRAZOLAMXANAXALPRAZLiquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Alprazolamng/mL
Anxiety10-40 (Dose 1-4 mg/d)
Phobia and Panic50-100 (Dose 6-9 mg/d)
ToxicGT 100
S CENTRAL STATES ALLERGENS 18SOCN18SOCN18ImmunoCap FEIA
TitleDescriptorRangesUnits
Alternaria tenuis IgELT 0.35kU/L
Aspergillus fumigatus IgELT 0.35kU/L
Bermuda Grass IgELT 0.35kU/L
Cat dander IgELT 0.35kU/L
Cockroach IgELT 0.35kU/L
Short (Common) Ragweed IgELT 0.35kU/L
D. farinae (mite) IgELT 0.35kU/L
D. pteronyssinus (mite) IgELT 0.35kU/L
Dog dander IgELT 0.35kU/L
Elm Tree IgELT 0.35kU/L
Cladosporium herbarum IgELT 0.35kU/L
Johnson Grass IgELT 0.35kU/L
Meadow (Ktky Blue) Grass IgELT 0.35kU/L
Oak Tree IgELT 0.35kU/L
Pecan (Hickory) Tree IgELT 0.35kU/L
Penicillium chrysogenum IgELT 0.35kU/L
Rough Marsh Elder IgELT 0.35kU/L
Walnut Tree IgELT 0.35kU/L
PEDIATRIC MARCH PROFILEPEDMARPEDMARImmunoCap FEIA
TitleDescriptorRangesUnits
Alternaria tenuis IgELT 0.35kU/L
Cat Dander IgELT 0.35
Cockroach IgELT 0.35
Cod Fish (Whitefish) IgELT 0.35
D. farinae (mite) IgELT 0.35
D. pteronyssinus (mite) IgELT 0.35
Dog dander IgELT 0.35
Egg white IgELT 0.35
Cows Milk IgELT 0.35
Peanut IgELT 0.35
Soybean IgELT 0.35
Wheat IgELT 0.35
Immunoglobulin E TotalkU/L
0-11 months1.4-52.3
1-4 years0.4-351.6
5-10 years0.5-393.0
11-15 years1.9-170.0
16+ years0.0-158.0
Minimum detectable concentration is 2.0 kU/L
PAIN MANAGEMENT ALTERNATE AMPHETAMINES (REFLEX)PMAAMPPMAAMPEmit/Confirmation by GC/MS
Alternate Amphetamines Screen          ng/mL
MDMA by GC/MS                          ng/mL
MDA by GC/MS                           ng/mL
MDEA by GC/MS                          ng/mL
ALUMINUMALUMINUMALElectrothermal (Flameless) AAS
TitleDescriptorRangesUnits
Aluminumug/L
Normal0-10
Normal for dialysis patients0-40
Increased aluminum uptake10-60
Potential clinical problems60-100
Generally leads to clinical symptomsGT 100
AMIKACIN, PEAKAMIK.PKAMIKPKEnzyme Immunoassay
TitleDescriptorRangesUnits
Amikacin, Peakug/mL
Peak10.0-30.0
ToxicGT 35.0
AMIKACIN, TROUGHAMIK.TRAMIKTREnzyme Immunoassay
TitleDescriptorRangesUnits
AmikacinTrough4.0-8.0ug/mL
ToxicGT 8.0
AMIKACIN, RANDOMAMIKAMIKREnzyme Immunoassay
TitleDescriptorRangesUnits
Amikacinug/mL
Trough4.0-8.0
ToxicGT 8.0
Peak10.0-30.0
ToxicGT 35.0
AMIODARONE AND METABOLITE AMIOAMIOQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Amiodarone and Metaboliteug/mL
Therapeutic Range0.5-2.0
Toxic LevelGT 3.0
AMITRIPTYLINE AND METABOLITEAMIAMITRHPLC
TitleDescriptorRangesUnits
Amitriptylineng/mL
No reference range established for parent drug. See Total for reference range, which takes into account all metabolites.
Nortriptylineng/mL
Therapeutic50-150
ToxicGT 499
Total Drugng/mL
Therapeutic80-220
ToxicGT 499
Studies have determined that Norpace will interfere with the measurement of the Amitriptyline metabolite, Nortriptyline. Nortriptyline results & total tricyclic results are not valid for patients on Norpace.
AMNIOTIC FLUID SCANDODAMNFSSpectrophotometry
Amniotic Fluid Scan
 Appearance
 Color
 RBCS
 Gestational Age        wk
 Abs at 450             Abs 
 Interpretation
BARBITURATE PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPBARPBARGas Chromatography Mass Spectrometry
Amobarbital     ng/mL    positive cutoff 200 ng/mL
Butalbital      ng/mL    positive cutoff 200 ng/mL
Pentobarbital   ng/mL    positive cutoff 200 ng/mL
Phenobarbital   ng/mL    positive cutoff 200 ng/mL
Secobarbital    ng/mL    positive cutoff 200 ng/mL
AMOXAPINE/ACTIVE METABOLITEAMOXAMOXHPLC
TitleDescriptorRangesUnits
Amoxapineng/mL
8-Hydroxyamoxapineng/mL
Optimal therapeutic range (Amoxapine + Active Metabolite)200-400ng/mL
AMPHETAMINE PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPAMPPAMPGas Chromatography Mass Spectrometry
Amphetamine            250   ng/mL    positive cutoff 250 ng/mL      
Methamphetamine        250   ng/mL    positive cutoff 250 ng/mL      
  D - Methamphetamine        %        reported in percent of total      
  L - Methamphetamine        %        reported in percent of total      
ORAL FLUID STAT 9 ORAL9ORAL9EIA or ELISA. Confirmatory Test: GC/MS or LC/MS/MS
Amphetamine Screen             Cutoff     50     ng/mL
  Amphetamine                  Cutoff     10.0
  Methamphetamine              Cutoff     10.0
  MDA                          Cutoff     10.0
  MDMA                         Cutoff     10.0
Barbiturates Screen            Cutoff     100    ng/mL
  Butalbital                   Cutoff     50.0
  Amobarbital                  Cutoff     50.0
  Pentobarbital                Cutoff     50.0
  Secobarbital                 Cutoff     50.0
  Phenobarbital                Cutoff     50.0
Benzodiazepines Screen         Cutoff     10     ng/mL
  Oxazepam                     Cutoff     5.0
  Alprazolam                   Cutoff     5.0
  Temazepam                    Cutoff     5.0
  Nordiazepam                  Cutoff     5.0
  Diazepam                     Cutoff     5.0
Cocaine Screen                 Cutoff     20     ng/mL
  Benzoylecgonine              Cutoff     3.0
  Cocaine                      Cutoff     2.0
Methadone Screen               Cutoff     50     ng/mL
  EDDP                         Cutoff     25.0
  Methadone                    Cutoff     25.0
Opiates Screen                 Cutoff     40     ng/mL
  Codeine                      Cutoff     2.0
  Morphine                     Cutoff     2.0
  Hydrocodone                  Cutoff     2.0
  Hydromorphone                Cutoff     3.0
  6-MAM                        Cutoff     2.0
  Oxycodone                    Cutoff     2.0
PCP Screen                     Cutoff     10     ng/mL
  Phencyclidine                Cutoff     10.0
  Propoxyphene Screen          Cutoff     50     ng/mL
  Propoxyphene                 Cutoff     10.0
  Norpropoxyphene              Cutoff     10.0
Cannabinoids Screen            Cutoff     4      ng/mL
  Native THC                   Cutoff     2.0
ORAL FLUID STAT 5 ORAL5ORAL5EIA or ELISA. Confirmatory Test: GC/MS or LC/MS/MS
Amphetamine Screen      Cutoff     50     ng/mL
  Amphetamine           Cutoff     10.0  
  Methamphetamine       Cutoff     10.0  
  MDA                   Cutoff     10.0  
  MDMA                  Cutoff     10.0  
Cocaine Screen          Cutoff     20     ng/mL
  Benzoylecgonine       Cutoff     3.0   
  Cocaine               Cutoff     2.0   
Opiates Screen          Cutoff     40     ng/mL
  Codeine               Cutoff     2.0   
  Morphine              Cutoff     2.0   
  Hydrocodone           Cutoff     2.0   
  Hydromorphone         Cutoff     3.0   
  6-MAM                 Cutoff     2.0   
  Oxycodone             Cutoff     2.0   
PCP Screen              Cutoff     10     ng/mL
  Phencyclidine         Cutoff     10.0  
Cannabinoids Screen     Cutoff     4      ng/mL
  Native THC            Cutoff     2.0   
ORAL FLUID STAT 7 ORAL7ORAL7EIA or ELISA. Confirmatory Test: GC/MS or LC/MS/MS
AMPHETAMINES                   Cutoff     50     ng/mL
  Amphetamine (LCMSMS)         Cutoff     10
  Methamphetamine (LCMSMS)     Cutoff     10
  MDA (LCMSMS)                 Cutoff     10
  MDMA (LCMSMS)                Cutoff     10
  MDEA (LCMSMS)                Cutoff     10
BARBITURATES                   Cutoff     50     ng/mL
  Butalbital (GC/MS)           Cutoff     50.0 
  Amobarbital (GC/MS)          Cutoff     50.0 
  Pentobarbital (GC/MS)        Cutoff     50.0 
  Secobarbital (GC/MS)         Cutoff     50.0 
  Phenobarbital (GC/MS)        Cutoff     50.0 
BENZODIAZEPINES                Cutoff     20     ng/mL
  Oxazepam (LCMSMS)            Cutoff     5.0  
  Alprazolam (LCMSMS)          Cutoff     5.0 
  Temazepam (LCMSMS)           Cutoff     5.0 
  Nordiazepam (LCMSMS)         Cutoff     5.0 
  Diazepam (LCMSMS)            Cutoff     5.0 
COCAINES                       Cutoff     20     ng/mL
  Benzoylecgonine (LCMSMS)     Cutoff     3.0 
  Cocaine (LCMSMS)             Cutoff     2.0 
OPIATES                        Cutoff     40     ng/mL
  Codeine (LCMSMS)             Cutoff     2.0 
  Morphine (LCMSMS)            Cutoff     2.0 
  Hydrocodone (LCMSMS)         Cutoff     2.0 
  Hydromorphone (LCMSMS)       Cutoff     3.0 
  6-MAM (LCMSMS)               Cutoff     2.0 
  Oxycodone (LCMSMS)           Cutoff     2.0 
PCP                            Cutoff     10     ng/mL
  Phencyclidine (GC/MS)        Cutoff     10.0
CANNABINOIDS                   Cutoff     4      ng/mL
  Native THC (GC/MS)           Cutoff     2.0 
ORAL FLUID STAT 10ORAL10ORAL10EIA or ELISA. Confirmatory Test: GC/MS or LC/MS/MS
AMPHETAMINES                   Cutoff     50     ng/mL
  Amphetamine (LCMSMS)         Cutoff     10
  Methamphetamine (LCMSMS)     Cutoff     10
  MDA (LCMSMS)                 Cutoff     10
  MDMA (LCMSMS)                Cutoff     10
  MDEA (LCMSMS)                Cutoff     10
BARBITURATES                   Cutoff     50     ng/mL
  Butalbital (GC/MS)           Cutoff     50.0 
  Amobarbital (GC/MS)          Cutoff     50.0 
  Pentobarbital (GC/MS)        Cutoff     50.0 
  Secobarbital (GC/MS)         Cutoff     50.0 
  Phenobarbital (GC/MS)        Cutoff     50.0 
BENZODIAZEPINES                Cutoff     20     ng/mL
  Oxazepam (LCMSMS)            Cutoff     5.0  
  Alprazolam (LCMSMS)          Cutoff     5.0 
  Temazepam (LCMSMS)           Cutoff     5.0 
  Nordiazepam (LCMSMS)         Cutoff     5.0 
  Diazepam (LCMSMS)            Cutoff     5.0 
COCAINES                       Cutoff     20     ng/mL
  Benzoylecgonine (LCMSMS)     Cutoff     3.0 
  Cocaine (LCMSMS)             Cutoff     2.0 
METHADONES                     Cutoff     50     ng/mL
  EDDP (LCMSMS)                Cutoff     25.0
  Methadone (LCMSMS)           Cutoff     25.0
OPIATES                        Cutoff     40     ng/mL
  Codeine (LCMSMS)             Cutoff     2.0 
  Morphine (LCMSMS)            Cutoff     2.0 
  Hydrocodone (LCMSMS)         Cutoff     2.0 
  Hydromorphone (LCMSMS)       Cutoff     3.0 
  6-MAM (LCMSMS)               Cutoff     2.0 
  Oxycodone (LCMSMS)           Cutoff     2.0 
PCP                            Cutoff     10     ng/mL
  Phencyclidine (GC/MS)        Cutoff     10.0
OXYCODONE                      Cutoff     40     ng/mL
  Oxycodone (GC/MS)            Cutoff     2.0 
PROPOXYPHENE                   Cutoff     40     ng/mL
  Propoxyphene (LCMSMS)        Cutoff     10.0
  Norpropoxyphene (LCMSMS)     Cutoff     10.0
CANNABINOIDS                   Cutoff     4      ng/mL
  Native THC (GC/MS)           Cutoff     2.0 
ORAL FLUID STAT 12 ORAL12ORAL12EIA or ELISA. Confirmatory Test: GC/MS or LC/MS/MS
AMPHETAMINES                   Cutoff     50     ng/mL
  Amphetamine (LCMSMS)         Cutoff     10   
  Methamphetamine (LCMSMS)     Cutoff     10   
  MDA (LCMSMS)                 Cutoff     10   
  MDMA (LCMSMS)                Cutoff     10   
  MDEA (LCMSMS)                Cutoff     10   
BARBITURATES                   Cutoff     50     ng/mL
  Butalbital (GC/MS)           Cutoff     50.0 
  Amobarbital (GC/MS)          Cutoff     50.0 
  Pentobarbital (GC/MS)        Cutoff     50.0 
  Secobarbital (GC/MS)         Cutoff     50.0 
  Phenobarbital (GC/MS)        Cutoff     50.0 
BENZODIAZEPINES                Cutoff     20     ng/mL
  Oxazepam (LCMSMS)            Cutoff     5.0  
  Alprazolam (LCMSMS)          Cutoff     5.0  
  Temazepam (LCMSMS)           Cutoff     5.0  
  Nordiazepam (LCMSMS)         Cutoff     5.0  
  Diazepam (LCMSMS)            Cutoff     5.0  
COCAINES                       Cutoff     20     ng/mL
  Benzoylecgonine (LCMSMS)     Cutoff     3.0  
  Cocaine (LCMSMS)             Cutoff     2.0  
METHADONES                     Cutoff     50     ng/mL
  EDDP (LCMSMS)                Cutoff     25    
  Methadone (LCMSMS)           Cutoff     25   
MEPERIDINE                     Cutoff     40     ng/mL
  Meperidine (LCMSMS)          Cutoff     10.0 
  Normeperidine (LCMSMS)       Cutoff     10.0 
OPIATES                        Cutoff     40     ng/mL
  Morphine (LCMSMS)            Cutoff     2    
  Hydromorphone (LCMSMS)       Cutoff     2    
  Codeine (LCMSMS)             Cutoff     2    
  Oxycodone (LCMSMS)           Cutoff     2    
  Hydrocodone (LCMSMS)         Cutoff     2    
  6-MAM (LCMSMS)               Cutoff     2     
PCP                            Cutoff     10     ng/mL
  Phencyclidine (GC/MS)        Cutoff     10.0 
OXYCODONE                      Cutoff     40     ng/mL
  Oxycodone (LCMSMS)           Cutoff     2    
PROPOXYPHENE                   Cutoff     40     ng/mL
  Propoxyphene (LCMSMS)        Cutoff     10.0 
  Norpropoxyphene (LCMSMS)     Cutoff     10.0 
CANNABINOIDS                   Cutoff     4      ng/mL
  Native THC (GC/MS)           Cutoff     2.0  
TRAMADOL                       Cutoff     40     ng/mL
  Tramadol (LCMSMS)            Cutoff     10.0 
AMYLASEAMYAMYEnzymatic
TitleDescriptorRangesUnits
AmylaseU/L
0-3 months3-23
3-12 months2-65
1-17 years26-110
18+ years16-108
RHEUMATOID ARTHRITIS PANEL (REFLEX)RAPTVMRAPTVMMultiplex luminex, Nephelometry, Enzymatic
ANA                        Negative
 A multiplex screen for 11 autoantibodies
 (dsDNA, Smith, Ribosomal P, Chromatin, RNP, 
 SmRNP, Scl-70, Centromere B, SSA, SSB and
 J0-1) was performed and no autoantibodies
 were detected. A negative multiplex ANA
 does not rule out all possibility of a 
 connective tissue or autoimmune disease,
 and further studies should be considered
 if clinical suspicion is high.
DSDNA Autoantibody    Negative       LT 5         IU/mL
                      Indeterminate  5-9
                      Positive       10 or more
Smith Autoantibody    Negative       LT 1.0       AI
                      Positive       1.0 or more  
Ribosomal P Auto-     Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
Chromatin Auto-       Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
RNP Autoantibody      Negative       LT 1.0       AI
                      Positive       1.0 or more 
SMRNP Auto-           Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
SCL-70 Auto-          Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
Centromere B Auto-    Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
SSA (RO) Auto-        Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
SSB (LA) Auto-        Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
JO-1 Autoantibody     Negative       LT 1.0       AI
 antibody             Positive       1.0 or more
RA                                   LT 20        IU/mL
CRP                                  1.5 or less  mg/dL
Uric Acid            0-16 years      2.0-5.5      mg/dL
                  M  17+ yrs         3.2-8.6
                  F  17+ yrs         2.2-7.1
ANA SCREEN (EIA) RFLXANAESRANAESREnzyme-Linked Immunosorbent Assay, Multiplex Luminex
TitleDescriptorRangesUnits
ANA by EIA, ABLT 1.0U
ANA by EIA, InterpNegative
ANA CONFIRMATORY ANTIBODIES
DSDNA AutoantibodyNegativeLT 5IU/mL
Smith AutoantibodyNegativeLT 1.0AI
JO-1 AutoantibodyNegativeLT 1.0AI
Ribosomal P AutoantibodyNegativeLT 1.0AI
Chromatin AutoantibodyNegativeLT 1.0AI
RNP AutoantibodyNegativeLT 1.0AI
SMRMP AutoantibodyNegativeLT 1.0AI
SCL-70 AutoantibodyNegativeLT 1.0AI
Centromere B AutoantibodyNegativeLT 1.0AI
SSA (RO) AutoantibodyNegativeLT 1.0AI
SSB (LA) AutoantibodyNegativeLT 1.0AI
ANA TITER (IFA) RFLXIFANARIFANARIFA
TitleDescriptorRangesUnits
ANA by IFA Titer LT 1:40Titer
ANA by IFA Pattern
ANA SPECIFIC ANTIBODIES
DSDNA AutoantibodyNegativeLT 5IU/mL
Smith AutoantibodyNegativeLT 1.0AI
JO-1 AutoantibodyNegativeLT 1.0AI
Ribosomal P AutoantibodyNegativeLT 1.0AI
Chromatin AutoantibodyNegativeLT 1.0AI
RNP AutoantibodyNegativeLT 1.0AI
SMRNP AutoantibodyNegativeLT 1.0AI
SCL-70 AutoantibodyNegativeLT 1.0AI
Centromere B AutoantibodyNegativeLT 1.0AI
SSA (RO) AutoantibodyNegativeLT 1.0AI
SSB (LA) AutoantibodyNegativeLT 1.0AI
ANA SPECIFIC ABANASABANASABMultiplex Luminex
TitleDescriptorRangesUnits
ANA SPECIFIC ANTIBODIES
DSDNA AutoantibodyNegativeLT 5IU/mL
Smith AutoantibodyNegativeLT 1.0AI
JO-1 AutoantibodyNegativeLT 1.0AI
Ribosomal P AutoantibodyNegativeLT 1.0AI
Chromatin AutoantibodyNegativeLT 1.0AI
RNP AutoantibodyNegativeLT 1.0AI
SMRNP AutoantibodyNegativeLT 1.0 AI
SCL-70 AutoantibodyNegativeLT 1.0AI
Centromere B AutoantibodyNegativeLT 1.0AI
SSA (RO) AutoantibodyNegativeLT 1.0AI
SSB (LA) AutoantibodyNegativeLT 1.0AI
AUTOIMMUNE PROFILE RFLXAIPAIPMultiplex luminex, Nephelometry
TitleDescriptorRangesUnits
ANANegative
A multiplex screen for 11 autoantibodies (dsDNA, Smith, Ribosomal P, Chromatin, RNP, SmRNP, Scl-70, Centromere B, SSA, SSB and J0-1) was performed and no autoantibodies were detected. A negative multiplex ANA does not rule out all possibility of a connective tissue or autoimmune disease, and further studies should be considered if clinical suspicion is high.
DSDNA AutoantibodyNegativeLT 5IU/mL
Indeterminate5-9
Positive10 or more
Smith AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Ribosomal P AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Chromatin AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
RNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SMRNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SCL-70 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Centromere B AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSA (RO) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSB (LA) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
JO-1 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Complement, C3mg/dL
0-1 day50-168
2-60 days55-170
2-5 months59-176
6-24 months66-180
25-60 months74-184
5-9 years74-190
10-14 years77-198
15+ years90-200
CRP1.5 or lessmg/dL
RALT 20IU/mL
CONNECTIVE TISSUE DISEASE RFLXCTDCTDMultiplex Luminex, Nephelometry, ELISA
TitleDescriptorRangesUnits
ANANegative
A multiplex screen for 11 autoantibodies (dsDNA, Smith, Ribosomal P, Chromatin, RNP, SmRNP, Scl-70, Centromere B, SSA, SSB and J0-1) was performed and no autoantibodies were detected. A negative multiplex ANA does not rule out all possibility of a connective tissue or autoimmune disease, and further studies should be considered if clinical suspicion is high.
DSDNA AutoantibodyNegativeLT 5IU/mL
Indeterminate5-9
Positive10 or more
Smith AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Ribosomal P AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Chromatin AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
RNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SMRNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SCL-70 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Centromere B AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSA (RO) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSB (LA) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
JO-1 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Complement, C30-1 days50-168mg/dL
2-60 days55-170
2-5 months59-176
6-24 months66-180
25-60 months74-184
5-9 years74-190
10-14 years77-198
15+ years90-200
Complement, C40-7 days0.0-45.7mg/dL
8-60 days1.5-47.9
2-5 months1.5-47.9
6-24 months3.0-47.9
25-60 months4.5-48.4
5-9 years5.3-50.6
10-14 years6.0-52.8
15+ years15.0-55.0
Cyclic Citrullinated Peptide Antibody, IgGNegativeLT 20EU
Positive20-39
Mod Positive40-59
Strong Positive60 or more
Approximately 70% of patients with RA are positive for CCP IgG, while only 2% of random blood donors and disease controls are positive. The diagnostic value of antibodies to arthritis patients has not been determined.
RALT 20IU/mL
ANALYZERANALZ4ANALZ4EIA/LIA
TitleDescriptorRangesUnits
ANALT 7.5IU/mL
ANA Pattern
dsDNA AutoAbsLT 5.0
RNP/SmNegativeLT 11
Borderline11-20
PositiveGT 20
Sm(Smith) IgG AutoAbsNegativeLT 11
Borderline11-20
PositiveGT 20
SS-A IgG AutoAbsNegativeLT 11
Borderline11-20
PositiveGT 20
SS-B IgG AutoAbsNegativeLT 11
Borderline11-20
PositiveGT 20
Scl-70 IgG AutoAbsNegativeLT 11
Borderline11-20
PositveGT 20
Thyroid Peroxidase AutoAbsLT 60U/mL
C3 Complement90-180mg/dL
C4 Complement16-47mg/dL
Rheumatoid FactorLT 14IU/mL
Ribosmal P AutoAbsNegativeLT 11Units
Borderline11-20
PositiveGT 20
ANA SCREEN RFLXANAMPANAMPMultiplex Luminex
TitleDescriptorRangesUnits
ANANegative
A multiplex screen for 11 autoantibodies (dsDNA, Smith, Ribosomal P, Chromatin, RNP, SmRNP, Scl-70, Centromere B, SSA, SSB and J0-1) was performed and no autoantibodies were detected. A negative multiplex ANA does not rule out all possibility of a connective tissue or autoimmune disease, and further studies should be considered if clinical suspicion is high.
DSDNA AutoantibodyNegativeLT 5IU/mL
Indeterminate5-9
Positive10 or more
Smith AutoantibodyNegativeLT 1.0AI
Positive 1.0 or more
Ribosomal P Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Chromatin Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SCL-70 Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Centromere B Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SSA (RO) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SSB (LA) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
ANCA PANEL W/ANA RFLXANCAMEANCAMEMultiplex luminex, IFA, ELISA
TitleDescriptorRangesUnits
ANANegative
A multiplex screen for 11 autoantibodies (dsDNA, Smith, Ribosomal P, Chromatin, RNP, SmRNP, Scl-70, Centromere B, SSA, SSB and J0-1) was performed and no autoantibodies were detected. A negative multiplex ANA does not rule out all possibility of a connective tissue or autoimmune disease, and further studies should be considered if clinical suspicion is high.
DSDNA AutoantibodyNegativeLT 5IU/mL
Indeterminate5-9
Positive10 or more
Smith AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Ribosomal P AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Chromatin AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
RNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SMRNP AutoantibodyNegativeLT 1.0AI
Positive 1.0 or more
SCL-70 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
Centromere B AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSA (RO) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSB (LA) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
JO-1 AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
ANCA Titer, IFA
ANCA Pattern
Proteinase 3 AntibodyNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
Myeloperoxidase AntibodyNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
ANCA PANEL NO ANA RFLXANCAPRANCAPRIFA, EIA
TitleDescriptorRangesUnits
ANCA Titer, IFANegativeLT 1:20
ANCA Pattern
Myeloperoxidase AntibodyNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
Proteinase 3 AntibodyNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
ANTABUSEANTABUSEABUSEGC
TitleDescriptorRangesUnits
Antabuseug/mL
None detected
Therapeutic0.3-1.5
LOW MOLECULAR WEIGHT HEPARINLMW.HEPARINHEPLMWAntiXa Chromogenic
Anti Xa                        IU/mL
Enoxaparin
 Target peak concentration for
 prophylaxis                   0.2-0.4
 Target peak concentration for
 treatment, 2 doses daily      0.6-1.0
 Target peak concentration for
 treatment, 1 dose daily       1.3-2.0
Dalteparin                     IU/mL                             
 Target peak concentration for 
 prophylaxis                   0.2-0.4
 Target peak concentration for 
 treatment, 2 doses daily      0.6-1.0
 Target peak concentration for
 treatment, 1 dose daily       0.85-1.25
ISLET CELL CYTOPLASMIC ANTIBODY, IGGISLETISLETIFA
TitleDescriptorRangesUnits
Anti-Islet Cell AbNo antibody detectedLT 1:4Titer
Islet cell antibodies have been associated with 'autoimmune' endocrine disorders and insulin-dependent diabetes. This disorder is characterized by the presence of antibodies in patients that may be detected years before the onset of the clinical symptoms. To calculate Juvenile Diabetes Foundation (JDF) units; multiply the titer x 5 (1.8 8x5=40 JDF Units).
ANTINEURONAL CELL ANTIBODYNCABUWNCABUWEnzyme Linked Immunosorbent Assay
Anti-Neuronal          Units
 Cell Ab
Interpretation
OVARIAN ANTIBODY SCREEN WITH REFLEX TO TITEROVABOVABIFA
Anti-Ovary Antibody       Negative
Anti-Ovary Antibody Titer Titer
ANTIBODY IDENTIFICATIONAB IDMABIDHemagglutination/Solid Phase
Antibody Screen 
Antibody ID
Antibody Titer
ANTIPHOSPHATIDYLSERINE, IGAAPSAAPSAELISA
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgANegativeLT 20APS U/mL
Positive20 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
PHOSPHATIDYLSERINE, ANTIBODIES, IGA, IGG, IGMAPSAGMAPSAGMEIA
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgANegativeLT 20APS U/mL
Positive20 or more
Antiphosphatidylserine, IgGNegativeLT 11GPS U/mL
Positive11 or more
Antiphosphatidylserine IgMNegativeLT 25MPS U/mL
Positive25 or more
The presence of phosphatidylserine antibodies may be associated with antiphospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
ANTIPHOSPHOLIPID PANEL 2 RFLXAPP2APP2EIA and Electromechanical
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgAAPS U/mL
NegativeLT 20
Positive 20 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Antiphosphatidylserine,IgGGPS U/mL
NegativeLT 11
Positive11 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Antiphosphatidylserine, IgMMPS U/mL
NegativeLT 25
Positive25 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Cardiolipin Ab IgAAPL
Negative0-11
Indeterminate12-20
PositiveGT 20
Cardiolipin Ab IgGGPL
Negative0-14
Indeterminate15-20
PositiveGT 20
Cardiolipin Ab IgMMPL
Negative0-12
Indeterminate13-20
PositiveGT 20
dRVVT31.8-45.7sec
dRVVT Mix RatioNegative for Lupus Inhibitor screenLT 1.2
dRVVT Confirm RatioNegative for Lupus Inhibitor screenLT 1.2
dRVVT Confirm Mix RatioNegative for Lupus Inhibitor screenLT 1.2
ANTIPHOSPHOLIPID PANEL 3 RFLXAPP3APP3EIA and Electromechanical
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgAAPS U/mL
NegativeLT 20
Positive20 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Antiphosphatidylserine,IgGGPS U/mL
NegativeLT 11
Positive11 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Antiphosphatidylserine, IgMMPS U/mL
NegativeLT 25
Positive25 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
Cardiolipin Ab IgAAPL
Negative0-11
Indeterminate12-20
PositiveGT 20
Cardiolipin Ab IgGGPL
Negative0-14
Indeterminate15-20
PositiveGT 20
Cardiolipin Ab IgMMPL
Negative0-12
Indeterminate13-20
PositiveGT 20
Beta-2 GlycoproteinSAU
Negative0-20
PositiveGT 20
Beta-2 Glycoprotein 1 Ab, IgGSGU
Negative0-20
PositiveGT 20
Beta-2 Glycoprotein 1 Ab, IgMSMU
Negative0-20
PositiveGT 20
dRVVT31.8-45.7Seconds
dRVVT Mix RatioNegative for Lupus Inhibitor screenLT 1.2
dRVVT Confirm RatioNegative for Lupus Inhibitor screenLT 1.2
dRVVT Confirm Mix RatioNegative for Lupus Inhibitor screenLT 1.2
ANTIPHOSPHATIDYLSERINE, IGGAPSGAPSGEIA
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgGNegativeLT 11GPS U/mL
Positive11 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
ANTIPHOSPHATIDYLSERINE, IGMAPSMAPSMEIA
TitleDescriptorRangesUnits
Antiphosphatidylserine, IgMNegativeLT 25MPS U/mL
Positive25 or more
The presence of phosphatidylserine Abs maybe associated with anti-phospholipid syndrome characterized by recurrent fetal loss, thrombosis and thrombocytopenia.
ANTITHROMBIN ACTIVITYTHROMBIN III.ACTAT3Chromogenic
TitleDescriptorRangesUnits
Antithrombin Activity1 day75-91%
3 days77-90
1 month-1 year93-136
1-5 years130-133
6-10 years122-136
11-16 years124-128
16+ years85-126
ACTIVATED PROTEIN C RESISTANCEAPCRESAPCRClot-based Assay
TitleDescriptorRangesUnits
APC ResistanceNormalGT 2.0ratio
PLATELET NEUTRALIZATION PROCEDUREPLTNPPLTNPElectromechanical (clot based)
TitleDescriptorRangesUnits
aPTT, Patient26-36sec
aPTT, Control Plasmasec
aPTT, Patient/Control Mixsec
A PTT mix that is not within 5 seconds of the control plasma usually suggests an inhibitor.
PNP0-7sec
Negative for Lupus Inhibitor< = 7.0 seconds
Positive Platelet Neutralization Procedure. Lupus Inhibitor present> = 7.1 seconds
A Lupus Inhibitor is diagnosed when prolongation of a phospholipid dependent coagulation test is due to the presence of an inhibitor and excess phospholipid can overcome the inhibition. Repeat evaluation after at least 12 weeks is suggested, as concensus guidelines suggest clinically significant Lupus Anticoagulants are persistant.
AQUAPORIN-4 RECEPTOR ABAQP4ABAQP4ABSemi-Quantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Aquaporin-Receptor Antibody 4Negative4 or lessU/mL
Indeterminate5
Positive6 or greater
ARIPIPRAZOLEARIARIHigh Performance Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Aripiprazoleng/mL
Steady state plasma levels in adults following a daily regimen have been reported as:
5 mg70-126
10 mg109-216
15 mg206-278
20 mg212-574
30 mg320-585
GM1 COMBINATIONGM1COMGM1COMELISA
TitleDescriptorRangesUnits
Asialo-GM1 Abs, IgG/IgMIV
GM1 Abs IgG/IgMIV
GM2 Abs IgG/IgMIV
GD1a Abs IgG/IgMIV
GD1b Abs IgG/IgMIV
GQ1b Abs IgG/IgMIV
Negative29 or less
Weak Positive30-50
Positive51-150
Strong Positive151 or more
ASTGOTASTEnzymatic
TitleDescriptorRangesUnits
ASTU/L
0-6 years20-60
6-10 years20-40
10-18 years14-40
18+ years10-45
B12 AND FOLATEB12/FOLB12FOLICMA
TitleDescriptorRangesUnits
B12DeficientLT 212pg/mL
Indeterminate212-246
Normal247-911
FolateDeficient0.4-3.4ng/mL
Indeterminate3.5-5.3
Normal5.4-24.0
VITAMIN B12B12B12ICMA
TitleDescriptorRangesUnits
B12DeficientLT 212pg/mL
Indeterminate212-246
Normal247-911
BAL, BODY FLUID CONSULT REVIEWBAL.REVBALVWI
BAL-Source
BAL-Interpretation
BARTONELLA DNA (RT-PCR)BARPCRBARPCRReal-Time PCR
TitleDescriptorRangesUnits
Bartonella henselae DNA by PCRNot detected
Bartonella quintana DNA by PCRNot detected
The detection of Bartonella henselae and Bartonella quintana DNA is based upon the amplification of specific Bartonella genomic DNA sequences by PCR form total DNA extracted from the specimen. Probes specific for B. henselae and B. quintana are used to identify and differentiate the products of the PCR amplification. The diagnosis of B. henselae or B. quintana infection should not rely solely upon the result of a PCR assay. A positive PCR result should be considered in conjunction with the clinical presentation and additional established diagnostic tests prior to establishing diagnosis.
A negative PCR result indicates only the absence of B. henselae or B. quintana DNA in the sample tested and does not exclude the diagnosis of disease.
BCL2/JH T(14:18), FLD (PCR)BCLJHTBCLJHTPCR
BCL-2/JH, t(14;18) mbr, Fluid
 Negative  bcl-2/JH major breakpoint region gene rearrangement is not detected.
 Positive  bcl-2/JH major breakpoint region gene rearrangement is detected.

BCL-2/JH, t(14;18) mcr, Fluid
 Negative  bcl-2/JH minor cluster region gene rearrangement is not detected.
 Positive: bcl-2/JH minor cluster region gene rearrangement is detected.
BENZENE, WHOLE BLOODBENZENEBENZWBHeadspace GC
TitleDescriptorRangesUnits
BenzeneFollowing exposure to 25 ppm in air for 2 hoursApproximately 0.2mcg/mL
BENZOYLECGONINE (COCAINE) PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPCOCPCOCGas Chromatography Mass Spectrometry
Benzoylecgonine   100   ng/mL    positive cutoff    
BETA 2 GLYCOPROTEIN 1, IGAB2GP1AB2GP1AEIA
TitleDescriptorRangesUnits
Beta-2 Glycoprotein 1 Ab, IgANegative0-20SAU
PositiveGT 20
BETA 2 GLYCOPROTEIN 1, IGG, IGMB2GPGMB2GPGMEIA
TitleDescriptorRangesUnits
Beta-2 Glycoprotein 1 Ab, IgGNegative0-20SGU
PositiveGT 20
Beta-2 Glycoprotein 1 Ab, IgMNegative0-20SMU
PositiveGT 20
BETA 2 GLYCOPROTEIN 1, IGGB2GP1GB2GP1GEIA
TitleDescriptorRangesUnits
Beta-2 Glycoprotein 1 Ab, IgGNegative0-20SGU
PositiveGT 20
BETA 2 GLYCOPROTEIN 1, IGMB2GP1MB2GP1MEIA
TitleDescriptorRangesUnits
Beta-2 Glycoprotein 1 Ab, IgMNegative0-20SMU
PositiveGT 20
BILE ACIDS, TOTALBILE ACIDSBILEAEnzymatic
TitleDescriptorRangesUnits
Bile AcidsFasting0-10umol/L
BILIRUBIN, TOTALBILTBILColorimetric
TitleDescriptorRangesUnits
Bilirubin, Total0-30 daysLT 11.7mg/dL
1 month-18 yearsLT 2.0
18-60 years0.1-1.5
60-90 years0.2-1.1
90+ years0.2-0.9
BIOAVAILABLE VITAMIN D 25BIO25DBIO25DImmunoassay/Spectrophotometry
TitleDescriptorRangesUnits
Bioavailable Vitamin D1.92-8.82ng/mL
Vitamin D Binding protein104-477ug/mL
Total Vitamin D (25 Hydroxy)ng/mL
Severe DeficiencyLT 10.0
Mild to Moderate Deficiency10.0-23.9
Optimum Levels24.0-80.0
Toxicity Possible
Pediatrics (0-18 years)80.0 or greater
Adults (19+ years)150.0 or greater
BLASTOMYCES AB (CF)BLASTO.CFBLASCFCF
TitleDescriptorRangesUnits
Blastomyces Ab (by CF)No antibody detectedLT 1:8Titer
AFP, AMNIOTIC FLUID RFLXAFAFPAFAFPICMA
TitleDescriptorRangesUnits
Blood Present
Alpha Fetoprotein, Amniotic Fluidug/mL
MoMLT 2.0MoM
InterpretationNegative Screen
Fetal Hemoglobin FNegative
BORON, SERUM OR PLASMABORONSBORONSICP/MS
TitleDescriptorRangesUnits
BoronNone Detectedmcg/L
NormallyLT 100
BROMIDEBROMIDEBROMIDSpectrophotometric
TitleDescriptorRangesUnits
Bromidemg/dL
Sedation10-50
Seizure control75-150
Toxic for many patients75-150
Possibly debilitatingly toxicGT 150
Possibly fatalGT 300
BRUCELLA AB, IGG, IGM RFLXBRUGMBRUGMImmunoassay
Brucella IgG	
Brucella IgM
BUPRENORPHINE PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPBUPPBUPGas Chromatography Mass Spectrometry
Buprenorphine      25      ng/mL      positive cutoff      
Nor-Buprenorphine  25      ng/mL      positive cutoff    
BUPROPIONBUPROPIONBUPROQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Bupropionng/mL
Therapeutic Range50-100
Toxic LevelGT 400
BUTALBITALBUTBUTALBQuantitative GC-MS
TitleDescriptorRangesUnits
Butalbitalug/mL
Therapeutic1-10
ToxicGT 30
C PEPTIDECPEPSCPEPSICMA
TitleDescriptorRangesUnits
C-PeptideFasting1.0-5.5ng/mL
CHLAMYDIA AB PANEL, IGG, IGMCHLGMCHLGMIFA
C. pneumoniae, IgM              
C. trachomatis, IgM              
C. psittaci, IgM                 
C. pneumoniae, IgG              
C. trachomatis, IgG              
C. psittaci, IgG
C-1 ESTERASE INHIB FUNCTIONALC-1 FUNCC1FUNCELISA
TitleDescriptorRangesUnits
C1 Esterase Inhibitor, FunctionalNormalGT 67%
Indeterminate41-67
Abnormal40 or less
FATTY ACID PROF, PEROXISOMALFATTYAFATTYAGC/MS Stable Isotope
TitleDescriptorRangesUnits
C22:096.3 or lessnmol/mL
C24:091.4 or lessnmol/mL
C26:01.30 or lessnmol/mL
C24:0/C22:01.39 or lessRatio
C26:0/C22:00.023 or lessRatio
Pristanic Acid0-4 mo0.60 or lessnmol/mL
5-8 mo0.84 or less
9-12 mo0.77 or less
13-24 mo1.47 or less
GT 24 mo2.98 or less
Phytanic Acid0-4 mo5.28 or lessnmol/mL
5-8 mo5.70 or less
9-12 mo4.40 or less
13-24 mo8.62 or less
GT 24 mo9.88 or less
Pristanic Acid/Phytanic Acid Ratio0-4 mo0.35 or lessRatio
5-8 mo0.28 or less
9-12 mo0.23 or less
13-24 mo0.24 or less
GT 24 mo0.39 or less
C3, C4 C3/C4C3C4Nephelometry
TitleDescriptorRangesUnits
C3Cmg/dL
0-1 days50-168
2-60 days55-170
2-5 months59-176
6-24 months66-180
25-60 months74-184
5-9 years74-190
10-14 years77-198
15+ years90-200
C4mg/dL
0-7 days0.0-45.7
8-60 days1.5-47.9
2-5 months1.5-47.9
6-24 months3.0-47.9
25-60 months4.5-48.4
5-9 years5.3-50.6
10-14 years6.0-52.8
15+ years15.0-55.0
COMPLEMENT C3C3C3Nephelometry
TitleDescriptorRangesUnits
C3Cmg/dL
0-1 days50-168
2-60 days55-170
2-5 months59-176
6-24 months66-180
25-60 months74-184
5-9 years74-190
10-14 years77-198
15+ years90-200
COMPLEMENT C4C4C4Nephelometry
TitleDescriptorRangesUnits
C4mg/dL
0-7 days0.0-45.7
8-60 days1.5-47.9
2-5 months1.5-47.9
6-24 months3.0-47.9
25-60 months4.5-48.4
5-9 years5.3-50.6
10-14 years6.0-52.8
15+ years15.0-55.0
CAFFEINECAFNCAFNEIA
TitleDescriptorRangesUnits
Caffeineug/mL
Therapeutic6-20
ToxicGT 40
CALCIUM, IONIZEDCAL-IONICALISE
TitleDescriptorRangesUnits
Calcium, Ionizedmg/dL
0-18 years4.90-5.50
19+ years4.75-5.30
Calcium, Normalizedmg/dL
0-18 years4.90-5.50
19+ years4.75-5.30
CALPROTECTIN, FECALCALPFCCALPFCELISA
TitleDescriptorRangesUnits
Calprotectin, Fecalug/g
Normal50 or less
Borderline elevated, test should be re-evaluated in 4-6 weeks51-120
Abnormal, suggestive of inflammatory bowel disease (IBD)121 or more
CANNABINOIDS (THC) CONFIRMATION TESTING BY GC/MSPTHCCPTHCCGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
Cannabinoids (THC)Positive cutoff20ng/mL
CARBAMAZEPINE EPOXIDE/TOTALCAREPOCAREPOQuantitative Liquid Chromatography-Tandem Mass Spectrometry/Quantitative Enzyme Multiplied Immunoassay Technique
TitleDescriptorRangesUnits
Carbamazepine 10-11 Epoxideug/mL
Therapeutic RangeNot well established
Toxic LevelGT 15.0
Carbamazepine, Totalug/mL
Therapeutic Range4.0-12.0
Toxic LevelGT 20.0
A proposed therapeutic range is 0.4-4.0 ug/mL. The metabolite, Carbamazepine-10, 11-Epoxide, has anticonvulsant activity to the parent drug.
CARBAMAZEPINECARBCARBICMA
TitleDescriptorRangesUnits
CarbamazepineTherapeutic4.0-12.0ug/mL
ToxicGT 15.0
Toxicity can also be seen at lower levels with combined therapy.
ANTIPHOSPHOLIPID PANEL 1 RFLXAPP1RAPP1RELISA and Electromechanical
TitleDescriptorRangesUnits
Cardiolipin Ab IgGGPL
Negative0-14
Indeterminate15-20
Positive> 20
Cardiolipin Ab IgMMPL
Negative0-12
Indeterminate13-20
Positive> 20
Beta-2 Glycoprotein 1 Ab, IgGSGU
Negative0-20
Positive> 20
Beta-2 Glycoprotein 1 Ab, IgMSMU
Negative0-20
Positive> 20
PT, PatientSeconds
0-1 month13.0-20.0
2+ months10.9-14.8
PT, PT/NL MixSeconds
Thrombin T, Pt15.6-20.0Seconds
TT, Pt/Ps MixSeconds
aPTT, PatientSeconds
0-1 month40-50
2 months-4 years25-40
5+ years26-36
aPTT, ControlSeconds
aPTT, PT Ct MixSeconds
HPNTSeconds
Negative< = 9.1
Positive> = 9.2
dRVVT31.8-45.7Seconds
dRVVT mix ratio0.0-1.2
CARDIOLIPIN AB PANEL, IGG, IGMCARD.ABCARDELISA
TitleDescriptorRangesUnits
Cardiolipin Ab, IgGNegative0-14GPL
Indeterminate15-20
PositiveGT 20
Cardiolipin Ab, IgMNegative0-12MPL
Indeterminate13-20
PositiveGT 20
CARDIOLIPIN AB, IGG, IGM, IGACARDSCARDSEIA
TitleDescriptorRangesUnits
Cardiolipin Ab, IgGGPL
Negative0-14
Indeterminate15-20
PositiveGT 20
Cardiolipin Ab, IgMMPL
Negative0-12
Indeterminate13-20
PositiveGT 20
Cardiolipin Ab, IgAAPL
Negative0-11
Indeterminate12-20
PositiveGT 20
CARDIOLIPIN AB, IGACARDACARDAEIA
TitleDescriptorRangesUnits
Cardiolipin Antibody, IgANegative0-11APL
Indeterminate12-20
PositiveGT 20
CARDIOLIPIN AB, IGGCARDGCARDGEIA
TitleDescriptorRangesUnits
Cardiolipin Antibody, IgGNegative0-14GPL
Indeterminate15-20
PositiveGT 20
CARDIOLIPIN AB, IGMCARDMCARDMELISA
TitleDescriptorRangesUnits
Cardiolipin Antibody, IgMNegative0-12MPL
Indeterminate13-20
PositiveGT 20
CARNITINE PANELCARNPACARNPATandem Mass Spectrometry
TitleDescriptorRangesUnits
Carnitine, Free
Carnitine, Total
Carnitine, Esterified
Carnitine Esterified/Free (Ratio)
Acylcarnitine, Plasma Interpretation
C2, Acetyl
C3, Propionyl
C4, Iso-/Butyryl
C5, Isovaleryl/2Mebutyryl
C5-DC, Glutaryl
C5-OH, 3-OH Isovaleryl
C6, Hexanoyl
C8, Octanoyl
C8:1, Octenoyl
C10, Decanoyl
C10:1, Decenoyl
C12, Dodecanoyl
C12:1, Dodencenoyl
C12-OH, 3-OH-Dodecanoyl
C14, Tetradecanoyl
C14:1, Tetradecenoyl
C14:2, Tetradecandienoyl
C14-OH, 3-OH-Tetradecanoyl
C14:1-OH, 3-OH-Tetradecnoyl
C16, Palmitoyl
C16:1, Palmitoleyl
C16-OH, 3-OH-Palmitoyl
C16:1-OH, 3-OH-Palmitoleyl
C18, Stearoyl
C18:1, Oleyl
C18:2, Linoleyl
C18-OH, 3-OH Stearoyl
C18:1-OH, 3-OH-Oleyl
C18:2-OH, #-OH- Linoleyl
CARNITINE, FREE AND TOTALCARFTRCARFTRTandem Mass Spectrophotometry
TitleDescriptorRangesUnits
Carnitine, Freeumol/L
0-31 days15-55
32 days-12 months29-61
13 months-6 years25-55
7-20 years22-63
21+ years25-60
Carnitine, Totalumol/L
0-31 days21-83
32 days-12 months38-73
13 months-6 years35-90
7-20 years31-78
21+ years34-86
Carnitine, Esterifiedumol/L
0-31 days4-29
32 days-12 months7-24
13 months-6 years4-36
7-20 years3-38
21+ years5-29
Carnitine, Esterified/FreeRatio
0-31 days0.2-0.8
32 days-12 months0.1-0.8
13 months-6 years0.1-0.8
7-20 years0.1-0.9
21+ years0.1-1.0
CATECHOLAMINES, PLASMA FRACTPCATPCATHPLC
TitleDescriptorRangesUnits
Catecholamines
Dopaminepg/mL
2 days-150 years0-20
Epinephrinepg/mL
2-10 days36-400
11 days-3 months55-200
4-11 months55-440
12-23 months 36-640
24-35 months18-440
3-17 years18-460
18+ years10-200
Norepinephrinepg/mL
2-10 days170-1180
11 days-3 months370-2080
4-11 months270-1120
12-23 months68-1810
24-35 months170-1470
3-17 years85-1250
18+ years80-520
All reference ranges assume patient is in a supine position.
DIFFERENTIAL SLIDE REVIEW BY PATHDIF.PATHPATHD2Microscopic
CBC with Manual Differential
Impression
Reviewed By
OBSTETRIC PANEL RFLX WITH CBCOBPAN1OBPAN1Hemagglutination, ICMA, Automated Hematology, EIA, Solid Phase
TitleDescriptorRangesUnits
CBCSee CBC
ABO
RH
Antibody ScreenNegative
Hepatitis B Surface AntigenNonreactive
Hepatitis B Surface Antigen Confirmation
Treponema pallidum Ab by EIANegative
RPRNonreactive
RPR TiterLT 1:1
Treponema pallidum Ab by TP-PANonreactive
Rubella Ab, IgGPresumed Immune10 or greaterIU/mL
Equivocal5-9
Presumed Non-ImmuneLT 5
Result flagging is based on presumed immune status
CEACEACEAICMA
TitleDescriptorRangesUnits
CEA (ICMA)Non-Smokers0.0-3.0ng/mL
Smokers0.0-5.0
CELIAC DISEASE GENOTYPINGHLACELHLACELPolymerase Chain Reaction/Fluorescence Monitoring
Celiac (HLA-DQA1*05)
Celiac (HLA-DQB1*02)
Celiac (HLA-DQB1*03:02)
Celiac HLA Interpretation 
CENTROMERE B AUTOANTIBODY, IGGCENTMPCENTMPMultiplex luminex
TitleDescriptorRangesUnits
Centromere B Autoantibody, IgGNegativeLT 1.0AI
Positive1.0 or more
CHLORALHYDRATECHLORALCHLORSGC
TitleDescriptorRangesUnits
Chloralhydratemcg/mL
Therapeutic (Post 1 gram dose)2-12
LIPID PANEL WITH REFLEX TO DIRECT LDLLIPREFLIPREFEnzymatic, Elimination/Enzymatic
Cholesterol                             mg/dL  
   LT 200           Desirable
   200-239          Borderline high
   240 or more      High
Triglycerides                           mg/dL
   LT 150           Normal
   150-199          Borderline high
   200-499          High
   500 or more      Very high
HDL                                     mg/dL
   LT 40            Low
   40-59            Within normal limits
   60 or more       High
HDL Cholesterol greater than or equal to 60 mg/dL is considered to be a 'negative'
risk factor, serving to remove one risk factor from the total count.
LDL (calculated)                        mg/dL
   LT 100           Optimal
   100-129          Near or above normal
   130-159          Borderline high
   160-189          High
   190 or more      Very high
To calculate 10-year cardiac risk for the patient, go to http://www.paml.com, click on
testing information, and then on lipid calculator.
Cholesterol/HDL Ratio
   LT 4.5           Female
   LT 5.0           Male
LDL Cholesterol, Direct                 mg/dL
   LT 100           Optimal
   100-129          Near or above normal
   130-159          Borderline high
   160-189          High
   190 or more      Very high
LIPID PROFILELIPIDLIPIDEnzymatic
Cholesterol                     mg/dL
 LT 200        Desirable
 200-239       Borderline high
 240 or more   High
Triglycerides                   mg/dL
 LT 150        Normal
 150-199       Borderline high
 200-499       High
 500 or more   Very high
HDL                             mg/dL
 LT 40         Low
 40-59         Within normal limits
 60 or more    High
 HDL Cholesterol greater than or equal
 to 60 mg/dL is considered to be a
 'negative' risk factor, serving to
 remove one risk factor from the total
 count.
LDL (calculated)                mg/dL
 LT 100        Optimal
 100-129       Near or above normal
 130-159       Borderline high
 160-189       High
 190 or more   Very high
 To calculate 10-year cardiac risk for
 the patient, go to http://www.paml.com,
 click on testing information, and then
 on lipid calculator
LIPID PROFILE & LP-PLA2 (PLAC)LIPID2LIPID2Enzymatic, ELISA
Cholesterol                     mg/dL
 LT 200        Desirable
 200-239       Borderline high
 240 or more   High
Triglycerides                   mg/dL
 LT 150        Normal
 150-199       Borderline high
 200-499       High
 500 or more   Very high
HDL                             mg/dL
 LT 40         Low
 40-59         Within normal limits
 60 or more    High
 HDL Cholesterol greater than or equal
 to 60 mg/dL is considered to be a
 'negative' risk factor, serving to
 remove one risk factor from the total
 count.
LDL (calculated)                mg/dL
 LT 100        Optimal
 100-129       Near or above normal
 130-159       Borderline high
 160-189       High
 190 or more   Very high
 To calculate 10-year cardiac risk for
 the patient, go to http://www.paml.com,
 click on testing, then on ranges/
 algorithms, and then on lipid results.
LP-PLA2 (PLAC) 0-200            ng/mL
A new consensus panel recommends a cutoff
value of 200 ng/mL for Lp-PLA2 (PLAC). 
Patients at moderate or high risk for CVD 
based on ATPIII criteria who also have an 
Lp-PLA2 value GT 200 ng/mL should be shifted
from high to very high risk. This will lower
the LDL goal for these patients.
CARDIAC RISK ASSESSMENTCRABATCRABATEnzymatic, Hexokinase, FPIA, Neph
TitleDescriptorRangesUnits
CholesterolDesirableLT 200mg/dL
Borderline high200-239
High240 or more
TriglyceridesNormalLT 150mg/dL
Borderline high150-199
High200-499
Very high500 or more
HDLLowLT 40mg/dL
Within normal limits40-59
High60 or more
HDL Cholesterol greater than or equal to 60 mg/dL is considered to be a 'negative' risk factor, serving to remove one risk factor from the total count.
LDL (calculated)OptimalLT 100 mg/dL
Near or above normal100-129
Borderline high130-159
High160-189
Very high 190 or more
To calculate 10-year cardiac risk for the patient, go to http://www.paml.com, click on testing, then on ranges/ algorithms, and then on lipid results.
LDL/HDL RatioNo longer applicable or reported
CHO/HDL RatioNo longer applicable or reported
High Sensitivity CRPLow riskLT 1.0mg/L
Average risk1.0-3.0
High riskGT 3.0
Relative risk categories follow the recommendations of the American Heart Association and the CDC. Measurement of hsCRP should be done twice (averaging results), optimally two weeks apart, in metabolically stable patients. If the hsCRP level is GT 10 mg/L, the test should be repeated and the patient examined for non-cardiovascular sources of inflammation, such as infection.
Homocysteine4.0-12.0umol/L
Glucose0-2 days premature30-80mg/dL
0-2 days fullterm40-90
2 days-1 month60-105
Adult65-99
Pregnant65-94
ADA Diagnostic Categories for nonpregnant adultsImpaired fasting glucose100-125mg/dL
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
CHOLESTEROLCHOCHOLEnzymatic
TitleDescriptorRangesUnits
CholesterolDesirableLT 200mg/dL
Borderline High200-239
High240 or more
ELECTROPHORESIS, LIPOPROTEINLIPELPLIPELPElectrophoresis, Spectrometry
TitleDescriptorRangesUnits
Cholesterol125-200mg/dL
Triglycerides5-19 yearsLT 130mg/dL
GT 19 yearsLT 150 Normal
150-199 Borderline high
200-499 High
GT 499 Very high
ChylomicronsNormal
Beta Lipoproteins42.3-69.5%
Pre Beta Lipoprotiens2.0-31.2%
Alpha Lipoproteins15.1-39.9%
Appearance Clear
Interpretation
HEART LIPID PANEL RFLXHRTLIPHRTLIPEnzymatic, Elimination/Enzymatic
TitleDescriptorRangesUnits
Cholesterolmg/dL
DesirableLT 200
Borderline high200-239
High240 or more
Triglyceridesmg/dL
NormalLT 150
Borderline high150-199
High200-499
Very high500 or more
HDLmg/dL
LowLT 40
Within normal limits40-59
High60 or more
HDL Cholesterol greater than or equal to 60 mg/dL is considered to be a 'negative' risk factor, serving to remove one risk factor from the total count.
LDL (calculated)mg/dL
OptimalLT 100
Near or above normal100-129
Borderline high130-159
High160-189
Very high190 or more
To calculate 10-year cardiac risk for the patient, go to http://www.paml.com, click on testing information, and then on lipid calculator.
Cholesterol/HDL Ratio
FemaleLT 4.5
MaleLT 5.0
LDL Cholesterol, Directmg/dL
OptimalLT 100
Near or above normal100-129
Borderline high130-159
High160-189
CHROMATIN AUTOANTIBODY, IGGCHROMPCHROMPMultiplex Luminex
TitleDescriptorRangesUnits
Chromatin Autoantibody, IgGNegativeLT 1.0AI
Positive1.0 or more
CHROMIUM, WHOLE BLOODCHROMCHROMInductively Coupled Plasma/Mass Spectrometry
TitleDescriptorRangesUnits
Chromium, BloodNormal blood valuesLT 1.0mcg/L
CYTOGENETICS, CHROMOSOME ANALYSIS, AMNIOTIC FLUIDAFCYTOCytogenetics
Chromosome Analysis, Amniotic Fluid
 Separate Report to Follow
CYTOGENETICS, CHROMOSOME ANALYSIS, LEUKEMIC BLOODLBCYTOCytogenetics
Chromosome Analysis, Leukemic Blood
 Separate Report to Follow
CYTOGENETICS, CHROMOSOME ANALYSIS, PLEURAL OR ASCITES FLUIDPLCYTOCytogenetics
Chromosome Analysis, Plueral or Ascites Fluid
 Separate Report to Follow
CYTOGENETICS, CHROMOSOME ANALYSIS, SOLID TISSUESTICYTCytogenetics
Chromosome Analysis, Solid Tissue
 Separate Report to Follow
CYTOGENETICS, CHROMOSOME ANALYSIS, MOSIAC, SOLID TISSUEMOSTICytogenetics
Chromosome Analysis, Solid Tissue Mosiac
 Separate Report to Follow
CYTOGENETICS, CHROMOSOME ANALYSIS, SOLID TUMORSTUCYTCytogenetics
Chromosome Analysis, Solid Tumor Tissue
 Separate Report to Follow
CIMETIDINETAGTAGHPLC
TitleDescriptorRangesUnits
Cimetidine (Tagamet)Therapeutic0.5-1.5mcg/mL
CITALOPRAMCELEXCELEXLC-MS/MS
TitleDescriptorRangesUnits
CitalopramSteady-state serum or plasmalevels from patients on a daily regimen of 30-60 mg citalopram9-200ng/mL
CITRATE GEL ELECTROPHORESISCITGELCITGELGel Electrophoresis
Citrate Gel Electrophoresis, Interpretation
Citrate Gel Electrophoresis, Reviewed by
CK, MBCKMBCKMBEnzymatic, Chemiluminescence Assays
TitleDescriptorRangesUnits
CK (CPK) TotalU/L
Male55-400
Female30-240
CK-MB7.4 or lessng/mL
Relative IndexTo be used only if CK-MB and total CK (CPK) are elevated.3.0 or less%
CREATINE KINASE (CK)CPKCKEnzymatic
TitleDescriptorRangesUnits
CK (CPK)Female30-240U/L
Male55-400
CREATINE KINASE ISOENZYMESISOCKAISOCKAQuantitative Enzymatic/Electrophoresis
TitleDescriptorRangesUnits
CK Total0-19 yearsBy Report
Male 20+ years20-200UI/L
Female 20+ years20-180UI/L
CK-MM96-100%
CK-MB0-4%
CK-BB0-0%
CK-Macro Type I0-0%
CK-Macro Type II0-0%
CLONAZEPAMCLONCLONQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Clonazepamng/mL
Therapeutic dose (Adult) 1-8 mg/d20-70
ToxicGT 80
Adverse effects may include drowsiness, headache, fatigue, and ataxia
CLONIDINECLONIDINECLONIDLC-MS/MS
TitleDescriptorRangesUnits
Clonidine (Catapres)Therapeutic0.5-4.5ng/mL
BASIC HEALTH PANEL RFLXBHPANBHPAN
CMPD
LIPREF
CBCP2
UAXM
CMV (CYTOMEGALOVIRUS) AB, IGGCMVGLCMVGLCLIA
TitleDescriptorRangesUnits
CMV Ab, IgGNegative - No significant level of IgG Ab detectedLT 0.60U/mL
Equivocal - Repeat testing of a second sample in 1-014 days may be helpful to determine presence or absence of infection0.60-0.69
IgG Ab detected - May indicate a recent or past infection0.70 or greater
CMV AB, IGG, IGMCMVGMLCMVGMLCLIA
TitleDescriptorRangesUnits
CMV AB, IgGNegativeLT 0.60U/mL
CMV AB, IgMNegativeLT 30.0AU/mL
TORCH TEST, IGG,IGM RFLXTORGMLTORGMLCLIA, EIA, ICMA
TitleDescriptorRangesUnits
CMV Ab, IgGNegativeLT 0.60U/mL
Toxoplama Ab, IgGNegativeLT 7.2IU/mL
Rubella Ab, IgGNegativeLT 5.0IU/mL
HSV I Type Specific Ab, IgGNegativeLT 0.90IV
HSV II Type Specific Ab, IgGNegativeLT 0.90IV
CMV Ab, IgMNegativeLT 30.0AU/mL
Toxoplama Ab, IgMNegativeLT 8.0AU/mL
Rubella Ab, IgMNegativeLT 0.9Index
HSV Ab, IgMNegativeLT 0.91OD
TORCH IgG & IgM Interp
TORCH TEST, IGGTORGLTORGLCLIA, EIA, ICMA
TitleDescriptorRangesUnits
CMV Ab, IgGNegativeLT 0.60U/mL
Toxoplasma Ab, IgGNegativeLT 7.2IU/mL
Rubella Ab, IgGNegativeLT 5.0IU/mL
HSV I Type Specific Ab, IgGNegativeLT 0.90IV
HSV II Type Specific Ab, IgGNegativeLT 0.90IV
TORCH IgG Interp
CMV (CYTOMEGALOVIRUS) AB, IGMCMVMLCMVMLCLIA
TitleDescriptorRangesUnits
CMV Ab, IgMNegative - No detectable IgM AbsLT 30.0AU/mL
A negative result does not always rule out acute infection as the IgM response is not always detectable in very early is immunocompromised. If exposure to CMV is suspected a second sample should be collected and tested in 7-14 days.
Equivocal30.0-34.9
Repeat testing in 10-14 days may be helpful to determine presence or absence of infection.
Positive - IgM antibody detected35.0 or greater
A positive CMV IgM result is generally indicative of acute infection, reactivation or persistent IgM production.
TORCH TEST, IGM RFLXTORMLTORMLCLIA, EIA
TitleDescriptorRangesUnits
CMV Ab, IgMNegativeLT 30.0AU/mL
Toxoplama Ab, IgMNegativeLT 8.0AU/mL
Rubella Ab, IgMNegativeLT 0.9Index
HSV Ab, IgMNegativeLT 0.91OD
TORCH IgM Interp
CMV, QUAL (RT-PCR)CMVRTPCMVRTPReal-time PCR
TitleDescriptorRangesUnits
CMV Source
CMV DNA PCRNot Detected
CARBON DIOXIDECO2CO2Enzymatic
TitleDescriptorRangesUnits
CO20-10 days13-22mmol/L
0-10 days13-22
11 days-4 yrs20-28
5+ yrs22-31
COCCIDIOIDES AB (CF/ID)COCC.CFCOCCABSemi-Quantitative Complement Fixation
TitleDescriptorRangesUnits
Coccidioides Ab by CFNo antibody detectedLT 1:2Titer
COCCIDIOIDES ABS PANEL, CSFCOC.AB-CSFCOCPSFCF, ELISA, ID
TitleDescriptorRangesUnits
Coccidioides Ab, CSF by CFNo Antibody DetectedLT 1:2
Coccidioides Ab, CSF, IgGIV
Negative - No significant level of Coccidioides IgG Ab detected0.9 or less
Equivocal - Questionable presence of Coccidioides IgG AB detected. Repeat testing in 10-14 days may be helpful1.0-1.4
Positive - Presence of IgG Ab to Coccidioides detected, suggestive of current or past infection1.5 or more
Coccidioides Ab, IgM, CSFIV
Negative - No significant level of Coccidioides IgM Ab detected0.9 or less
Equivocal - Questionable presence of Coccidioides IgM Ab detected. Repeat testing in 10-14 days may be helpful1.0-1.4
Positive - Presence of IgM Ab to Coccidioides detected, suggestive of current or past infection1.5 or more
Coccidioides Ab, CSF by IDNone detected
COCCIDIOIDES AB, IGG, IGMCOCABCOCABELISA
TitleDescriptorRangesUnits
Coccidioides Ab, IgGNegative-no significant level of Coccidioides IgG Ab detected0.9 or lessIV
Equivocal-Questionable presence of Coccidioides IgG Ab detected. Repeat testing in 10-14 days may be helpful1.0-1.4
Positive-Presence of IgG Ab Coccidiodes detected, suggestive of current or past infection. IgG Abs usually appear by the third week of infection and may persist for years. Both tube precipitin (TP) and CF antigens are represented by the ELISA tests1.5 or greater
Coccidioides Ab, IgMNegative-No significant level of Coccidioides IgM Ab detected0.9 or lessIV
Equivocal-Questionable presence of Coccidioides IgM Ab detected. Repeat testing in 10-14 days may be helpful1.0-1.4
Positive-Presence of IgM Ab to Coccidioides detected, suggestive of current or past infection. In most symptomatic patients, IgM Abs usually appear by the second week of infection and disappear by the fourth month. Both tube precipitin (TP) and CF antigens are represented in the ELISA tests1.5 or greater
Note: Negative fungal serology does not rule out the possibility of current infection.
OPIATE COMPLIANCE PANEL 7CPOP7CPOP7Tandem Mass Spectrometry
TitleDescriptorRangesUnits
CodeinePositive cutoff50ng/mL
MorphinePositive cutoff50ng/mL
HydrocodonePositive cutoff50ng/mL
HydromorphonePositive cutoff50ng/mL
OxycodonePositive cutoff50ng/mL
OxymorphonePositive cutoff50ng/mL
6 MAM (Heroin Metabolite)Positive cutoff10ng/mL
COLLAGEN TYPE II ABCT2ABICT2ABIELISA
TitleDescriptorRangesUnits
Collagen Type II AntibodiesNegativeLT 20EU/mL
Borderline20-25
Equivocal
PositiveGT 25
Anti-collagen II Abs occur in 22% of patients with idiopathic SNHL, 30% of patients with sudden deafness and 20% of patients with Meniere's disease. Anti-collagen II antibodies also occur in patients with relapsing poly-chondritis and in rheumatoid arthritis.
This test was developed and its performance characteristics determined by IMMCO. It has not been cleared or approved by the U.S. Food and Drug Administration.
MERCURY, URINE 24HRHGUQTHGUQTQuantitative Inductively Coupled Plasma-Mass Spectrometry
Collect Time,                               hr
Total Volume,                               mL
Creatinine,                                 mg/dL
Creatinine,Urine                            mg/d
3-8 yrs         M   140-700       F  140-700
9-12 yrs        M   300-1300      F  300-1300
13-17 yrs       M   500-2300      F  400-1600
18-50 yrs       M   1000-2500     F  700-1600
51-80 yrs       M   800-2100      F  500-1400
81 yrs +        M   600-2000      F  400-1300
Mercury, Urine      0-10                         ug/L
Mercury, Urine      0-15                         ug/day
Mercury, Urine per gm creatinine   35 or less    ug/g CRT
PROTEIN, URINE 24HRPRO-UPROUQPColorimetric
Collection Period                    h
Volume                               mL
Protein, Urine
 50-80   At Rest                     mg/24h
 LT 250  Following intense exercise  
Protein/Creatinine Ratio     LT 0.2  Ratio
PROTEIN, URINE 12HRPRO-U.12PROUQ1Colorimetric
Collection Period                   h
Volume                              mL
Protein, Urine
 No normals established for 12 hr   mg/12h
Protein/Creatinine Ratio   LT 0.2   Ratio
MICROALBUMIN, URINE 24HRM.ALBMALBUQImmunoturbidimetric
Collection Period               h
Volume                          mL
Microalbumin, Urine             mg/L
 LT 18
Microalbumin, Excretion Rate    ug/min
 0-20
Microalbumin, 24h Excretion     mg/24h
 0-30
PHOSPHORUS, URINE 24HRPHO-UPHOSUQColorimetric
Collection Period               h
Volume                          mL
Phosphorus, Urine  400-1300     mg/24h
POTASSIUM, URINE 24HRPOT-UKUQISE
Collection Period             h
Volume                        mL
Potassium, Urine  25-125      mmol/24h
MAGNESIUM, URINE 24HRMAG-UMGUQColorimetric
Collection Period          h
Volume                     mL
Magnesium, Urine   72-120  mg/24h
CREATINE, URINE 24HRCREATINE-UCRTUQEnzymatic, Colorimetric
TitleDescriptorRangesUnits
Collection Periodh
VolumemL
Creatine, Urinemg/24h
Male6-56
Female8-170
Creatinine, Urineg/24h
3-8 years0.11-0.68
9-12 years0.17-1.41
13-17 years0.29-1.87
18+ years0.63-2.50
HEAVY METALS, URINE 24HRHVY-UHMUQElectrothermal (Flameless) AAS and Mercury Hydride
TitleDescriptorRangesUnits
Collection Periodh
VolumemL
Lead, Urineug/L
Lead, Urineug/24h
NormalLT 80
Inconclusive80-125
AbnormalGT 125
Up to 125 ug/24h is probably not associated with lead poisoning.
Mercury, Urineug/L
Mercury, Urineug/24h
Non-exposedLT 20
Potentially toxicGT 150
Arsenic, Urineug/L
Arsenic, Urine5-50ug/24h
LEAD, URINE 24HRLEAD-UPBUQElectrothermal (Flameless) AAS
TitleDescriptorRangesUnits
Collection Periodh
VolumemL
Lead, Urineug/L
Lead, Urineug/24h
NormalLT 80
Inconclusive80-125
ToxicGT 125
Urine lead up to 125 is probably not associated with lead poisoning.
MERCURY, URINE 24HRMERC-UHGUQMercury Hydride AAS
TitleDescriptorRangesUnits
Collection Periodh
VolumemL
Mercury, Urineug/L
Mercury, Urineug/24h
Non ExposureLT 20
Inconclusive20-150
Potentially ToxicGT 150
The concentration of mercury at which toxicity is expressed is widely variable among patients. 50 ug/24h is the lowest concentration at which toxicity may be apparent.
VMA, URINE 24HRVMAVMAUQHPLC/Electrochemical Detection
TitleDescriptorRangesUnits
Collection Periodh
VolumemL
VMA, Urineug/mg Cr
0-1 years6.0-24.0
1-8 years2.6-16.0
9-16 years2.0-12.0
17-110 years1.5-7.0
FORMIC ACID, URINE 24HRFORM-UFAUQGC/Colorimetry
TitleDescriptorRangesUnits
Collection Periodh
VolumemLs
Creatinine, Urine
U.S. population (10th-90th percentiles, median)
All participantsmedian 1180 (n=22,245)335-2370mg/L
Malesmedian 1370 (n=10,610)495-2540mg/L
Femalesmedian 994 (n=11,635)273-2170mg/L
Formic Acid, Urine5-36g/mL
Normal range for 95% of population
Formic Acid, Urine
Occupational exposure thresholdmg/gCr
Following exposure to methanol80 mg formic acid/g creatinine collected before the shift at the end of the workweek
FAT, FECAL QUANTITATIVEFATQNTFATQNTNuclear Magnetic Resonance Spectrometry
TitleDescriptorRangesUnits
Collection Periodhr
Fecal Total Weightg
Fecal Fats
0-5 years0.0-2.0g/24h
6+ years0.0-6.0
FECAL LYTES/OSMOLALITY PROFILEFCELOSFCELOSQuantitative Ion-Selective Electrode/Freezing Point
Collection time     hr
Fecal weight        g
Fecal Magnesium     0-110   mg/dL
Fecal Magnesium     0-355   mg/d
Fecal Sodium        Reference interval not established   mmol/L
Fecal Potassium     Reference interval not established   mmol/L
Calculated Osmolality, Fecal   mOsm/kg
Osmolal Gap                    mOsm/kg
Osmolality, Fecal    280-303   mOsm/kg
BENCE JONES PROTEIN, UR 24HRBJKLQBJKLQQualitative Immunofixation Electrophoresis/Quantitative Nephelometry
TitleDescriptorRangesUnits
Collection Timehr
Total VolumemL
Total Protein10-140mg/d
Albumin, UrineDetected
Alpha-1, UrineNone detected
Alpha-2, UrineNone detected
Urine Beta GlobulinNone detected
Gamma, UrineNone detected
Free Urinary Kappa Light Chains0.14-2.42mg/dL
Free Urinary Kappa Excretion/daymg/d
Free Urinary Lambda Light Chainsmg/dL
Free Urinary Lambda Excretion/day0.02-0.67mg/dL
Free Urinary Kappa/Lambda Ration2.04-10.37ratio
IFE Interpretation
Total urinary protein is determined nephelometrically by adding the albumin and kappa and/or lambda light chains. This value may not agree with the total protein as determined by chemical methods, which characteristically underestimate urinary light chains.
GENERAL HEALTH PANELGHPNAGHPNA
Comprehensive Metabolic Panel
CBC
TSH
GENERAL HEALTH PANEL RFLXGHPNARGHPNAR
Comprehensive Metabolic Panel
CBC
TSH (Reflex)
CHEMISTRY RFLXCHEMRACHEMRA
Comprehensive Metabolic Panel
Lipid Profile
TSH (Reflex)
DEXAMETHASONE SUPPRESSION, RANDST1DST1ICMA
Cortisol  ug/dL
Normal patients suppress their cortisol levels to LT 5.0
CORTISOL STIMULATION TESTCOR-STIMCSTICMA
TitleDescriptorRangesUnits
Cortisol BaselineAM Sample4.3-22.4ug/dL
PM Sample3.0-16.0
Time Drawn
Cortisol Post-Stimug/dL
Normal peak serum cortisol is GT 20 ug/dL, 30 to 60 minutes after 25 units cosyntropin IV.
Time Drawn
CORTISOL STIMULATION (3 SPEC)COR-STIM2CST3ICMA
TitleDescriptorRangesUnits
Cortisol Baselineug/dL
AM Sample4.3-22.4
PM Sample3.0-16.0
Time Drawn
Cortisol, Post #1ug/dL
Time Drawn
Cortisol, Post #2ug/dL
Normal peak serum cortisol is GT 20 ug/dL, 30 to 60 minutes after 25 units cosyntropin IV.
Time Drawn
DEXAMETHASONE SUPPRESSION TESTDST2DSTICMA
Cortisol Pre Suppression        ug/dL
 4.3-22.4                       
Time Drawn
Cortisol Post Suppression       ug/dL
 Normal patients suppress their        
 cortisol levels to LT 5.0 g/dL.
Time Drawn
DEXAMETHASONE SUPPRESSION (X4)DST4DST4ICMA
TitleDescriptorRangesUnits
Cortisol Pre-Suppression ug/dL
4.3-22.4
Time Drawn
Cortisol Post-Suppression #1 ug/dL
Normal patients suppress their
cortisol levels to LT 5.0.
Time Drawn
Cortisol Post-Suppression #2 ug/dL
Time Drawn
Cortisol Post-Suppression #3 ug/dL
Time Drawn
DEXAMETHASONE SUPPRESSION (X3)DST3DST3ICMA
TitleDescriptorRangesUnits
Cortisol Pre-Suppression ug/dL
4.3-22.4
Time Drawn
Cortisol Post-Suppression #1 ug/dL
Normal patients suppress their
cortisol levels to LT 5.0
Time Drawn
Cortisol Post-Suppression #2 ug/dL
Time Drawn
CORTISOL, RANDOMCORRANCORRANICMA
TitleDescriptorRangesUnits
Cortisol, Random3.0-22.4ug/dL
The reference ranges for Cortisol are dependent on the time of draw.
CortisolAM4.3-22.4ug/dL
CortisolPM3.0-16.0ug/dL
CORTISOL, SALIVA (LCMSMS)CORTSLCORTSLLiquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Cortisol, Salivary8-10 AM0.04-0.56mcg/dL
4-6 PMLT or = 0.15mcg/dL
10-11 PMLT or = 0.09mcg/dL
CORTISOL, FREE, SERUMFCORTSFCORTSEquilibrium Dialysis/Quantitative Electrochemiluminescent Immunoassay
TitleDescriptorRangesUnits
Cortisol, Serum Freeug/dL
8-10 AM0.31-1.19
4-6 PM0.15-0.94
CORTISOL PAIRED SPECIMENSCOR-2CORPICMA
TitleDescriptorRangesUnits
CortisolAM4.3-22.4ug/dL
CortisolPM3.0-16.0ug/dL
CREATINE, SERUM OR PLASMAKREATSKREATSLiquid Chromatography/Tandem Mass Spectrophotometry
TitleDescriptorRangesUnits
Creatine10 years or less37.0-117.0umol/L
11 years or greater9.0-90.0
CREATININE, AMNIOTIC FLUIDCRE.ACREAFEnzymatic (IDMS Traceable)
Creatinine Amniotic Fluid    mg/dL
 Amniotic fluid creatinine increases with gestational age.
5-HIAA, URINE RANDOMHIAURHIAURHPLC/Electro Det/Enzymatic (IDMS traceable)
TitleDescriptorRangesUnits
Creatinine, Urine Random19-311mg/dL
5-HIAA, Urine RandomNo reference range establishedmg/L
5-HIAA, Urine Random3-8 years1.2-16.2mg/gCr
9-12 years2.4-8.7
13-17 years1.8-5.5
Adults1.3-6.9
Please note: A 24-hr urine collection is the preferred specimen. These reference ranges for random urine collections are based on literature review.
CATECHOLAMINES, URINE RANDOMCATEURCATEURHPLC/Enzymatic (IDMS Traceable)
TitleDescriptorRangesUnits
Creatinine, Urine Random19-311mg/dL
Epinephrine, Urine RandomNo reference range establishedug/L
Epinephrine (Calculation)ug/gCr
0-1 years0-375
2-4 years0-82
5-10 years0-93
11-Adults9-58
Norepinephrine, Urine RandomNo reference range establishedug/L
Norepinephrine (Calculation)ug/gCr
0-1 year25-310
2-4 years25-390
5-10 years27-108
11-Adults4-105
Dopamine, Urine RandomNo reference range establishedug/L
Dopamine (Calculation)ug/gCr
0-1 year240-1290
2-4 years80-1220
5-10 years220-720
11-Adults120-450
Please note: A 24-hr urine collection is the preferred specimen. These reference ranges for random urine collections are based on literature review.
METANEPHRINES, URINE (RANDOM)METAURMETAURHPLC/Electro Det/Enzymatic (IDMS traceable)
TitleDescriptorRangesUnits
Creatinine, Urine Random19-311mg/dL
Metanephrine, Urine RandomNo reference range establishedmg/L
Metanephrine, Urine Randomug/gCr
3-8 years47-240
9-12 years40-220
13-17 years33-145
Adults31-140
NormetanephrineNo reference range establishedmg/dL
Normetanephrineug/gCr
3-8 years62-705
9-12 years81-583
13-17 years95-375
Adults47-310
Total MetanephrinesNo reference range establishedmg/dL
Patients on Buspirone therapy will show falsely elevated metanephrine levels.
Please note: A 24-hr urine collection is the preferred specimen. These reference ranges for random urine collections are based on literature review.
ORGANIC ACIDS, URINEORAURAORAURAGas Chromatography/Mass Spectrometry
TitleDescriptorRangesUnits
Creatinine, Urinemg/dL
Organic Acids, Urine InterpretationNormal
Lactic Acid, Ur0-1 mo0-160mmol/molCRT
1 mo-12 yr0-150
12 yrs+0-50
Pyruvic Acid, Ur0-1 mo0-50mmol/molCRT
1 mo-12 yr0-30
12 yrs+0-15
Succinic Acid, Ur0-1 mo0-125mmol/molCRT
1 mo-12 yr0-80
12 yrs+0-20
Fumaric Acid, Ur0-1 mo0-14mmol/molCRT
1 mo-12 yr0-10
12 yrs+0-4
2-Ketoglutaric Acid, Ur0-1 mo0-525mmol/molCRT
1 mo-12 yr0-120
12 yrs+0-75
Methylmalonic Acid, Ur0-1 mo0-5mmol/molCRT
1 mo-12 yr0-5
12 yrs+0-5
3-OH-Butyric Acid, Ur0-1 mo0-10mmol/molCRT
1 mo-12 yr0-4
12 yrs+0-4
Acetoacetic Acid, Ur0-1 mo0-4mmol/molCRT
1 mo-12 yr0-4
12 yrs+0-4
2-Keto-3-methylvaleric Acid, Urine0-1 mo0-10mmol/molCRT
1 mo-12 yr0-10
12 yrs+0-10
2-Ketoisocaproic Acid Urine0-1 mo0-5mmol/molCRT
1 mo-12 yr0-4
12 yrs+0-4
2-Ketoisovaleric Acid Urine0-1 mo0-5mmol/molCRT
1 mo-12 yr0-4
12 yrs+0-4
Ethylmalonic Acid, Urine0-1 mo0-10mmol/molCRT
1 mo-12 yr0-15
12 yrs+0-4
Adipic Acid, Urine0-1 mo0-35mmol/molCRT
1 mo-12 yr0-35
12 yrs+0-35
Suberic Acid, Urine0-1 mo0-10mmol/molCRT
1 mo-12 yr0-10
12 yrs+0-3
Sebacic Acid, Urine0-1 mo0-10mmol/molCRT
1 mo-12 yr0-3
12 yrs+0-3
4-OH-phenylactic Acid, Urine0-1 mo0-150mmol/molCRT
1 mo-12 yr0-100
12 yrs+0-25
4-OH-phenyllactic Acid, Urine0-1 mo0-20mmol/molCRT
1 mo-12 yr0-4
12 yrs+0-4
4-OH-phenylpyruvic Acid, Urine0-1 mo0-20mmol/molCRT
1 mo-12 yr0-2
12 yrs+0-2
Succinyl-acetone, Urine0-1 mo0-0mmol/molCRT
1 mo-12 yr0-0
12 yrs+0-0
PHENOL EXPOSURE, (QUANTITATIVE)PHEXPUPHEXPUGC, Colorimetry
TitleDescriptorRangesUnits
Creatinine, Urinemg/L
U.S. population (10th-90th percentiles, median)
All participantsmedian 1180 (n=22,245)335-2370mg/L
Malesmedian 1370 (n=10,610)495-2540mg/L
Femalesmedian 994 (n=11,635)273-2170mg/L
Phenol, Urinemg/L
In unexposed individualsLT 10mg/L
When chronically exposed to 0.5-4.0 ppm Benzene in airLT 30mg/L
Average during chronic exposure to 25 ppm Benzene in air200mg/L
Phenol, Urinemcg/gCR
Biological exposure index for monitoring exposure to phenol250 mg total phenol/g creatinine measured in an end of shift specimen
ARS, INORGANIC, UR (SPECIATED)ARTISUARTISUICP/MS, Colorimetric
TitleDescriptorRangesUnits
Creatinine, UrACGIH Normal adult range300-3400mg/L
Arsenic, Total Inorganic, Urmeausred in the end of work week specimen-ACGIH35ug/L
Arsenic, Totalug/gCr
Inorganic, Ur (Creatinine corrected)
Various states require that levels above certain cutoffs must be reported to the state in which the patient resides.
CRYPTOCOCCUS AB, CSFCRYPTO.AB.CSFCRYPSFImmunofluorescence Assay
TitleDescriptorRangesUnits
Cryptococcus Ab, IFATiter
Antibody Not DetectedLT 1:1
Antibody DetectedGT or = 1:1
Diagnosis of infections of the central nervous system can be accomplished by demonstrating the presence of intrathecally-produced specific Ab. However, interpretation of results is complicated by low Ab levels found in CSF, passive transfer of Ab from blood, and contamination via bloody taps.
CULT E COLI 0157/SHIGA RFLXCECSTCECSTCulture and Enzyme Immunoassay
Culture, E.coli 0157 with Shiga Toxin Report
Culture, E.coli 0157 with Shiga Toxin Status
CULTURE ESBL CONFIRMATIONCESBLSCESBLSDisk diffusion
Culture, ESBL Confirmation Report
Culture, ESBL Confirmation Report Status
CULTURE STOOL/YER/SHIGA RFLXCSTLYSCSTLYSCulture and Enzyme Immunoassay
Culture, Stool with Yersinia & Shiga Toxin, Result
Culture, Stool with Yersinia & Shiga Toxin, Status
CULTURE MYCOPLASMA/UREAPLASMACURMYCURMYCulture
Culture, Ureaplasma urealyticum/Mycoplasma hominis Result
Culture, Ureaplasma urealyticum/Mycoplasma hominis Status
CONNEXIN 26 CODING RGNCON26CON26Nucleic Acid Probe/Fluorescence Signal Amplification/Polymerase Chain Reaction/Sequencing
CX26SEQ Specimen
Connexin 26, Full Gene Sequencing
CYANIDECYANIDECYANIDQuantitative Colorimetric
TitleDescriptorRangesUnits
Cyanideug/mL
Non-smokersLT 20
SmokersLT 40
Toxic LevelGT 100
CYCLIC CITRULLINE PEP AB, IGGCCPABGCCPABGEIA
TitleDescriptorRangesUnits
Cyclic Citrullinated Peptide Ab, IgGNegativeLT 20Units
Weak positive20-39
Moderate positive40-59
Strong positive60 or greater
Approximately 70% of patients with RA are positive for CCP IgG, while only 2% of random blood donors and disease controls are positive. The diagnostic value of antibodies to CCP in juvenile rheumatoid arthritis patients has not been determined.
CYCLOSPORINE, HEART TRANSPLANTCYCLO.WB.TDXCYCTDXCMIA
TitleDescriptorRangesUnits
Cyclosporine TDXTherapeutic trough150-250ng/mL
ToxicGT 600
CYTOCHROME P450 2C9CP450ACP450APolymerase Chain Reaction/DNA Hybridization/Electrochemical Detection
CYP 2C9 Specimen
CYP2CP Allele 1
CYP2CP Allele 2
CYP2CP Gene Mutation Interp
CYTOCHROME P450 CYP2D6CYP2D6CYP2D6Polymerase Chain Reaction (PCR), Single Nucleotide Primer Extension Reaction (SNP-IT)
CYP2D6 Result
CYSTATIN CCYSTCGCYSTCGNephelometry
TitleDescriptorRangesUnits
Cystatin C0.53-0.95mg/L
Estimated Glomerular Filtration RateChronic kidney disease, if over a 3 month periodLT 60mL/min/1.73m2
Kidney FailureLT 15
CYSTIC FIBROSIS SCREEN RFLXCFSCRACFSCRAPolymerase Chain Reaction (PCR) and Oligonucleotide Ligation Assay (OLA)
Cystic Fibrosis Carrier Screen or Diagnosis,   
 Interpretation and Comments
CYSTICERCOSIS AB, IGG, CSFCYSGCFCYSGCFELISA
Cysticercosis Antibody IgG, CSF    OD
 0.34 or less Negative-no significant
 level of cysticercosis IgG antibody
 detected.
 0.35-0.50    Equivocal-questionable
 presence of cysticercosis IgG. Repeat
 testing in 10-14 days may be helpful.
 0.51 or more Positive-IgG antibody
 detected, which may suggest current
 or past infection.
 Diagnosis of central nervous system
 infections can be accomplished by
 demonstrating the presence of intrathe-
 cally produced specific antibody. 
 Interpretation of results may be
 complicated by low antibody levels
 found in CSF, passive transfer of
 antibody from blood, and contamination
 via bloody taps.
MICROARRAY, PRENATALSNPAFSNPAFGenomic Microarray (oligo- and SNP-based array)
Cytogenomic SNP Microarray   Result/Interpretation
MICROARRAY, POCSNPPOCSNPPOCGenomic Microarray (oligo- and SNP-based array)
Cytogenomic SNP Microarray   Result/Interpretation
DENGUE FEVER VIRUS AB, IGG, IGMDENGUEDENGUESemi-Quantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Dengue Fever Virus Antibody, IgGIV
Negative. No significant level of detectable Dengue Fever Virus IgG Ab.1.64 or less
Equivocal. Questionable presence of Abs.Repeat testing in 10-14 days may be helpful.1.65-2.84
Positive. IgG Ab to Dengue Fever Virus detected which may indicate a current or past infection.2.85 or more
Dengue Fever Virus Ab, IgMIV
Negative. No significant level of detectableDengue Fever Virus IgM Ab.1.64 or less
Equivocal. Questionable presence of Antibody. Repeat testing in 10-14 days may be helpful.1.65-2.84
Positive. IgM Ab to Dengue Fever Virus detected which may indicate a current or recent infection. The best evidence for current infection is a significant change on two appropriately timed specimens where both tests are done in the same laboratory at the same time.2.85 or more
HSV IGG 1 AND 2 (IMMBLOT)HSVB12HSVB12Immunoblot
Descriptor
Negative for antibody to HSV 1 and HSV 2 by Immunoblot. No evidence of past infection with HSV 1 or 2. Individuals infected with HSV may not exhibit detectable IgG Ab to glycoprotein G in the early stages of infection and 5-10% of infections may occur with glycoprotein G-deficient virus.
Detection of antibody presence in these cases may only be possible using a non-type, specific screening test. All results from this and other serologies must be correlated with clinical history, epidemiological data, and other date available to the attending physician in making the differentiation between HSV type 1 and HSV type 2 infection.
ANA TITER (IFA)IFANAIFANAIFA
DescriptorRange
ANA by IFA TiterLT 1:40 Titer
ANA by IFA Pattern
BILIRUBIN, NEONATALNBILNBILSpectrophotometric (diazonium salt)
DescriptorRangeUnits
0-30 days< 11.7mg/dL
Critical Value (Neonates)> or = 12.0mg/dL
B-TYPE NATRIURETIC PEPTIDEBTNPBNPEPRICMA
DescriptorRangeUnits
B-Type Natriuretic PeptideLT 100pg/mL
ANTI-THYROID PEROXIDASE ANTIBODY (TPOAB)TPOABUTPOABURIA
DescriptorRangeUnits
TPO-ABLT 1.0IU/mL
HEMOGLOBIN A1CGLHBGLHBIon-Exchange Chromatography Quantitative
DescriptorRangesUnits
18+ years4.0-6.0%
CALCITONINCALCTNCALCTNImmunoassay
DescriptorRangesUnits
Adult MalesLT or = 10pg/mL
Adult FemalesLT or = 5pg/mL
Children (Males and Females)
Less than 6 monthsLT or = 41pg/mL
6 months - 3 yearsLT or = 14pg/mL
3 - 17 yearsLT or = 6pg/mL
BILIRUBIN, DIRECTDBILDBILColorimetric
DescriptorRangesUnits
Bilirubin, Direct0.0-0.4mg/dL
BUNBUNBUNEnzymatic
DescriptorRangesUnits
BUN (UREA)8-25mg/dL
BILIRUBIN, FLUIDBILFLBILFLColorimetric
DescriptorUnits
Bilirubin, Fluidmg/dL
No reference range established.
Method not validated for this fluid.
Clinical correlation necessary.
DIAZEPAM AND NORDIAZEPAMVALIUMDIAZQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Diazepam (Valium)Therapeutic - Based on normal dosages0.2-1.0ug/mL
NordiazepamTherapeutic - Based on normal dosages0.1-1.5ug/mL
ToxicGT 2.5
DIFFERENTIAL, MANUALDIF.ADAMDIF2Microscopic
TitleDescriptorRangesUnits
Differential
Segs%
0-1 day33-70
1-7 days15-50
7-30 days15-45
1-12 months15-70
1-4 years25-70
4-10 years30-70
10-14 years25-70
14-18 years30-70
18+ years38-70
Segs, AbsK/uL
0-1 day3.00-12.00
1-7 days2.00-6.00
1 wk-1 yr1.50-5.00
1-4 years1.50-7.50
4-10 years1.80-7.00
10-18 years1.50-7.00
18+ years1.80-7.70
Bands%
0-18 years0-9
18+ years0-8
Bands, AbsK/uL
0-1 day0.00-1.50
1-7 days0.00-1.20
7-30 days0.00-0.50
1-12 months0.00-0.40
1-4 years0.00-0.30
4-10 years0.00-0.20
10-18 years0.00-0.20
Lymphocytes%
0-1 day10-35
1-7 days15-70
1 week-4 years30-70
4-6 years20-70
6-10 years20-50
10-18 years20-40
19+ years15-48
Lymphocytes, AbsK/uL
0-1 day2.00-11.00
1-7 days2.00-7.00
7-30 days3.00-7.00
1-12 months1.50-8.50
1-4 years1.50-5.00
4-10 years1.20-5.00
10-18 years1.10-4.50
19+ years1.00-3.90
Variant Lymph0-6%
Variant Lymphs, AbsK/uL
Monocytes%
0-18 years0-10
18+ years3-11
Monocytes, AbsK/uL
0-1 day0.00-1.10
1-7 days0.00-0.90
7-30 days0.00-0.60
1-12 months0.00-0.50
1-4 years0.00-0.50
4-10 years0.00-0.40
10-18 years0.00-0.90
18+ years0.00-0.80
Eosinophils%
0-18 years0-4
18+ years0-7
Eosinophils, AbsK/uL
0-1 day0.00-0.40
1-7 days0.00-0.50
7 days-1 year0.00-0.30
1-10 years0.00-0.30
10-18 years0.00-0.20
18+ years0.00-0.50
Basophils%
1-18 years0-1
18+ years0-2
Basophils, AbsK/uL
0-7 days0.00-0.10
1 week-4 years0.00-0.01
4-18 years0.00-0.01
18+ years0.00-0.20
Metamyelocytes%
Myelocytes%
Promyelocytes%
Blast Cells%
Other%
NRBC/100WBC
Meg Frag/100WBC
RBC Morph
WBC Morph
Platelet Morph
Cells Counted
DIGITOXINDGTXNDGTXNQuantitative CEDIA Immunoassay
TitleDescriptorRangesUnits
Digitoxinng/mL
Therapeutic10.0-32.0
ToxicGT 35.0
DIGOXINDIGDIGICMA
TitleDescriptorRangesUnits
Digoxinng/mL
Therapeutic0.8-2.0
ToxicGT 2.5
Increased risk of Digoxin toxicity at levels GT 2.0 ng/mL, with a wide zone of concentrations that may be toxic in one individual and not in another. The risk is greater with CHD and with decreases in Potassium, Calcium and Magnesium. Digoxin distribution phase complete after 8-15 hours.
HYDROMORPHONE, FREEHYDRMEHYDRMELiquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Dihydrocodeine/Hydrocodol - FreeAdult therapeutic range72-150ng/mL
Hydrocodone - FreeAdult therapeutic range6-29ng/mL
Hydromorphone - FreeAdult therapeutic range5-20ng/mL
OPIATES - FREE (UNCONJUGATED) SERUM/PLASMAOPIFUSOPIFUSGas Chromatography/Mass Spectrometry
TitleDescriptorRangesUnits
Dihydrocodeine/Hydrocodol Freeng/mL
Usual therapeutic range50-100ng/mL
Codeine Freeng/mL
Therapeutic range30-120ng/mL
Morphine Freeng/mL
Chronic pain patients receiving an average of 90 mg (range 20-1460) daily oral morphine had average serum concentrations of 73 ng/mL (range 13-170) morphine.
Hydrocodone Freeng/mL
Following a single 10 mg oral doseUp to 39ng/mL
6-Monacetylmorphine Freeng/mL
Hydromorphone Freeng/mL
Peak plasma concentrations ranged from 18-27 ng/mL (mean 22 ng/mL) one hour after a 4 mg oral dose.
Oxycodone Freeng/mL
Peak plasma concentrations 1 hour after a single ng/mL immediate-release tablet preparation containing 5 mg of Oxycodone9-38ng/mL
Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone13-46ng/mL
Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation39-100ng/mL
Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.
Oxymorphone Freeng/mL
ANTI CONVULSANT PROFILECONV-PANCONVICMA
TitleDescriptorRangesUnits
DilantinTherapeutic10.0-20.0ug/mL
ToxicGT 25.0
PhenobarbitalTherapeutic15.0-40.0ug/mL
ToxicGT 50.0
HUMORAL IMMUNITY PANEL 1HUMIMMHUMIMMQuantitative Nephelometry/Semi-Quantitative Multiplex Bead Assay
TitleDescriptorRangesUnits
Diphtheria Ab, IgGAntibody concentration of GT 0.1 is usually considered protectiveIU/mL
Tetanus Ab, IgGAntibody concentration of GT 0.1 is usually considered protectiveIU/mL
Pneumococcal Serotype 1, IgGug/mL
Pneumococcal Serotype 3, IgGug/mL
Pneumococcal Serotype 4, IgGug/mL
Pneumococcal Serotype 5, IgGug/mL
Pneumococcal Serotype 6B, IgGug/mL
Pneumococcal Serotype 7F, IgGug/mL
Pneumococcal Serotype 8, IgGug/mL
Pneumococcal Serotype 9N, IgGug/mL
Pneumococcal Serotype 9V, IgGug/mL
Pneumococcal Serotype 12F, IgGug/mL
Pneumococcal Serotype 14, IgGug/mL
Pneumococcal Serotype 18C, IgGug/mL
Pneumococcal Serotype 19F, IgGug/mL
Pneumococcal Serotype 23F, IgGug/mL
Pneumococcal Serotype Interpretation
All serotypes tested are present in the 23-valent pure polysaccharide pneumococcal vaccine. Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F are contained in the conjugated pneumococcal vaccine. Long-term protection is generally thought to be associated with a 1 month vaccine response of at least 1 ug/mL in children and adults.
Responder status is determined once reaching the minimum level of 1 ug/mL according to the ratio of postvaccianation to prevaccination concentration of pneumococcal IgG antibody as follows:
A ratio of LT two-fold is considered a non-responder.
A ratio of two-to-four-fold is a weak responder.
A ratio of fourfold is a good responder.
IgA0-30 days1-7mg/dL
1 month1-53
2 months3-47
3 months5-46
4 months4-72
5 months8-83
6 months8-67
7-8 months11-89
9-11 months16-83
1 year14-105
2 years14-122
3 years22-157
4 years25-152
5-7 years33-200
8-9 years45-234
10+ years68-378
IgG0-30 days611-1542mg/dL
1 months241-870
2 months198-577
3 months169-558
4 months188-536
5 months165-781
6 months206-676
7-8 months208-868
9-11 months282-1026
1 year331-1164
2 years407-1009
3 years423-1090
4 years444-1187
5-7 years608-1229
8-9 years584-1509
10+ years68-1632
IgM0-30 days0-24mg/dL
1 month19-83
2 months16-100
3 months23-85
4 months26-96
5 months31-103
6 months33-97
7-8 months32-120
9-11 months39-142
1 year41-164
2 years46-160
3 years45-190
4 years41-186
5-7 years46-197
8-9 years49-230
10+ years60-263
IgG Subclass 1Cord blood435-1084mg/dL
0-2 months218-498
3-5 months143-394
6-8 months190-388
9-23 months288-880
2 years170-950
3-4 years290-1065
5-6 years330-1065
7-8 years225-1100
9-10 years390-1235
11-12 years380-1420
13-14 years165-1440
IgG Subclass 2Cord blood143-453mg/dL
0-2 months40-167
3-5 months23-147
6-8 months37-60
9-23 months30-327
2 years22-440
3-4 years28-315
5-6 years57-345
7-8 years42-375
9-10 years61-430
11-12 years73-455
13-14 years71-460
15+ years124-549
IgG Subclass 3Cord blood27-146mg/dL
0-2 months4-23
3-5 months4-70
6-8 months12-62
9-23 months13-82
2 years4-69
3-4 years4-71
5-6 years8-126
7-8 years9-107
9-10 years10-98
11-12 years16-194
13-14 years12-178
15+ years21-134
IgG Subclass 4Cord blood1-47mg/dL
0-2 months1-33
3-5 months1-14
6-8 months1-16
9-23 months1-65
2 years0-120
3-4 years0-90
5-6 years2-116
7-8 years0-138
9-10 years1-95
11-12 years1-153
13-14 years2-143
15+ years7-89
DISOPYRAMIDEDISOPDISOPImmunoassay
TitleDescriptorRangesUnits
Disopyramideug/mL
Therapeutic2.0-5.0
ToxicGT 7.0
DSDNA (CRITHIDIA IFA)IFDNAIFDNAIFA-Crithidia
TitleDescriptorRangesUnits
DNA Double Strand (Crithidia)NegativeLT 1:10
DRUG FACIL SEXUAL ASSAULT PNLDSFA1DSFA1EMIT/Confirmation by GC/MS, LC/MS, TLC, GC/FID or Refract
TitleDescriptorRangesUnits
Drug Survey Comprehensive
Codeinepositive cutoff50ng/mL
Morphinepositive cutoff50ng/mL
Hydrocodonepositive cutoff50ng/mL
Hydromorphonepositive cutoff50ng/mL
Oxycodonepositive cutoff50ng/mL
Oxymorphonepositive cutoff50ng/mL
6 MAM (Heroin metabolite)positive cutoff10ng/mL
Clonazepamng/mL
Ketamineng/mL
Flunitrazepamng/mL
GHBmcg/mL
pH3.0-11.0
CreatinineLT 19mg/dL
Specific Gravity
DILUTE RUSSELL VIPER RFLXADRVVTADRVVTElectromechanical
TitleDescriptorRangesUnits
dRVVT31.8-45.7sec
dRVVT Mix RatioNegative for Lupus Inhibitor Screen0.0-1.2
dRVVT Confirm RatioNegative for Lupus Inhibitor Screen< 1.2
dRVVT Confirm Mix RatioNegative for Lupus Inhibitor Screen< 1.2
DSDNA AUTOANTIBODY, IGGDNAMPDNAMPMultiplex luminex
TitleDescriptorRangesUnits
DSDNA Autoantibody, IgGNegativeLT 5IU/mL
Indeterminate5-9
Positive10 or more
DULOXETINEDULDULHigh Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
TitleDescriptorRangesUnits
Duloxetineng/mL
Steady state trough plasma concentrations after 5 days of oral therapy
20 mg twice daily4-20
30 mg twice daily8-48
40 mg twice daily12-60
DYPHYLLINEDYPDYPHPLC
TitleDescriptorRangesUnits
DyphyllineTherapeutic10-20mcg/mL
EBV AB VIRAL CAPSID AG, IGGEBVGLEBVGLCLIA
EBV Ab to Viral Capsid Antigen, IgG                   U/mL
 Negative      LT 18.0           No significant level of     
                                 IgG Ab detected.
 Equivocal     18.0-21.9         Repeat testing of a sample
                                 in 10-14 days may be helpful 
                                 in determing presence or absence
                                 of infection. 
 Positive      22.0 or greater   IgG antibody detected.
                                 May indicate a recent or past
                                 infection.
EBV AB PANELEBPANLEBPANLCLIA
EBV Capsid Ab, IgG                 U/mL
 Negative      LT 18.0           No significant level of     
                                 IgG Ab detected.
 Equivocal     18.0-21.9         Repeat testing of a sample
                                 in 10-14 days may be helpful 
                                 in determing presence or absence
                                 of infection. 
 Positive      22.0 or greater   IgG antibody detected.
                                 May indicate a recent or past
                                 infection.Negative    LT 18.0
EBV Capsid Ab, IgM                 U/mL
 Negative    LT 36.0
EBV Nuclear Ab                     U/mL
 Negative    LT 18.0    
EBV Early Ab   
 Negative    LT 9.0 
Interpretation
EBV AB VIRAL CAPSID AG, IGMEBVMLEBVMLCLIA
EBV Capsid Ab, IgM                                U/mL                       ISR
 LT 36.0          Negative No detectable IgM Abs. If
                          exposure to EBV is suspected, 
                          a second sample should be 
                          collected and tested in 7-14 
                          days.     
 36.0-43.9        Equivocal Repeat testing in 10-14 days
                          may be helpful to determine
                          absence or presence of 
                          infection. 
 44.0 or greater  Positive IgM antibody detected. Specific
                          IgM Abs are usually found in
                          patients with recent primary
                          infection, but may also be
                          found in patients with re-
                          activated infection.
                          Suggestive of current
                          or recent infection.
EBV AB EARLY AG, DIFFUSE, IGGEBVEALEBVEALCLIA
EBV, Early AG, IgG  Negative   LT 9.0 No significant     U/mL
                               level of EBV EA-D IgG Abs
                               detected. 
                    Equivocal  9.0-10.9 Repeat testing of 
                               second sample in 10-14 days
                               may be helpful to determine
                               presence or absence of
                               infection.
                    Positive   11.0 or greater. EBV EA-D IgG
                               Antibody detected.
EBV AB NUCLEAR AG, IGGEBVNALEBVNALCLIA
TitleDescriptorRangesUnits
EBV, Nuclear Ab, IgGU/mL
NegativeLT 18.0 - No significant level of EBVA IgG Abs detected.
A negative result generally excludes past EBV infection. If exposure to EBV is suspected a second sample should be collected and tested in 7-10 days.
Equivocal18.0-21.9 - Repeat testing of a second sample in 10-14 days may be helpful to determine presence or absence of infection.
Positive22.0 or greater - EBNA IgG Abs detected.
A positive result is indicative of past infection.
ECHINOCOCCUS, AB, IGGECHINGECHINGSemi-Quantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Echinococcus Antibody IgG0.00-0.89IV
Negative - No significant level of Echinococcus IgG antibody detected.0.00-0.89IV
Equivocal - Questionable presence of Echinococcus IgG antibody detected. Repeat testing in 10-14 days may be helpful.0.90-1.09IV
Positive - Presence of IgG antibody to Echinococcus detected, suggestive of current or past infection.1.10 IV or greaterIV
FOOD ALLERGEN PROFILE 10FOOD10FOOD10ImmunoCap FEIA
TitleDescriptorRangesUnits
Egg White IgELT 0.35kU/L
Cows Milk IgELT 0.35kU/L
Codfish (Whitefish) IgELT 0.35kU/L
Wheat IgELT 0.35kU/L
Corn (Maize) IgELT 0.35kU/L
Peanut IgELT 0.35kU/L
Soybean IgELT 0.35kU/L
Shrimp IgELT 0.35kU/L
Walnut IgELT 0.35kU/L
Clam IgELT 0.35kU/L
UPEP, URINE RANDOMELP-RPELPURAgarose Gel ELP (High Resolution)
Electrophoresis, Urine, Random
IMMUNOFIXATION, URINE RANDOMIEP-RUIEPURImmunofixation ELP/High Resolution
ELP Urine Interp
Immunofixation Urine Interp
IMMUNOFIXATION, SER/UR RANDOMIEP.SU-RIEPSURImmunofixation ELP/High Resolution
ELP, Serum
ELP, Serum Interpretation
Monoclonal Peak
Immunofixation Serum Interp
ELP Urine Interp
Immunofixation Urine Interp
EASTERN EQUINE AB, IGGEEEGABEEEGABIFA
Encephalitis, Eastern Equine Antibody, IgG      
 LT 1:16          No antibody detected  
 1:16 or more     Antibody detected
 Specimens positive for arbovirus antibody
 are CDC-reportable. Please contact your
 local public health agency.
 Detection of IgG antibody indicates
 either past or recent infection. 
 Human infections are seasonal, from
 mid-summer to late summer, occurring
 from New England to Texas. Minimal
 cross-reactivity with other Group A
 arboviruses; i.e. Western equine 
 encephalitis virus is observed.
EASTERN EQUINE AB, IGMEEEMABEEEMABIFA
Encephalitis, Eastern Equine Antibody, IgM      
 LT 1:20          No antibody detected  
 1:20 or more     Antibody detected
 Specimens positive for arbovirus antibody
 are CDC-reportable. Please contact your
 local public health agency.
 Detection of IgM antibody indicates
 recent or current infection. 
 Human infections are seasonal, from
 mid-summer to late summer, occurring
 from New England to Texas. Minimal
 cross-reactivity with other Group A
 arboviruses; i.e. Western equine 
 encephalitis virus is observed.
ST LOUIS ENCEPH AB, IGG, CSFENSTLGENSTLGIFA
TitleDescriptorRangesUnits
Encephalitis, St. Louis Antibody, IgGA positive result for IgG may suggest current or past infectionLT 1:1CSF
This test is intended to be used as a semi-quantitative means of detecting St. Louis virus-specific IgG in CSF samples in which there is a clinical suspicion of St. Louis virus infection.
This test should not be used solely for quantitative purposes, nor should the results be used without correlation to clinical history or other data. Because other members of the Flaviviridae family such as West Nile virus, show extensive cross-reactivity with St. Louis virus, serologic testing specific for these specimens should also be performed.
ST LOUIS ENCEPH AB, IGM, CSFENSTLMENSTLMIFA
TitleDescriptorRangesUnits
Encephalitis, St. Louis Antibody, IgMA positve result for IgM may suggest current or recent infectionLT 1:1CSF
This test is intended to be used as a semi-quantitative means of detecting St. Louis virus-specific IgM in CSF samples in which there is a clinical suspicion of St. Louis virus infection.
This test should not be used solely for quantitative purposes, nor should the results be used without correlation to clinical history or other data. Because other members of the Flaviviridae family such as West Nile virus, show extensive cross-reactivity with St. Louis virus, serologic testing specific for these specimens should also be performed.
E. HISTOLYTICA (AMBIASIS) ABAM-ABAMOEBAEIA
Entamoeba histolytica Ab, IgG       IV
 0.79 or less    Negative-no significant level
                 of detectable E. histolytica I
                 IgG Ab.
 0.80-1.19       Equivocal-repeat testing in
                 10-14 days may be helpful.
 1.20 or more    Positive-IgG Ab to E. histo-
                 lytica detected suggestive of 
                 a current or recent infection.
 Seroconversion between acute and convalescent
 sera is considered strong evidence of recent
 infection. The best evidence for infection
 is a significant change on two appropriately
 timed specimens where both tests are done
 in the same laboratory at the same time.
EBV AB VCA, IGG, IGMEBVGMLEBVGMLCLIA
Epstein Barr Virus Ab to Viral Capsid Antigen, IgG    U/mL
 
Negative      LT 18.0           No significant level of     
                                 IgG Ab detected.
 Equivocal     18.0-21.9         Repeat testing of a sample
                                 in 10-14 days may be helpful 
                                 in determing presence or absence
                                 of infection. 
 Positive      22.0 or greater   IgG antibody detected.
                                 May indicate a recent or past
                                 infection.
Epstein Barr Virus Ab to Viral Capsid Antigen, IgM   U/mL
     Negative    LT 36.0
ESCITALOPRAMESCIESCILC-MS/MS
Escitalopram/     Steady state peak plasma levels for          ng/mL
 Citalopram       patients on regimen of 10 or 30 mg/day:
                  21 and 64 ng/mL respectively, and occur at
                  approximately 4 hours post dose. This test
                  is not chiral specific. Patients who have
                  taken racemic Citalopram (Celexa), as opposed to
                  Escitalopram (Lexapro), within the past 3 days may
                  have falsely elevated values.
ESTRONE SULFATEESTRSESTRSHydrolysis, Extraction, Chromatography, Radioimmunoassay
TitleDescriptorRangesUnits
Estrone Sulfatepg/mL
Adult Males230-2200
Premenopausal Females, Follicular Phase300-2600
Premenopausal Females, Luteal Phase100-3200
Postmenopausal Females100-1300
ETHYL GLUCURONIDE/SULFATEETGAETGALC-MS/MS
TitleDescriptorRangesUnits
ETGPositive cutoff250ng/mL
ETSPositive cutoff150ng/mL
ETHOSUXIMIDEETHOETHOEnzyme Immunoassay
TitleDescriptorRangesUnits
EthosuximideTherapeutic40-100ug/mL
ToxicGT 150
ETHOTOINETHOTOINETHOTGC
TitleDescriptorRangesUnits
Ethotoin (Peganone)ug/mL
Therapeutic5-50 (Adult dose) 1-3 g/d
ToxicGT 55
FACTOR II/PROTHROMBIN ACTIVITYFAC2F02ACTElectromechanical
TitleDescriptorRangesUnits
Factor II1 day46-66%
3 days56-69
1 month-1 year69-98
1-5 years78-103
6-10 years75-104
11-16 years68-102
16+ years87-131
FACTOR IX ACTIVITYFAC9F09ACTElectromechanical
TitleDescriptorRangesUnits
Factor IX1 day31-36%
3 days45-53
1 month-1 year44-67
1-5 years45-70
6-10 years49-80
11-16 years65-119
16+ years60-140
FACTOR VIII COAGULANT ACTIVITYFAC8ASF08ACTElectromechanical
TitleDescriptorRangesUnits
Factor VIII Coagulant Activity1 day111-170%
3 days88-142
1 month-1 year57-75
1-5 years38-96
6-10 years55-94
11-16 years62-103
16+ years55-150
FACTOR VII ACTIVITYFAC7F07ACTElectromechanical
TitleDescriptorRangesUnits
Factor VII1 day57-80%
3 days74-98
1 month-1 year79-137
1-5 years79-137
6-10 years77-143
11-16 years76-183
16+ years67-182
FACTOR V ACTIVITYFAC5F05ACTElectromechanical
TitleDescriptorRangesUnits
Factor V1 day57-83%
3 days83-124
1 month-1 year84-113
1-5 years60-102
6-10 years50-113
11-16 years60-113
16+ years70-122
FACTOR XII/HAGEMAN ACTIVITYFAC12F12ACTElectromechanical
TitleDescriptorRangesUnits
Factor XII1 day43-80%
3 days19-70
1 month-1 year29-98
1-5 years50-98
6-10 years50-99
11-16 years50-85
16+ years50-150
FACTOR XI ACTIVITYFAC11F11ACTElectromechanical
TitleDescriptorRangesUnits
Factor XI1 day7-28%
3 days23-54
1 month-1 year60-86
1-5 years63-112
6-10 years63-112
11-16 years63-96
16+ years65-135
FACTOR X ACTIVITYFAC10F10ACTElectromechanical
TitleDescriptorRangesUnits
Factor X1 day41-60%
3 days41-67
1 month-1 year68-108
1-5 years64-111
6-10 years60-111
11-16 years47-108
16+ years85-152
FELBAMATEFELBAMATEFELBQuantitative High Performance Liquid Chromatography
Felbamate                       ug/mL
 Not well established
 The proposed therapeutic range for
 seizure control is 30-60 ug/mL. 
 Parmacokinetics varies widely,
 particularly with co-medication,
 age and/or compromised renal
 function. No critical value has
 been defined.
FENTANYL PAIN MANAGEMENT CONFIRMATION TESTING BY LCMSMSPFENTPFENTGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
FentanylPositive cutoff2ng/mL
NorfentanylPositive cutoff2ng/mL
FIBRINOGENXFIBXFIBElectromechanical
TitleDescriptorRangesUnits
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
Abnormalities of fibrinogen function may result in low reported levels. Additional testing, including thrombin times, may be useful in interpreting low fribrinogen levels.
FIBRINOGEN RFLX TTQFIBQFIBElectromechanical
TitleDescriptorRangesUnits
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
Thrombin Time Patient15.6-20.0sec
Thrombin Time Control15.6-20.0sec
Thrombin Time PT/CT Mixsec
Thrombin Time PT/PSO4 Mixsec
HCV FIBROSUREHCVFSHCVFS
TitleDescriptorRangesUnits
Fibrosure Score0.00-0.21
Fibrosure Stage
Necroinflammat Activity Score0.00-0.17
Necroinflammat Activity Grade
Alpha 2-Macroglobulins, QN110-276mg/dL
Haptoglobin34-200mg/dL
Apolipoprotein A-1Male110-180
Female110-205
Bilirubin, Total24 hrs old0.0-8.0mg/dL
48 hrs old0.0-13.2
72 hrs old0.0-15.6
96 hr to 1 mo0.0-16.6
GT 1 mo old0.0-1.2
GGTMale0-65IU/L
Female0-60
ALT (SGPT)Male0-55IU/L
Female0-40
FILARIA IGG4 ABICFIGAICFIGAELISA
Filaria Ab IgG4                      IV
 Negative     0.8 or less       No significant level
                                of Filaria IgG4 Ab 
                                detected.
 Equivocal    0.9-1.0           Questionable presence
                                of Filaria IgG4 Ab detected.
                                Repeat testing in 10-14 days
                                may be helpful.
 Positive     1.1 or greater    Presence of specific Filaria
                                IgG4 Ab detected suggestive
                                of current infection.
FIRST SCREENMFSGZMFSGZ
First Screen   See separate report
FISH ASSAY, HER2 GENE AMPLIFICATION, BREAST CANCERFISHERFluorescent In Situ Hybridization (FISH) with the PathVysion HER-2/neu probe
FISH HER-2/NEU    Separate Report to Follow
FISH ASSAY, ANIRIDIAFIPAX6FIPAX6FISH
FISH, Aniridia
 Separate Report to Follow
FLECAINIDEFLECFLECQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Flecainide0.20-1.00ug/mL
ToxicGT 1.50
FLEXERILFLEXERILFLEXLiquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
FlexerilReported therapeutic range in plasmaApproximately 4-40ng/mL
FLT3 MUTATION DETECTION (PCR)FLT3MTFLT3MTQualitative Polymerase Chain Reaction/Capillary Electrophoresis
FLT3 Mutation Detection by PCR
CONSULT/REVIEW, FLUIDREVFLREVFLVisual Microscopic
Fluid, Interpretation
Fluid, Reviewed by
FLOURESCENT PARASITE SMEARCRYSMCRYSMConcentration/Mod. Acid Fast Stain
Fluorescent Parasite Smear   Negative
Report Status
FLUORIDE EXPOSURE BIOUPTAKEFLUOR.EXP.UFLUURIon Specific Electrode
TitleDescriptorRangesUnits
Fluoride, UrineNormalLT 2.1mg/L
Concentration dependent on dietary intake.
Biological Expsoure Index (ACGIH) for monitoring workplace exposure to Flourides, measured in urine specimens collected:
Prior to shift2mg/L
End of shift3mg/L
FLUOXETINE AND NORFLUOXETINEFLUOXFLUOXQuantitative High Performance Liquid Chromatography
TitleDescriptorRangesUnits
FluoxetineDose-related range100-800ng/mL
NorfluoxetineDose-related range100-600ng/mL
Fluoxentine and NorfluoxetineToxicGT 2000ng/mL
FLUPHENAZINEFLUPHENAZINEFLUPHQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Fluphenazineng/mL
Therapeutic0.5-2.0
ToxicNot well established
FLURAZEPAMDALMANE-QFLURAZGC
TitleDescriptorRangesUnits
Flurazepamug/mL
Therapeutic Range0.01-0.14 (Adult dose) 15-30 mg/d
ToxicGT 0.20
FOLATE, RBCFOL-RRBCFOLICMA
TitleDescriptorRangesUnits
Folate, RBCng/mL
Deficient0-144
Indeterminate145-279
Normal280-800
FOLATEFOLATEFOLICMA
TitleDescriptorRangesUnits
Folateng/mL
Deficient0.4-3.4
Indeterminate3.5-5.3
Normal5.4-24.0
XSENSE®, FRAGILE X, RFLXFRAGXAFRAGXAPolymerase Chain Reaction (PCR) with Detection by Capillary Electrophoresis
Fragile X PCR
Fragile X SB
F. TULARENSIS AB, IGG, IGMFTAGMAFTAGMASemi-Quantative ELISA
Francisella tularensis Ab, IgG    Negative 9 or less     U/mL
Francisella tularensis Ab, IgM    Negative 9 or less     U/mL
 
F. TULARENSIS AB, IGGFTABGAFTABGASemi-Quantative ELISA
TitleDescriptorRangesUnits
Francisella tularensis Ab, IgGNegative9 or lessU/mL
F. TULARENSIS AB, IGMFTABMAFTABMASemi-Quantative ELISA
TitleDescriptorRangesUnits
Francisella tularensis Ab, IgMNegative9 or lessU/mL
CARBAMAZEPINE, FREECARB.FREECARBFRQuantitative Enzyme Multiplied Immunoassay Technique
TitleDescriptorRangesUnits
Free Carbamazepine1.0-3.0ug/mL
Toxic rangeGT 3.8
Total Carbamazepine4.0-12.0ug/mL
Toxic rangeGT 20
% Free Carbamazepine8.0-35.0%
FATTY ACIDS, FREEFATTYFATTYFSpectrophotometry
TitleDescriptorRangesUnits
Free Fatty Acids mmol/L
0-30 days0.43-1.37
1 month-10 years0.50-0.90
11+ years0.10-0.60
T4, FREE (EQUIL DIALYSIS)FT4TMSFT4TMSQuantitative Equilibrium Dialysis/High Performance Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Free T4 by Equilibrium Dialysis-TMSng/dL
25-30 weeks0.5-3.3
31-36 weeks1.3-4.7
birth-1 week2.2-5.3
2-3 weeks0.9-4.0
1-5 months1.1-2.2
6 months-6 years1.4-2.7
7-17 years1.1-2.0
18 yrs and older1.1-2.4
Pregnancy
1st Trimester0.7-2.0
2nd Trimester0.7-2.1
3rd Trimester0.5-1.6
T4, FREEFREE T4FT4ICMA
TitleDescriptorRangesUnits
Free T4ng/dL
Birth-7 days1.4-3.3
8 days-1 month0.6-2.5
1-12 months0.7-1.4
12 months-18 years0.6-1.2
18+ years0.7-1.5
FSH (FOLLICLE STIM HOROMONE)FSHFSHICMA
FSH                            mIU/mL
 M  7-9 yrs          0.3-2.3
    10-12 yrs        0.5-4.4
    13-15 yrs        1.0-6.7
    16-17 yrs        0.8-7.0
    18 yrs +         1.4-11.2
   Tanner Stage I    0.3-2.6
   Tanner Stage II   0.5-4.3
   Tanner Stage III  0.9-5.8
   Tanner Stage IV-V 0.9-7.3    
 F  7-9 yrs          0.4-4.0
    10-12 yrs        0.6-7.5
    13-15 yrs        0.9-8.2
    16-17 yrs        0.4-8.9
    18 yrs+           
   Follicular        3.2-11.3
   Midcycle peak     4.2-19.4       
   Luteal phase      1.5-6.9                   
   Postmenopausal    23.2-121.3
   Tanner Stage I    0.5-7.6
   Tanner Stage II   0.5-8.0
   Tanner Stage III  0.5-8.0
   Tanner Stage IV-V 0.6-8.4
HYPOTHYROID PROFILEHYPOAHYPOICMA
FTI                     5.0-12.0
T3 Uptake               22.5-37.0       %
T4                                      ug/dL
 M      0-30 days       3.0-14.3
        1-12 mo         5.2-16.3
        1-5 yrs         5.5-11.4
        5-10 yrs        5.3-10.5
        10-15 yrs       4.5-10.3
        15-18 yrs       4.9-8.8
 F      0-30 days       3.0-13.3
        1-12 mo         4.6-13.3
        1-5 yrs         6.3-12.8
        5-10 yrs        5.3-10.8
        10-15 yrs       4.9-10.0
        15-18 yrs       5.1-10.0
 Adults 18+ yrs         4.7-11.3
TSH                                     uIU/mL
 M      0-30 days       0.52-16.00
        1 mo-5 yrs      0.55-7.10
        5-18 yrs        0.37-6.00
        18+ yrs         0.45-5.10
 F      0-30 days       0.72-13.10
        1 mo-5 yrs      0.46-8.10
        5-18 yrs        0.36-5.80
        18+ yrs         0.45-5.10
GABAPENTINGABAPGABAPLiquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Gabapentinug/mL
Therapeutic Range2-20
ToxicNot well established
ANTI-MULLERIAN HORMONEAMUHPAMUHPImmunoassay
GenderDescriptorRangesUnits
Femalesng/mL
LT 14 years0.49-3.15
14-19 years1.28-16.37
20-29 years0.76-11.34
30-39 yearsLT 9.24
40-49 yearsLT 4.50
50+ years, post menopauseLT 0.45
Malesng/mL
LT 1 year37.20-345.67
1-6 years59.54-320.65
7-11 years40.99-203.67
12-17 yearsLT 128.29
17+ years1.15-15.23
INSULIN-LIKE GROWTH FACTOR 1IGFIL1IGFIL1Chemiluminescent immunoassay (CLIA)
GenderDescriptorRangesUnits
Male1-2 years30-122ng/mL
3 years20-141
4 years25-157
5 years30-174
6 years37-192
7 years44-211
8-18 yearsRefer to Tanner Stages
19-20 years281-510
21-30 years155-432
31-40 years132-333
41-50 years121-237
51-60 years68-245
61-70 years60-220
71-80 years36-215
Tanner Stage I (8-15 years)52-391
Tanner Stage II & III (8-16 years)39-648
Tanner Stage IV & V (11-18 years)277-434
Female1-2 years56-144ng/mL
3 years26-162
4 years32-179
5 years39-198
6 years55-238
7 years55-268
8-18 yearsRefer to Tanner Stages
19-20 years217-475
21-30 years87-368
31-40 years106-368
41-50 years118-298
51-60 years53-287
61-70 years75-263
71-80 years54-205
Tanner Stage I (8-12 years)64-358
Tanner Stage II (8-14 years)89-566
Tanner Stage III (9-15 years)192-568
Tanner Stage IV & V (11-18 years)268-430
GENTAMICIN, PEAKGENT.PKGENPKEnzyme Immunoassay
TitleDescriptorRangesUnits
Gentamicin, Time of last dose
Gentamicin, Peak5.0-10.0ug/mL
ToxicGT 12.0
GENTAMICIN, TROUGHGENT.TRGENTREnzyme Immunoassay
TitleDescriptorRangesUnits
Gentamicin, Trough1.0-2.0ug/mL
ToxicGT 2.0
GENTAMICIN, INFUSIONGENT2GENTINEnzyme Immunoassay
TitleDescriptorRangesUnits
Gentamicin, Troughug/mL
1.0-2.0
ToxicGT 2.0
Gentamicin Time, Troughh
Gentamicin, Peakug/mL
5.0-10.0
ToxicGT 12.0
Gentamicin Time, Peakh
GENTAMICIN, RANDOMGENTGENREnzyme Immunoassay
TitleDescriptorRangesUnits
Gentamicinug/mL
Trough1.0-2.0
ToxicGT 2.0
Peak5.0-10.0
ToxicGT 12.0
LIVER HEALTH PANELLHPANLHPAN
GGT
HFPA
GGTGGTGGTColorimetric
TitleDescriptorRangesUnits
GGTU/L
0-2 days19-270
3-5 days13-198
6-10 days0-130
11 days-4 months4-120
5 -12 months5-65
13 months-16 years0-23
17-19 years0-35
20+ years5-75
GLIADIN ABS, IGA, IGGGLIGAGLIGAEIA
TitleDescriptorRangesUnits
Gliadin Ab, IgAUnits
NegativeLT 20
Weak to Mod Pos20-30
PositiveGT 30
This test was performed using a deamidated gliadin peptide (DGP) assay.
Gliadin Ab, IgGUnits
NegativeLT 20
Weak to Mod Pos20-30
PositiveGT 30
This test was performed using a deamidated gliadin peptide (DGP) assay.
GLOMERULAR BASEMENT MEMBRANEGLBMABGLBMABEIA
TitleDescriptorRangesUnits
Glomerular Basement Membrane AbU/mL
Negative0-20
Weak Positive21-30
Moderate-Strong PositiveGT 30
This test is designed for the in-vitro measurement of specific IgG auto- antibodies against the glomerular basement membrane (GBM). It is intended as an aid in the diagnosis of Good- pasture's syndrome. Some patients with other renal diseases may exhibit positive results. Glomerular Basement Membrane antibodies are not found in normal healthy individuals.
Results were obtained with the QUANTA Lite GBM ELISA assay. Values obtained from different manufacturers assays cannot be used interchangeably. The magnitude of the reported IgG levels cannot be correlated to an endpoint titer.
ESTIMATED GFR (CALC)GFRGFRCalculation
TitleDescriptorRangesUnits
Glomerular Filtration Rate EstimatedmL/min/1.73m2
Chronic kidney disease, if found over a 3-month period.LT 60
Kidney failureLT 15
For African Americans, multiply the calculated GFR by 1.21.
HEART METABOLIC SYNDROME RFLXHRTMTBHRTMTB
GLU
GLYCO
HRTLIP
ADIPO 
CYSTCG
OXLDL
GLUCAGONGLUCQGLUCQExtraction, Radioimmunoassay (RIA)
TitleDescriptorRangesUnits
Glucagonpg/mL
Adult Reference Range for Glucagon
Males and FemalesLT or = to 134
Pediatric Reference Ranges for Glucagon
Cord BloodLT or = to 215
Day 1LT or = to 240
Day 2LT or = to 400
Day 3LT or = to 420
Day 4-3 yearsNot Established
4-14 daysLT or = to 148
GLUCOSE CHALLENGEGCT.PGGCTPGHexokinase
TitleDescriptorRangesUnits
Glucose, 1 hr (Pregnant)50-129mg/dL
Presumptive Gestational Diabetes Mellitus
130 mg/dL or greater (identifies 90% of patients with GDM)
140 mg/dL or greater (identifies 80% of patients with GDM)
These threshold values apply to a blood glucose drawn 1 hour after a 50 gram oral glucose load. An abnormal result must be verified by either a 3-hour (100 gram) or a 2-hour (75 gram) glucose tolerance test for gestational diabetes.
GLUCOSE, CSFGLU-CGLUSFEnzymatic
TitleDescriptorRangesUnits
Glucose, CSFmg/dL
0-10 years60-80
10+ years40-70
GLUCOSEGLUGLUHexokinase
TitleDescriptorRangesUnits
Glucose, Fasting or Random0-2 day premature30-80mg/dL
0-2 day full-term40-90
2 days-1 months60-105
Adult65-99
Pregnant Female65-94
ADA Diagnostic Categories for non-pregnant adults
Impaired fasting glucose: 100-125 mg/dL.
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
GLUCOSE TOLERANCE, 2HR-F/2HGTOL2GTOL2Hexokinase
TitleDescriptorRangesUnits
Glucose, Fastingmg/dL
0-2 days premature30-80
0-2 days full-term40-90
2 days-1 month60-105
Adult65-99
Glucose, 2 hrmg/dL
NormoglycemiaLT 140
Impaired glucose tolerance140-199 mg/dL
Indicates diabetes if confirmed on a subsequent day.200 or more
These criteria apply to the 2 hour (75 gram) ADA glucose tolerance testing protocol for non-pregnant adults.
GLUCOSE, FLUIDGLU-FLDGLUFLEnzymatic
TitleDescriptorRangesUnits
Glucose, Fluidmg/dL
Serous Fluidequal to the serum glucose value
Synovial FluidLT 10 mg/dL when compared to the serum glucose value.
Method not validated for body fluid. Clinical correlation necessary.
GLUCOSE TOLERANCE, GEST 3 HRGTPGGTPGHexokinase
TitleDescriptorRangesUnits
Glucose, Pregnantmg/dL
Two or more of the following threshold values must be met or exceeded to confirm gestational diabetes
Fasting95
1 hour180
2 hour155
3 hour140
These criteria apply to the 3-hour (100 gram) ACOG glucose tolerance testing protocol for gestational diabetes.
GLUCOSE-6-PHOSPHATE DEHYDROGENASEG6ARUPG6ARUPEnzymatic
Glucose-6-Phosphate Dehydrogenase   7.0-20.5 U/gHgb
GLYBURIDEGLYGLYHPLC
TitleDescriptorRangesUnits
Glyburidemcg/mL
Peak level following single 5 mg oral doseApproximately 0.4
METABOLIC HEALTH PANELMHPANMHPAN
GLYCO   
MCUC   
GLU
GANGLIOSIDE AB, IGG, IGMGM1ABSGM1ABSSemi-Quantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
GM1 AB, IgGIV
GM1 AB, IgMIV
GM1 ABS, IGG & IGMNegative29 or less
Equivocal30-50
Positive51-100
Strong Positive101 or greater
GOLD, SERUMGOLDGOLDSGFAAS
TitleDescriptorRangesUnits
Goldmcg/mL
NormalLT 2.5
Therapeutic3000-8000
HALOPERIDOLHALDOLHALQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Haloperidolng/mL
Therapeutic Range5.0-20.0
ToxicGT 42
HBSAG CONFIRMATIONHBSAG.CONFIRMHBSAGCICMA Neutralization
HBsAg Confirmation
CARDIAC HEALTH PANELCHPANCHPAN
HCRP
APOLB
HOMCY
HEART INFLAMMATION PANELHRTINFHRTINF
HCRP   
PLACA2   
MCUC   
FISOP   
MPOENZ   
OXLDL
HUNTINGTON DISEASE DNA SCREENHUNDUWHUNDUWPCR Capillary Electrophoresis
HD allele 1
HD allele 2
HD Clinical Information
HD Interpretation
HDL CHOLESTEROL BATTERYHDLHDLElimination/Enzymatic
TitleDescriptorRangesUnits
HDLmg/dL
LowLT 40
Within normal limits40-59
High60 or more
HDL Cholesterol greater than or equal to 60 mg/dL is considered to be a 'negative' risk factor, serving to remove one risk factor from the total count.
LDL (calculated)mg/dL
OptimalLT 100
Near or above normal100-129
Borderline high130-159
High160-189
Very high190 or more
To calculate 10-year cardiac risk for the patient, go to http://www.paml.com, click on testing, then on ranges/algorithms, and then on lipid results.
HEAVY METALS PANEL, WHOLE BLDHVYHVYMTLAA/ICP-MS
TitleDescriptorRangesUnits
Heavy Metals, Blood
Arsenic0.0-13.0ug/L
Potentially toxicGT 600
Lead, VenousNormal0.0-4.9ug/dL
Mercury0-10ug/L
H. PYLORI AB, IGAHPYAHPYAEIA
TitleDescriptorRangesUnits
Helicobacter pylori Ab, IgA
Negative-no significant level of IgA antibody to H. pylori detected. A negative result indicates no IgA antibody to H. pylori or levels below the detection limit of the assay.0.0-20.0
If a primary infection is suspected, another specimen should be collected in 4-6 weeks.
Equivocal Suggest repeat serologic testing in 10-14 days or order culture of biopsy material, breath test, or stool antigen test.20.1-24.9
Positive-IgA Ab to H. pylori detected, suggestive of active infection. Helicobacter pylori IgG and IgA seroconversion both occur about 2 months after infection.25.0 or greater
Symptomatic individuals who have a high titer of both IgG and IgA to H. pylori may have an active infection. However, a positive H. pylori IgA result can only suggest active infection and should be confirmed by bacterial isolation or other diagnostic testing.
H. PLYORI AB, IGMHPMAGHPMAGELISA
TitleDescriptorRangesUnits
Helicobacter pylori Antibody, IgMEV
Negative-no significant level of IgM antibody to H. pylori detected.0.8 or less
Equivocal-Repeat testing in 10-14 days may be helpful.0.9-1.1
Positive-IgM antibody to H. pylori detected, suggestive of active infection.1.2 or more
Gastric colonization by Helicobacter pylori has been implicated in the development of some cases of gastritis and peptic or duodenal ulcer. The critical utility of H. pylori IgM antibody measurement has not been clearly established.
HGB/THALASSEMIA PANEL RFLXHGB.THAL.PANELHGTHALIon Exchange/HPLC
TitleDescriptorRangesUnits
Hemoglobin A20-3 mo0.0-3.6%
4+ mo1.0-3.8
Hemoglobin F0-30 days61.0-88.5%
1 mo45.7-67.3
2 mo29.4-60.8
3 mo14.8-55.9
4 mo9.4-28.5
5 mo2.3-22.4
6-11 mo2.3-13.0
1 yr1.3-5.0
13 mo+0.0-2.0
Hgb Other
Hgb S (Relative)LT 1.0%
Brilliant Cresyl Blue (No longer performed)
ZPP/Heme Ratio23-78umol/mol
Kleinhauer Betke Stain
Hemoglobin S SolubilityNegative
Monoclonal C
Citrate Gel Electro
Monoclonal E
Cellulose Electro
Unstable Hgb
Slide Interpretation
Interpretation
Reviewed By
HEMOGLOBIN A2 QUANTITATIONA2A2QTHPLC
TitleDescriptorRangesUnits
Hemoglobin A2%
0-3 months0.0-3.6
4+ months1.0-3.8
HEMOGLOBIN F QUANTITATIONHGBFFQTHPLC
TitleDescriptorRangesUnits
Hemoglobin F%
0-30 days61.0-88.5
1 months45.7-67.3
2 months29.4-60.8
3 months14.8-55.9
4 months9.4-28.5
5 months2.3-22.4
6-11 months2.3-13.0
1 year1.3-5.0
13+ months0.0-2.0
HEPARIN ASSAYHEPARINHEPASYAnti-Xa Chromogenic
TitleDescriptorRangesUnits
Heparin LevelTherapeutic Range0.30-0.70IU/mL
HEPATITIS B SURFACE AB, QUANTANTI-HBSHBSABICMA
TitleDescriptorRangesUnits
Hepatitis B Surface AbNon-Immune< 10.0mIU/mL
Indicates vaccine response or HBV infection> = 10.0
Samples with a calculated value of 10 mIU/mL or greater are considered reactive (protective) in accordance with the CDC guidelines
HEPATITIS PANEL, CHRONIC RFLXHEPCHRHEPCHRICMA
TitleDescriptorRangesUnits
Hepatitis B Surface AbNon-Immune< 10.0mIU/mL
Indicates vaccine response or HBV infection> = 10.0
Samples with a calculated value of 10 mIU/mL or greater are considered reactive (protective) in accordance with the CDC guidelines
HBV PROGNOSIS PANEL RFLXHBCHRHBCHRICMA
TitleDescriptorRangesUnits
Hepatitis B Surface AbNon-Immune< 10.0mIU/mL
Indicates vaccine response or HBV infection> = 10.0
Samples with a calculated value of 10 mIU/mL or greater are considered reactive (protective) in accordance with the CDC guidelines
HEPATITIS D VIRUS AB, TOTALHEPDABHEPDABEIA
Hepatitis D Virus Antibody, Total
 Negative
 Interpretive Criteria
  Negative-Antibody not detected
  Equivocal-Submission of a second
   specimen (collected 3-4 weeks after
   initial specimen) suggested if
   clinically warranted.
  Positive-Antibody detected.
  Hepatitis D virus (HDV) infection
  occurs in association with HBV
  infection. A positive result for
  HDV total antibody may indicate either
  acute or chronic HDV infection. HDV
  antibodies appear transiently during
  acute infection, and typically
  disappear with resolution of the
  infection. In contrast, HDV antibodies
  usually persist in chronic infection.
  Measurment of HDV IgM may help distinguish
  acute from chronic infection.
HEREDITARY HEMOCHROMATOSISHHPCR3HHCPCRPCR
Hereditary Hemochromatosis Result
Genotype
Interpretation
 Patients receiving genetic testing
 should consider genetic counseling.
 Counseling of potentially affected
 family members may also be warranted.
Comment
 Patient DNA is assayed for the C282Y,
 H63D and S65C point mutations in the
 HFE gene by polymerase chain reaction
 (PCR).
HSV (WB)HSVUWBHSVUWBWestern Blot
Herpes Simplex Virus by Western Blot Source
Herpes Simplex Virus by Western Blot Result
Herpes Simplex Virus by Western Blot Interpretation
HSV 1 AND/OR 2, IGMHSVIGMHSVIGMEIA
TitleDescriptorRangesUnits
Herpes Simplex Virus IgM AntibodyOD
Negative-No clinically significant level of HSV IgM Ab detectedLT 0.91
Indeterminate-Unable to determine the presence or absence of HSV IgM Ab. Repeat testing in 10-14 days may be helpful0.91-1.09
Positive-IgM Ab to HSV detected. May indicate current or recent infection or reactivationGT 1.09
HEXPHOSPHOLIPID NEUTRALIZATIONHPNTHPNTElectromechanical (clot based)
TitleDescriptorRangesUnits
Hexagonal Phospholipid Neutralizationseconds
Negative< = 9.1
A Lupus Inhibitor is not ruled out by a negative Hexagonal Phospholipid Neutralization alone. Additional tests,such as DRVVT may be necessary to rule out a Lupus Inhibitor.
Positive for the Lupus Inhibitor> = 9.2
Repeat evaluation after at least 12 weeks is suggested, as consensus guidelines suggest clinically significant lupus anticoagulants are persistent.
HGB/THALASSEMIA SCREENHGSCRNHGSCRNHPLC
TitleDescriptorRangesUnits
Hgb A
Hgb A20-3 months0.0-3.6%
4+ months1.0-3.8
Hgb F0-30 days61.0-88.5%
1 month45.7-67.3
2 months29.4-60.8
3 months14.8-55.9
4 months9.4-28.5
5 months2.3-22.4
6-11 months2.3-13.0
1 year1.3-5.0
13+ months0.0-2.0
Other Hemoglobins SeenNo variant hemoglobins detected
Comment
HSCRP AND CHOLESTEROL PROFILEHCRPPHCRPPEnzymatic, Nephelometry
TitleDescriptorRangesUnits
High Sensitivity CRPmg/L
Low riskLT 1.0
Average risk1.0-3.0
High riskGT 3.0
Relative risk categories follow the recommendations of the American Heart Association and the CDC. Measurement of hsCRP should be done twice (averaging results), optimally two weeks apart, in metabolically stable patients. If the hsCRP level is GT 10 mg/L, the test should be repeated and the patient examined for non-cardiovascular sources of inflammation, such as infection.
Cholesterolmg/dL
DesirableLT 200
Borderline high200-239
High240 or more
HDLmg/dL
LowLT 40
Within normal limits40-59
High60 or more
HDL Cholesterol greater than or equal to 60 mg/dL is considered to be a 'negative' risk factor, serving to remove one risk factor from the total count.
CRP, HIGH SENSITIVITYHCRPHCRPNephelometry
TitleDescriptorRangesUnits
High Sensitivity CRPmg/L
Low riskLT 1.0
Average risk1.0-3.0
High riskGT 3.0
Relative risk categories follow the recommendations of the American Heart Association and the CDC. Measurement of hsCRP should be done twice (averaging results), optimally two weeks apart, in metabolically stable patients. If the hsCRP level is GT 10 mg/L, the test should be repeated and the patient examined for non-cardiovascular sources of inflammation, such as infection.
CHRONIC URTICARIA PANELCURTPCURTPImmunochemiluminometric Assay by ADVIA Centaur, Cell Culture, Immunoassay
TitleDescriptorRangesUnits
Histamine ReleaseLT 16%
Thyroid Peroxidase AntibodyLT 9IU/mL
Thyroglobulin AntibodyLT 2IU/mL
If the sample contains anti-thyroglobuin antibodies of greater than 19 IU/mL, the presence of these antibodies may cause falsely low thyroglobulin values.
TSH, 3rd GenerationmIU/L
Premature Infants, 28-36 weeks
1st week of life0.20-27.90mIU/L
Term infants, (GT 37 weeks)
Serum or Cord Blood1.00-39.00mIU/L
LT or = 4 days3.20-35.00mIU/L
5-6 daysNot Established
1-4 weeks1.70-9.10mIU/L
1-11 months0.80-8.20mIU/L
1-19 years0.50-4.30mIU/L
20+ years0.40-4.50mIU/L
Pregnancy Ranges
First Trimester0.26-2.66
Second Trimester0.55-2.73
Third Trimester0.43-2.91
TSH levels decline rapidly during the first week of life in most children, but may remain transiently elevated in a few individuals despite normal free T4 levels. For confirmatory testing following a positive newborn thyroid screen, a free (or total) T4 level is usually required for proper interpretation of TSH levels in this group.
HISTAMINE, PLASMAHISTPHISTPQuantitative Enzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Histamine, Plasma0-8nmol/L
HISTONE AB, IGGHISTONEHISTOGELISA
TitleDescriptorRangesUnits
Histone Antibody (Hrana)Units
Negative0.9 or less
Weak Positive1.0-1.5
Moderate Positive1.6-2.5
Strong Positive2.6 or greater
HISTOPLASMA AB PANELHISABPHISABPCF/ID
TitleDescriptorRangesUnits
Histoplasma Ab Mycelia, CFNo antibody detectedLT 1:8
Histoplasma Ab Yeast, CFNo antibody detectedLT 1:8
Greater than or equal to 1:8 with either antigen are generally considered presumptive evidence of histoplasmosis.
Greater than 1:32 or rising titers indicate strong presumptive evidence of histoplasmosis. Titer of greater than or equal to 1:8 with one or both antigens may occur; yeast phase regarded as more sensitive.
Approximately 90-95% of cases have positive titers to one or both antigens. Titers to mycelial antigen are higher in chronic infection. Cross reactions, ususally lower titers, may occur with fungal disease. Rising titers suggest progression of infection. Skin tests in individuals previously exposed may cause titer elevation in 17-20% of cases.
Histoplasma Ab, IDNone detected
In general immunodiffusion measures IgG and a postive result may suggest active or recent infection.
HISTOPLASMA AGHISAGHISAGQuantitative sandwich enzyme immunoassay (EIA)
TitleDescriptorRangesUnits
Histoplasma Antigenng/mL
NegativeNone detected
Positive, Below the Limit of Quantification< 0.4
Positive0.4-19
Positive, Above the Limit of Quantification> 19
HLA A GENOTYPEHLAGTHLAGTPCR/Sequence Oligonucleotide Probe Hybridization
HLA Class I, Locus A*, Allele 1   
HLA Class I, Locus A*, Allele 2   
HLA-A Genotype Interpretation
HLA-B GENOTYPEHLBGTHLBGTPCR/Sequence Specific Oligonucleotide Probe Hybridization
HLA Class I, Locus B*, Allele 1   
HLA Class I, Locus B*, Allele 2   
HLA-B Genotype Interpretation
HLA C GENOTYPEHLCGTHLCGTPCR/Sequence Specific Oligonucleotide Probe Hybridization
HLA Class I, Locus Cw*, Allele 1   
HLA Class I, Locus Cw*, Allele 2   
HLA-C Genotype Interpretation
HLA DR GENOTYPING HLADRGHLADRGPCR/Sequence Specific Oligonucleotide Probe Hybridization
HLA Class II, Locus DRB1*, Allele 1
HLA Class II, Locus DRB1*, Allele 2
HLA-DR Genotyping Interpretation
HUMAN METAPNEUMOVIRUS (RT-PCR) HMEPCRHMEPCRRT-PCR
HMPV Source
Human Metapneumovirus by RT-PCR    Not detected
FREE KAPPA LAMBDA LIGHT CHAINSBJPQLABJPQLAQualitative Immunofixation Electrophoresis/Quantitative Nephelometry
Hours Collected                         hr
Total Volume                            mL
Total Protein             10-140        mg/d
Albumin, Urine            Detected   
Alpha-1, Urine            None Detected   
Alpha-2, Urine            None Detected   
Urine Beta Globulin       None Detected   
Gamma, Urine              None Detected   
IFE Interpretation
PLATELET ANTIBODY DETECTION, INDIRECTPLTABIPLTABIELISA
HPA1a/1a, HPA3a/3a, HPA4a    Not Detected
HPA1b/1b, HPA3b/3b, HPA4a    Not Detected
HPA 5b/5b                    Not Detected
HPA 5a/5a                    Not Detected
GPIb/IX                      Not Detected
GPIV                         Not Detected                        
HLA                          Not Detected                        
Comment
 This indirect platelet antibody test will
 detect platelet specific antibodies. It is
 not specific for immune thrombocytopenic
 purpura and does not distinguish between
 allo and auto antibodies.
 Antibodies directed against platelet antigens
 may be found in numerous situations
 including ITP, and neonatal alloimmune
 thrombocytopenia, and post transfusion
 purpura. HLA alloantibodies may be
 associated with refractoriness to
 platelet transfusion.
 The test will detect antibodies to platelet
 glycoproteins IIb/IIIa (HPA 1a/1b[PI A1 &
 PI A2], HPA 3a/3b, and HPA 4a), Ia/IIa (HPA
 5a/5b), Ib/IX, and IV, as well as HLA
 class I antigens.
 Tests for neonatal alloimmune thrombo-
 cytopenia should be performed on maternal
 serum to reduce false negative clinical
 results.
HEART MONITORING PANEL RFLXHRTMONHRTMON
HRTLIP   
APOAB   
HCRP
HEART ADVANCED LIPID RFLXHRTADVHRTADV
HRTLIP   
APOAB   
LPA   
HOMCY
SDLDL
HSV IGG AND IGM PANELHSGMHSGMEIA
HSV I IgG Type-Specific Ab                   IV
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type I Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type I
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type I
           Glycoprotein detected. May 
           indicate a current or past
           infection.                      
HSV II IgG Type-Specific Ab                  IV 
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type II Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type II
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type II
           Glycoprotein detected. May 
           indicate a current or past
           infection.
Herpes Simplex Virus IgM Antibody            OD
 LT 0.91   Negative-No clinically
           significant level of HSV
           IgM Ab detected.
 0.91-1.09 Indeterminate-Unable to
           determine the presence or
           absence of HSV IgM Ab.
           Repeat testing in 10-14 
           days may be helpful.
 GT 1.09   Positive-IgM Ab to HSV 
           detected. May indicate 
           current or recent infection
           or reactivation.
HSV TYPE 1, IGGHSV1GHSV1GEIA
HSV I IgG Type-Specific Ab                   IV
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type I Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type I
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type I
           Glycoprotein detected. May 
           indicate a current or past
           infection.
HSV IGG TYPE SPECIFIC PANELHERP I&II.IGGHSVGEIA
HSV I IgG Type-Specific Ab                  IV
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type I Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type I
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type I
           Glycoprotein detected. May 
           indicate a current or past
           infection.                      
HSV II IgG Type-Specific Ab                 IV 
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type II Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type II
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type II
           Glycoprotein detected. May 
           indicate a current or past
           infection.
HSV TYPE 2, IGGHSV2GHSV2GEIA
HSV II IgG Type-Specific Ab                   IV
 LT 0.90   Negative-No significant 
           level of detectable IgG
           Ab to HSV Type 2 Glycoprotein
           G.
 0.90-1.10 Indeterminate-Questionable
           presence of Ab to HSV Type 2
           Glycoprotein G. Repeat testing
           may be helpful.
 GT 1.10   Positive-IgG Ab to HSV Type 2
           Glycoprotein detected. May 
           indicate a current or past
           infection.
HU/YO/RI AB, CSF RFLXHYRCSFHYRCSFImmunofluorescence Assay
Hu Ab, IFA, CSF                         Negative   
Hu Ab, Western Blot, CSF                Negative   
Hu Ab Titer, CSF                        No Hu antibodies detected in
                                        undiluted CSF samples                   titer
      
Yu Ab. IFA CSF                          Negative   
Yu Ab, Western Blot, CSF                Negative   
Yu Ab Titer, CSF                        No Yo antibodies detected in
                                        undiluted CSF                           titer
      
Ri Ab Screen, IFA, CSF                  Negative   
Ri Ab, Western Blot, CSF                Negative   
Ri Ab Titer, CSF                        No Ri antibodies detected in
                                        undiluted CSF                           titer
HU/YO/RI AB RFLXHUYORIHUYORIImmunofluorescence Assay
Hu Ab, IFA, Serum                       Negative   
Hu Ab, Western Blot, Serum              Negative   
Hu Ab Titer, Serum                      < 1:40               titer
      
Yo Ab, IFA, Serum                       Negative   
Yo Ab, Western Blot, Serum              Negative   
Yo,Ab Titer, Serum                      < 1:40               titer
       
Neuronal Nuc Ab (RI), IFA               Negative   
Ri Ab, Western Blot                     Negative   
Ri Ab Titer                             < 1:40               titer   
HUMAN ANTI-MOUSE ABHAMAFHAMAFELISA
TitleDescriptorRangesUnits
Human Anti-Mouse Abng/mL
Normal levelLT 75
Increased level75 or more
IBUPROFENIBUIBUHPLC
TitleDescriptorRangesUnits
Ibuprofenug/mL
Therapeutic10-50 May be seen with common dosages
ToxicGT 200
IMMUNOGLOBULIN A, SERUMIGAIGANephelometry
IgA                    mg/dL
 0-30 days   1-7
 1 mo        1-56 
 2 mo        3-49 
 3 mo        5-48
 4 mo        4-76
 5 mo        8-87
 6 mo        8-70
 7-8 mo      12-93
 9-11 mo     17-87
 1 yr        15-110
 2 yrs       15-128
 3 yrs       23-164
 4 yrs       26-474
 5-7 yrs     35-210
 8-9 yrs     47-245
 10+ yrs     71-397
CELIAC PROFILE PEDS, EXTENDEDCELPROCELPROEIA/Nephelometry
TitleDescriptorRangesUnits
IgA0-30 days1-7mg/dL
1 mo1-56
2 mo3-49
3 mo5-48
4 mo4-76
5 mo8-87
6 mo8-70
7-8 mo12-93
9-11 mo17-87
1 yr15-110
2 yrs15-128
3 yrs23-164
4 yrs26-474
5-7 yrs35-210
8-9 yrs47-245
10+ yrs71-397
Tissue Transglutaminase Ab, IgANegativeLT 4.0U/mL
Weak Positive4.0-10.0
PositiveGT 10.0
Gliadin Ab, IgANegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
This test was performed using a deamidated gliadin peptide (DGP) assay.
Gliadin Ab, IgGNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
This test was performed using a deamidated gliadin peptide (DGP) assay.
tTG antibody, especially IgA, is sensitive and specific for untreated celiac disease. Levels can decrease significantly in response to a gluten-free diet. The IgG assay is used mainly to detect celiac patients who are IgA-deficient.
CELIAC PROFILE PEDIATRIC BASICCELPEDCELPEDEIA/Nephelometry
TitleDescriptorRangesUnits
IgA0-30 days1-7mg/dL
1 mo1-56
2 mo3-49
3 mo5-48
4 mo4-76
5 mo8-87
6 mo8-70
7-8 mo12-93
9-11 mo17-87
1 yr15-110
2 yrs15-128
3 yrs23-164
4 yrs26-474
5-7 yrs35-210
8-9 yrs47-245
10+ yrs71-397
Tissue Transglutaminase Ab, IgANegativeLT 4.0U/mL
Weak Positive4.0-10.0
PositiveGT 10.0
tTG antibody, especially IgA, is sensitive and specific for untreated celiac disease. Levels can decrease significantly in response to a gluten-free diet. The IgG assay is used mainly to detect celiac patients who are IgA-deficient.
IMMUNOGLOBULIN E, TOTALIGECIGECFEIA
IgE                        kU/L
 0-11 mo     1.4-52.3
 1-4  yrs    0.4-351.6
 5-10 yrs    0.5-393.0
 11-15 yrs   1.9-170.0
 16+ yrs     0.0-158.0
 Minimum detectable concentration is
 2.0 kU/L.
ANTI-IGE RECEPTOR ANTIBODYIGERABIGERABFlow Cytometry
IgE Receptor Ab             0.0-5.0     %
IgE Receptor Ab Comment     Normal ranges for non-chronic urticaria
                            patients is less than 5% positive CD203c.
                            1 in 17 patients with a positive autologous
                            serum skin test (ASST) showed a resonse of
                            less than 5% CD203+ cells while 16 ir 17 showed
                            a response of greater than 5%.
BIRD FANCIERS PROFILE PNL IIIICBFP3ICBFP3Gel Diffusion (Ouchterlony), Immulite 2000, FEIA
TitleDescriptorRangesUnits
IgE1-11 months0-12IU/mL
1 year0-15
2 years1-29
3 years4-35
4 years2-33
5 years8-56
6 years3-95
7 years2-88
8 years5-71
9 years3-88
10 years7-110
11-14 years7-111
15-19 years6-96
20-30 years4-59
31-51 years5-79
51-80 years3-48
Chicken Feathers IgELT 0.35kU/L
Parrot Australian (Budgerigar) Droppings IgELT 0.35kU/L
Parrot Australian (Budgerigar) Feathers IgELT 0.35kU/L
Parrot Australian (Budgerigar) Serum Proteins IgELT 0.35kU/L
Pigeon Droppings IgELT 0.35kU/L
Canary Droppings Gel DiffusionNegative
Chicken Serum Gel DiffusionNegative
Cockatiel Droppings Gel DiffusionNegative
Finch Droppings Gel DiffusionNegative
Parakeet Droppings Gel DiffusionNegative
Parakeet Serum Gel DiffusionNegative
Parrot Droppings Gel DiffusionNegative
Parrot Serum Gel DiffusionNegative
Pigeon/Dove Droppings Gel DiffusionNegative
Pigeon/Dove Serum Gel DiffusionNegative
Aspergillus fumigatus Mix Gel DiffusionNegative
Aureobasidium pullulans Gel DiffusionNegative
IGF BINDING PROTEIN-1 (IGFBP-1)IGFP1IGFP1Radioimmunoassay
TitleDescriptorRangesUnits
IGF Binding Protein-1ng/mL
Adult5-34ng/mL
5-9 years15-95ng/mL
10-14 years8-64ng/mL
15-18 years5-40ng/mL
IGF BINDING PROTEIN-3IGFB3AIGFB3AChemiluminescent Immunoassay
IGF Binding Protein-3                            ng/mL
 Age - MALE                       Range
   0-12 mo                       1039-3169
   1-3 yrs                       972-4123
   4-5 yrs                       1843-4968
   6-7 yrs                       1838-4968
   8-9 yrs                       1932-5858
   10-11 yrs                     1828-6592
   12-13 yrs                     2134-6598
   14-15 yrs                     2330-6550
   16-17 yrs                     2380-6400
   18-19 yrs                     2340-6632
   20-24 yrs                     2404-5948
   25-29 yrs                     2614-5792
   30-34 yrs                     2500-5806
   35-39 yrs                     2474-5208
   40-44 yrs                     2360-5560
   45-49 yrs                     2314-5700
   50-54 yrs                     2528-5050
   55-59 yrs                     2482-5460
   60-64 yrs                     2592-4770
   65 yrs+                       2698-5688
   Tanner Stage I                1878-6190
   Tanner Stage II               2112-6208
   Tanner Stage III              2372-6602
   Tanner Stage IV-V             2336-6414
 Age - FEMALE
   0-12 mo                       1039-3169
   1-3 yrs                       1590-4225
   4-5 yrs                       2169-4790
   6-7 yrs                       2188-4996
   8-9 yrs                       2072-55-4
   10-11 yrs                     2456-6992
   12-13 yrs                     2838-6846
   14-15 yrs                     2654-6680
   16-17 yrs                     2756-6908
   18-19 yrs                     2700-6492
   20-24 yrs                     3032-5992
   25-29 yrs                     2926-5858
   30-34 yrs                     2878-6650
   35-39 yrs                     2786-6084
   40-44 yrs                     2514-6014
   45-49 yrs                     2838-4954
   50-54 yrs                     2562-5596
   55-59 yrs                     2574-5914
   60-64 yrs                     2684-5130
   65 yrs +                      2465-5274
   Tanner Stage I                2314-6086
   Tanner Stage II               2732-6738
   Tanner Stage III              2870-7068
   Tanner Stage IV-V             2756-7232
                    

IGF BINDING PROTEIN-3 (IGFBP-3)IGFB3PIGFB3PImmunoassay
IGF- Binding Protein-3                  mg/L      
   1-7 days              LT 0.7  
   8-15 days             0.5-1.4         
   16 days-1 yr          0.7-3.6         
   2 yrs                 0.8-3.9         
   3 yrs                 0.9-4.3         
   4 yrs                 1.0-4.7         
   5 yrs                 1.1-5.2         
   6 yrs                 1.3-5.6         
   7 yrs                 1.4-6.1         
   8 yrs                 1.6-6.5         
   9 yrs                 1.8-7.1         
   10 yrs                2.1-7.7         
   11 yrs                2.4-8.4         
   12 yrs                2.7-8.9         
   13 yrs                3.1-9.5         
   14 yrs                3.3-10.0         
   15 yrs                3.5-10.0         
   16 yrs                3.4-9.5         
   17 yrs                3.2-8.7         
   18 yrs                3.1-7.9         
   19 yrs                2.9-7.3         
   20 yrs                2.9-7.2         
   21-30 yrs             3.4-7.8         
   31-40 yrs             3.4-7.0         
   41-50 yrs             3.3-6.7         
   51-60 yrs             3.4-6.9         
   61-70 yrs             3.0-6.6         
   71-80 yrs             2.5-5.7         
   81-85 yrs             2.2-4.5         
   85+ yrs              No primary data         
            
   Tanner Stage         
   Females         
   Tanner I              1.2-6.4         
   Tanner II             2.8-6.9         
   Tanner III            3.9-9.4         
   Tanner IV             3.3-8.1         
   Tanner V              2.7-9.1         
   Males         
   Tanner I              1.4-5.2         
   Tanner II             2.3-6.3         
   Tanner III            3.1-8.9         
   Tanner IV             3.7-8.7         
   Tanner V              2.6-8.6         
            
Insulin-like growth factor binding proteins bind IGF-I and IGF-II with high 
affinity but do not bind insulin.  Of the 6 distinct IGF binding proteins
structurally characterized at this time, IGFBP-3 has been shown to be the major
carrier of the IGFs, transporting approximately 95% of the circulating IGF-I
and IGF-II.  IGFBP-3 is growth hormone (GH) responsive.  Thus levels are high
in acromegaly and low in hypopituitarism, and levels increase in GH-deficient
children after GH administration.  Other causes of short stature that result in
reduced IGFBP-3 levels include poorly controlled diabetes.  The IGFBP-3 assay is
useful in assessing nutritional status, since IGFBP-3 decreases during both caloric
and protein restriction.            
IMMUNOGLOBULIN G, SERUMIGGIGGNephelometry
IgG                      mg/dL
 0-30 days  603-1523
 1 mo       238-860
 2 mo       195-570
 3 mo       166-551
 4 mo       185-530
 5 mo       163-772
 6 mo       204-668
 7-8 mo     206-857
 9-11 mo    279-1014
 1 yr       327-1150
 2 yrs      402-997
 3 yrs      417-1077
 4 yrs      438-1173
 5-7 yrs    600-1214
 8-9 yrs    576-1490
 10+ yrs    758-1612
BULLOUS PEMPHIGOID AG IGGBPHAGGBPHAGGEnzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
IgG BP 180 antibodiesNegative< 9units
Positive> or = 9units
IgG BP 230 antibodiesNegative< 9units
Positive> or = 9units
IMMUNOGLOBULIN G, SUBCLASSESIGGSBIGGSBNephelometry
TitleDescriptorRangesUnits
IgG Subclass 1mg/dL
0-1 years151-792
1-3 years265-938
3-6 years362-1228
6-12 years377-1131
12-18 years362-1027
18+ years405-1011
IgG Subclass 2mg/dL
0-1 years26-136
1-3 years28-216
3-6 years57-290
6-12 years68-388
12-18 years81-472
18+ years169-786
IgG Subclass 3mg/dL
0-1 years9-92
1-3 years9-86
3-6 years13-79
6-12 years16-89
12-18 years14-106
18+ years11-85
IgG Subclass 4mg/dL
0-1 years0-46
1-3 years1-74
3-6 years1-145
6-12 years1-170
12-18 years5-199
18+ years3-201
The total IgG (mg/dL) can be derived from the sum of the subclass IgG1, IgG2, IgG3, and IgG4 values. However, a confirmatory and more precise total IgG is available by the nephelometric method for quantitative total IgG.
New method as of May 28, 2013. Results obtained by using The Binding Site reagents on a Siemens' BN II analyzer. Results may vary from previous method.
CSF/SERUM IGG INDEXIGG INDEXIGGINephelometry
TitleDescriptorRangesUnits
IgG, CSF0.5-7.7mg/dL
Albumin, CSF5-30mg/dL
IgG, Serum0-30 days603-1523mg/dL
1 month238-860
2 months195-570
3 months166-551
4 months185-530
5 months163-772
6 months204-668
7-8 months206-857
9-11 months279-1014
1 year327-1150
2 years402-997
3 years417-1077
4 years438-1173
5-7 years600-1214
8-9 years576-1490
10+ years758-1612
Albumin, Serum0-4 days2900-4600mg/dL
4 days-14 years3900-5600
14-18 years3300-4700
18-60 years3500-5000
60-90 years3300-4800
90+ years3000-4700
CSF/Serum Index0.25-0.75
OLIGOCLONAL BAND PROFILEOLIBNDOLIBNDIsoelectric Focusing/ Nephelometry/IF
IgG, Serum				mg/dL
 0-30 days		611-1542
 1 mo			241-870
 2 mo			198-577
 3 mo			169-558
 4 mo			188-536
 5 mo			165-781
 6 mo			206-676
 7-8 mo			208-868
 9-11 mo		282-1026
 1 yr			331-1164
 2 yrs			407-1009
 3 yrs			423-1090
 4 yrs			444-1187
 5-7 yrs		608-1229
 8-9 yrs		584-1509
 10+ yrs		768-1632
IgG, CSF		0.0-6.0		mg/dL
Albumin, CSF		0-35		mg/dL
Albumin, Index		0.0-9.0		ratio
IgG Index		0.28-0.66	ratio
CSF IgG/Albumin Ratio	0.09-0.25	ratio
CSF Oligoclonal Bands Number	0-1	bands
CSF Oligoclonal Bands Negative
Interpretation
CSF IgG Synthesis	8.0 or		mg/d
 Rate                 less
Albumin, Serum        3500-5200         mg/dL
IGH CCND1 (BCL-1/JH) FLD (PCR)BCL1FABCL1FAPCR
IGH-CCND1, Source               
IGH-CCND1 (BCL-1/JH) t(11;14) PCR         Negative: bcl-1/JH gene rearrangement is not
                                          detected.
                                          Positive: blc-1/JH gene rearrangement is
                                          detected.
                                          A positive result indicates the presence of a
                                          bcl-1/JH (11;14) chromosomal translocation.
                                          A negative result does not entirely exclude
                                          the presence of a bcl-1/JH chromosomal
                                          t(11;14) translocation.
IL28B-ASSOC VARIANTS, 2 SNPSIL28BAIL28BAQualitative Polymerase Chain Reaction/Qualitative Fluorescence Monitoring
IL28B-Associated Variants,2 SNP's Specimen Type
IL28B rs12979860
IL28B rs8099917
IL28B Associated Variants, SNPs Interpretation

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc. 
IMIPRAMINE & METABOLITEIMIIMDESHPLC
TitleDescriptorRangesUnits
Imipramineng/mL
No reference range established for parent drug. See Total for reference range, which takes into account all metabolites.
Desipramineng/mL
Therapeutic150-300
ToxicGT 499
Total Drugng/mL
Therapeutic150-300
ToxicGT 499
IMMUNE CELL FUNCTIONIMMCFAIMMCFALuminometer
TitleDescriptorRangesUnits
Immune Cell Functionng/mL ATP
Low Immune Cell ResponseLT or = 225
Moderate Immune Cell Response 226-524
High Immune Cell ResponseGT or = 525
CUTANEOUS BIOPSY (DIRECT IF)CUDIBACUDIBADirect Immunofluorescence (Direct Fluorescent Antibody Stain)
Immunodermatology Report
ALLERGIC BRONCH ASPERGIL PANELICABAPICABAPQuantitative ImmunoCAP® Fluorescent Enzyme Immunoassay/Qualitative Immunodiffusion
TitleDescriptorRangesUnits
Immunoglobulin E0-5 months2-13IU/mL
6-12 months2-34IU/mL
1-2 years2-97IU/mL
3 years2-199IU/mL
4-6 years2-307IU/mL
7-8 years2-403IU/mL
9-12 years2-696IU/mL
13-15 years2-629IU/mL
16-17 years2-537IU/mL
18+ years2-214IU/mL
A. fumigatus #1 AB, PrecipitinNone Detected
A. fumigatus #6 AB, PrecipitinNone Detected
Allergen, Fungi/Mold, A. fumigatusNo significant level detectedLT 0.10kU/L
Clinical revelance undetermined0.10-0.34kU/L
Low0.35-0.70kU/L
Moderate0.71-3.50kU/L
High3.51-17.50kU/L
Very High17.51 or greaterkU/L
Allergen, Interp, Immunocap Score IgE See below
IMMUNOPHENOTYPE SCREEN RFLXIPSCRNIPSCRNFlow Cytometry
Immunophenotyping Result
IMMUNOPHENOTYPE TISSUE SCREEN RFLXIPTISSIPTISSFlow Cytometry
Immunophenotyping Result
FRAGILE X SYNDROME MUTATION ANALYSISFRGXGFRGXGPCR & SB
Indication
Results
Comments
Method
Signed
INFLUENZA A VIRUS, IGGFLUAGFLUAGELISA
Influenza A Virus Antibody, IgG          IV
 0.89 or less      Negative-no significant
 level of influenza A virus IgG 
 antibody detected.
 0.90-1.10         Equivocal-questionable
 presence of influenza A virus IgG  
 antibody  detected. Repeat testing in 1
 0-14 days may be helpful.
 1.11 or more      Positive-IgG antibody
 to influenza A virus detected, which 
 may suggest current or past infection.
INFLUENZA B VIRUS, IGGFLUBGFLUBGELISA
Influenza B Virus Antibody, IgG          IV
 0.89 or less      Negative-no significant
 level of influenza B virus IgG 
 antibody detected.
 0.90-1.10         Equivocal-questionable
 presence of influenza B virus IgG  
 antibody  detected. Repeat testing in 1
 0-14 days may be helpful.
 1.11 or more      Positive-IgG antibody
 to influenza B virus detected, which 
 may suggest current or past infection.
INHIBIN AINHAINHAQuantitative Chemiluminescent Immunoassay
TitleDescriptorRangesUnits
Inhibin A (Dimer)pg/mL
Female Normal Cycling
Early follicular phase (-14 to -10)1.8-17.3
Mid-follicular phase (-9 to -4)3.5-31.7
Late follicular phase (-3 to -1)9.8-90.3
Mid-cycle (day 0)16.9-91.8
Early luteal ( 1 to 3)16.1-97.5
Mid-luteal (4-11)3.9-87.7
Late luteal (12 to 14)2.7-47.1
IVF Peak levels354.2-1690.0
PCOS
Ovulatory5.7-16.0
PostmenopausalLT 6.9
MaleLT 2.1
This assay is performed using the Beckman Coulter Unicel DxI Assay. Values may be elevated during normal pregnancy. Preclampsia, Down syndrome, and some cancers may increase Inhibin-A values.
EPIDERMAL (SKIN) ABEPIDABEPIDABIFA
TitleDescriptorRangesUnits
Intercellular Substance AntibodyLT 1:10Titer
Basement Membrane AntibodyLT 1:10Titer
Interpretive Criteria
Antibody not detectedLT 1:10
Antibody detected1:10 or more
This assay tests for two antibody specificities:
1) Autoantibodies to intercellular substance of the epidermis. This antibody strongly suggests the diagnosis of pemphigus (all forms), although it may be rarely present in burn patients and trichophyton infections. The rise and fall of the titer may be indicative of relapse and remission of the disease respectively.
2) Antibody to the dermal-epidermal basement membrane. This antibody is highly specific for bullous pemphigoid and is present in 80% of these patients.
INTERFERON-BETA, IGGINFBEGINFBEGELISA
Interferon-Beta Used for Treatment
Interferon-Beta, IgG     LT 4.0   Units
 Some multiple sclerosis patients
 receiving recombinant interferon-
 beta (IFNb) develop IFNb-specific
 antibodies that may block the
 therapeutic effect of the treatment.
 This assay screens for IgG antibodies
 capable of binding to IFNb; all samples
 with detectable IFNb binding antibodies
 should be tested for IFNb neutralizing
 antibodies.
IODINE, URINE 24HRIODUQMIODUQMInductively Coupled Plasma-Mass Spectrometry
TitleDescriptorRangesUnits
Iodine, 24 hr16-150 yrs93-1125mcg/species
Collection Periodhrs
Urine VolumemL
Iodine Concentration16-150 yrs26-705mcg/L
IRON, LIVER IRNLIAIRNLIAQuantitative Inductively Coupled Plasma-Mass Spectrometry
TitleDescriptorRangesUnits
Iron Weightmg
Hepatic Iron ConcentrationMale200-2,000ug/g of tissue
Female200-1,600
Hepatic Iron IndexLT 1.0
ISOAGGLUTININ TITER, ANTI-AISOATISOATHemagglutination
Isoagglutinin Titer, Anti-A     Titer
ISOAGGLUTININ TITER, ANTI-BISOBTISOBTHemagglutination
Isoagglutinin Titer, Anti-B     Titer
ITRACONAZOLE, HPLCITRACITRACHigh Performance Liquid Chromatography
TitleDescriptorRangesUnits
Itraconazole is metabolized in humans to hydroxyitraconazole, a bioactive metabolite. Both itraconazole and hydroxyitraconazole levels are determines and reported. Levels may vary based on route and regimen of dosing (IV and Oral).
200 mg dosing steady state ranges:
ItraconazoleIV, 7 days1.0-4.8mcg/mL
Hydroxyitraconazole1.3-2.5mcg/mL
ItraconazoleOral, 36 days0.6-3.4mcg/mL
Hydroxyitraconazole0.9-4.3mcg/mL
JO-1 AUTOANTIBODY, IGGJO1MPJO1MPMultiplex Luminex
JO-1 Autoantibody, IgG     Negative       LT 1.0       AI
                           Positive       1.0 or more
JUNIPER WESTERN IGEICJWEIICJWEIRIA
TitleDescriptorRangesUnits
Juniper Western IgELT 0.35kU/L
Juniper Western Class
FREE LIGHT CHAINS PANELGAMPANGAMPANNephelometry/Agarose Gel ELP, IFE
TitleDescriptorRangesUnits
Kappa FLC0.33-1.94mg/dL
Lambda FLC0.57-2.63
Kappa/Lambda FLC Ratio0.26-1.65
Results obtained by using The Binding Site reagents on a Siemens' BN II analyzer.
Protein, Totalg/dL
0-12 months4.3-6.9
1-3 years5.2-7.4
3-6 years5.6-7.7
6-10 years6.5-8.3
10-18 years6.1-8.0
18-60 years6.3-8.0
60+ years6.1-7.8
Albuming/dL
0-4 days2.9-4.6
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
Alpha-10.1-0.4g/dL
Alpha-20.5-1.1g/dL
Beta-10.4-0.8g/dL
Beta-20.2-0.5g/dL
Gamma0.6-1.5g/dL
Albumin45.0-80.0%
Alpha-11.0-6.0%
Alpha-26.0-17.0%
Beta-15.0-13.0%
Beta-22.0-8.0%
Gamma7.5-24.0%
Interpretation
Monoclonal Peak
If Positive
Monoclonal Proteing/dL
Monoclonal Protein %%
Monoclonal Protein (2)g/dL
Monoclonal Protein (2)%%
Immunofixation Interpretation
KELL ANTIGENKELL.AGKELLAGTube Agglutination
Kell Antigen
 Separate Report to Follow
KEPPRA (LEVETIRACETAM)KEPKEPEIA
Keppra        5-30             ug/mL
 The proposed therapeutic range for
 seizure control is 5-30 ug/mL. 
 Pharmacokinetics of levetiracetam
 are affected by renal function. The
 relationship between serum concen-
 trations and toxicity is not known.
KETAMINE AND METABOLITE SCREEN, SERUM/PLASMA (REFLEX)KETACOKETACOGC/MS
Ketamine                         ng/mL
Norketamine                      ng/mL
Ketamine, Confirmation           ng/mL
 500-6500 ng/mL reported level during
 anesthesia.
Norketamine, Confirmation        ng/mL
 The intravenous administration of 2
 ng/kg of ketamine followed by 
 continuous infusion of 41 mcg/kg/min
 produced an average steady-state 
 plasma concentration of 2200 ng
 ketamine/mL and a average peak nor-
 ketamine level of 1050 ng/mL which
 occurred near the end of the 3-hour
 infusion.
LEISHMANIA PANELLEISIBLEISIBIFA
L. donovani, IgG      LT 1:16
L. donovani, IgM      LT 1:20
Interpretation
L. braziliensis, IgG  LT 1:16
L. braziliensis, IgM  LT 1:20
Interpretation
L. mexicana, IgG      LT 1:16
L. mexicana, IgM      LT 1:20
Interpretation
L. tropicalis, IgG    LT 1:16
L. tropicalis, IgM    LT 1:20
Interpretation
LACOSAMIDE, SERUM/PLASMALACOSLACOSHigh Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
TitleDescriptorRangesUnits
Lacosamidemcg/mL
Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively.
Mean plasma concentrations following maintenance doses
200 mg/day4.99 +/-2.51mcg/mL
400 mg/day9.35 +/-4.22mcg/mL
600 mg/day12.46 +/-5.60mcg/mL
NMS Labs derived data
5th - 95th Percentile Data1.8 - 13.0mcg/mL
Mean5.3mcg/mL
(N = 14900)
DISACCHARIDASE ANALYSISDISACDISACSpectrphotometry
TitleDescriptorRangesUnits
LactaseNormal16.5-32.5uM/min/gram protein
AbnormalLT 15.0
SucraseNormal29.0-79.8uM/min/gram protein
AbnormalLT 25.0
MaltaseNormal98.0-223.6uM/min/gram protein
AbnormalLT 100.0
PalatinaseNormal4.6-17.6uM/min/gram protein
AbnormalLT 5.0
Interpretation
ORGANIC ACIDS, URINEORAUORAUGas Chromatography/Mass Spectrometry
TitleDescriptorRangesUnits
LacticLT 1 monthLT 125mg/gC
1 month-1 yearLT 95
GT 1 yearLT 80
*PyearuvicLT 1 monthLT 60mg/gC
1 month-1 yearLT 60
GT 1 yearLT 51
3-OH-ButyearicLT 1 monthLT 150mg/gC
1 month-1 yearLT 150
GT 1 yearLT 150
AcetoaceticLT 1 monthLT 59mg/gC
1 month-1 yearLT 59
GT 1 yearLT 59
EthylmalonicLT 1 monthLT 32mg/gC
1 month-1 yearLT 26
GT 1 yearLT 19
FumaricLT 1 monthLT 45mg/gC
1 month-1 yearLT 40
GT 1 yearLT 40
GlutaricLT 1 monthLT 20mg/gC
1 month-1 yearLT 28
GT 1 yearLT 29
3-MethylglutaricLT 1 monthLT 10mg/gC
1 month-1 yearLT 10
GT 1 yearLT 10
3-MethylglutaconicLT 1 monthLT 35mg/gC
1 month-1 yearLT 45
GT 1 yearLT 45
AdipicLT 1 monthLT 24mg/gC
1 month-1 yearLT 64
GT 1 yearLT 25
2-KetoglutaricLT 1 monthLT 448mg/gC
1 month-1 yearLT 544
GT 1 yearLT 153
SubericLT 1 monthLT 42mg/gC
1 month-1 yearLT 46
GT 1 yearLT 32
SebacicLT 1 monthLT 38mg/gC
1 month-1 yearLT 25
GT 1 yearLT 14
Interpretation
RDS BY LAMELLAR BODY COUNTLBCLBCAutomated Cell Count
Lamellar Body Counts   Mature       GT 50000    Lamellar bodies/uL
                       Transitional 35000-50000
                       Immature     LT 35000
LIPID ASSOCIATED SIALIC ACIDLASALASASpectrophotometric
LASA    0-20     mg/dL
LACTATE DEHYDROGENASELDHLDEnzymatic
LD                        U/L
 0-4 days      290-816
 4-10 days     545-2105
 10 days-24 mo 180-453
 24 mo-12 yrs  110-311
 12-60 yrs     115-225
 60-90 yrs     110-221
 90 yrs+       99-299
LD, FLUIDLDH.FLDLDFLEnzymatic
LD, Fluid           U/L
 Exudate      200 or greater
 Transudate   LT 200
 Method not validated for body fluid.
 Clinical correlation necessary.
LACTATE DEHYDROGENASE, ISOENZYMESLDISOLDISOQuantitative Enzymatic/Electrophoresis
TitleDescriptorRangesUnits
LDH, TotalU/L
0-30 days200-465
1-17 months200-450
18 months-10 years165-430
11-16 years127-287
17+ years105-230
LD114-27%
LD229-42%
LD318-30%
LD48-15%
LD56-23%
DIRECT LDLDLDLDLDLElimination/Enzymatic
TitleDescriptorRangesUnits
LDL Cholesterol, DirectOptimalLT 100mg/dL
Near or above optimal100-129
Borderline high130-159
High160-189
Very high190 or more
LDL PARTICLE SIZELDLPSLDLPS
LDL Particle Size     Separate Report to Follow
LEAD AND ZPP OSHA PROFILEOSHAPROSHAPRAA800 & AA600
TitleDescriptorRangesUnits
Lead, Bloodug/dL
0-15 years0-5
15+ years0-10
Critical highGT 70
Zinc Protoporphyrinumol/mol
23-78
ZPP-OSHA Calculationug/dL
13-46
Note
Number of TestsAction Requiredug/dL Lead
1Notification of greater workers in writing; medical examination of workers and consultation40.0 or greater
3 (average)Removal of worker greater job with potential lead exposure50.0 or greater
1Removal of worker greater from job with potential lead exposure60.0 or greater
2Reinstatement of worker less in job with potential lead exposure is based on symptoms and medical evaluation40.0 or less
Federal lead construction standards require workers to be notified and removed from job at lead levels of 50 ug/dL and higher until a physician authorizes return. OSHA requirements in effect since 1978 call for the measurement of whole blood lead and zinc protoporphyrin (ZPP NCCLS document C42-A, Nov. 1996) to evaluate the occupational exposure to lead. OSHA requires ZPP whole blood testing in units of ug/dL. For adults, conversion of ZPP units to ug/dL whole blood assumes a hematocrit of 45%. Conversion factor: mol/mol heme x 0.584 = ug/dL.
LEAD, WHOLE BLOODLEADPBAA800 & AA600
TitleDescriptorRangesUnits
Lead, Bloodug/dL
0-15 years0-5
15+ years0-10
Critical highGT 70
LEAD, SERUMLEAD.SPBSNMSInductively Coupled Plasma/Mass Spectrometry
TitleDescriptorRangesUnits
Lead, SerumNormal< 1mcg/dL
LEGIONELLA ANTIBODY, IGG/IGM/IGALEGLEGABEIA
TitleDescriptorRangesUnits
Legionella Ab, IgG/IgM/IgAODR
Negative - Antibodies to Legionella pneumophila serogroups 1-6 not detectedLT 0.91
Equivocal - Testing of a second specimen in 3 to 9 weeks suggested0.91-1.09
Positive - Suggestive of Legionella pneumophila infectionGT 1.09
LEGIONELLA PNEUMOPHILA ANTIBODY 1-6, IGMLEGABMLEGABMIFA
Legionella pneumophila Antibody 1-6, IgM
 LT 1:16
 IgM antibody to Legionella pneumophila serotypes 1-6 is measured 
 using an IgM-specific conjugate.
 It is recommended that the IgM test
 always be performed in conjunction
 with IgG antibody test. The IgM
 response to Legionella tends to
 develop concurrently with the IgG
 response and may remain elevated as
 long as the IgG response remains
 elevated. Cross-reactions have
 been described with several species
 of bacteria and mycoplasma.
LEMON IGEICFLEMICFLEMImmunoCap FEIA
TitleDescriptorRangesUnits
Lemon IgELT 0.35kU/L
LEPTINLEPTNALEPTNAQuantitative Chemiluminescent Immunoassay
TitleDescriptorRangesUnits
Leptin0-17 yearsNot Establishedng/mL
Adult Male0.5-12.7
Adult Female0.5-15.2
LEPTOSPIROSIS ANTIBODYLEPTOSPIROSISLEPTSemi-Quantitative Indirect Hemagglutination
Leptospira Ab                                  Titer
 LT 1:50            No antibody detected                
 1:50               Borderline positve-patients
                    should be evaluated for
                    clinical correlation with
                    active of recent leptospirosis.
                    Suggest repeat testing in 2-3 weeks.
 1:100 or greater   Positive-suggestive of current or
                    recent leptospirosis.
LEUCINE AMINOPEPTIDASELEUCINELEUCINSpectrophotometric
Leucine Aminopeptidase      U/mL
 M  1.1-3.4    
 F  1.2-3.0
LUTEINIZING HORMONE & FOLICLE STIMULATING HORMONELH/FSHLHFSHICMA
LH                             mIU/mL
 M 7-9 yrs           0.0-0.7
   10-12 yrs         0.0-3.4
   13-15 yrs         0.3-5.6
   16-17 yrs         1.1-9.0
   18 yrs+           1.7-8.6
   Tanner Stage I    0.0-1.0
   Tanner Stage II   0.0-3.6
   Tanner Stage III  0.2-6.4
   Tanner Stage IV-V 0.9-8.3
 F 7-9 yrs           0.0-0.7
   10-12 yrs         0.0-6.8
   13-15 yrs         0.3-23.0
   16-17 yrs         0.0-26.4
   18 yrs+
  Follicular         2.4-12.6
  Mid-cycle          14.00-95.6
  Luteal phase       1.0-11.4  
  Post menopausal    7.7-58.5
  Tanner Stage I     0.0-9.3
  Tanner Stage II    0.0-16.0
  Tanner Stage III   0.0-23.0
  Tanner Stage IV-V  0.0-19.1
FSH                            mIU/mL
 M  7-9 yrs          0.3-2.3
    10-12 yrs        0.5-4.4
    13-15 yrs        1.0-6.7
    16-17 yrs        0.8-7.0
    18 yrs +         1.4-11.2
   Tanner Stage I    0.3-2.6
   Tanner Stage II   0.5-4.3
   Tanner Stage III  0.9-5.8
   Tanner Stage IV-V 0.9-7.3    
 F  7-9 yrs          0.4-4.0
    10-12 yrs        0.6-7.5
    13-15 yrs        0.9-8.2
    16-17 yrs        0.4-8.9
    18 yrs+           
   Follicular        3.2-11.3
   Midcycle peak     4.2-19.4       
   Luteal phase      1.5-6.9                   
   Postmenopausal    23.2-121.3
   Tanner Stage I    0.5-7.6
   Tanner Stage II   0.5-8.0
   Tanner Stage III  0.5-8.0
   Tanner Stage IV-V 0.6-8.4
WOMEN'S HORMONE HEALTH PANELWHOPANWHOPAN
LHFSH   
ESTF   
DHEAS   
TESAMS   
PROGES
LIBRIUM AND NORDIAZEPAMLIBLIBHPLC
TitleDescriptorRangesUnits
Libriumug/mL
Dose (Adult): 5-100 mg0.5-3.0
ToxicGT 5.0
Nordiazepamug/mL
Based on normal dosages0.1-1.5
ToxicGT 2.5
LIDOCAINELIDOCNLIDOCNEIA
Lidocaine              ug/mL
 Therapeutic  1.5-5.0  
 Toxic        GT 6.0
LIME IGEICLEIICLEIImmunoCap FEIA
TitleDescriptorRangesUnits
Lime IgELT 0.35kU/L
Lime Class
LIPASELIPASELIPAColorimetric
TitleDescriptorRangesUnits
Lipaseat 37C7-60U/L
LIPOPROTEIN (A)LPALPARate Nephelometry
TitleDescriptorRangesUnits
Lipoprotein (a)2-72mg/dL
African-American4-109
LISTERIA ANTIBODYLISABLISABCF
Listeria Antibody   LT 1:8      No antibody detected.
                    1:8 or more Antibody detected.
                    Single titers of 1:8 or greater are
                    suggestive of listeria infection.
                    A four-fold or greater increase
                    in titer between acute and convalescent
                    specimens confirms the diagnosis.
          
           
LITHIUMLILISpectrophotometric
TitleDescriptorRangesUnits
LithiumTherapeutic0.5-1.5mmol/L
ToxicGT 2.0
LIVER CYTOSOL AUTOANTIBODIES (LC-1)LIVCYTLIVCYTEIA
Liver Cytosol Autoantibodies      U/mL
 LT 15
LORAZEPAMLORLORQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Lorazepamng/mL
Therapeutic (Adult) dose 1-10 mg/d50-240
ToxicGT 300
LOXAPINELOXALOXAHPLC
Loxapine            ng/mL
 Peak concentration following a single
 oral 25 mg dose    6-13 at 1-2 h post dose.
 Peak plasma concentrations following
 an equivalent IM dose are similar.
B. BURGDORFERI AB (LYME), CSFLYMECFLYMECFELISA
TitleDescriptorRangesUnits
Lyme (B.burgdorferi) Ab, CSFLIV
Negative-Antibody to Borrelia burgdorferi not detected0.99 or less
Equivocal-Repeat testing in 10-14 days may be helpful1.00-120
Positive-Probable presence of antibody to Borrelia burgdorferi detected 1.21 or more
B. BURGDORFERI IDXLYME.CSF&SER.SBIDXSBELISA
Lyme Serum and CSF
LYMPHOCYTE ANTIGEN & MITOGEN PROLIFERATION PANELLAMALAMACell Culture
Lymphocyte Antigen & Mitogen Proliferation Panel
LYSOZYMEMURLYSOZRID
Lysozyme      9-17     ug/mL
MYELIN ASSOC. GLYCOPROTEIN (MAG) ANTIBODY W/REFLEX TO MAG-SGPG & MAG, EIAMYAGABMYAGABWestern Blot/Enzyme Immunoassay
MAG Ab (IgM), Western Bl      Neg         
MAG-SGPG Ab                   < or = 1:1600       titer   
MAG Ab, (IgM), EIA            < 1:1600            titer   
CATHARTIC LAXATIVES PROF, STOOLCLAXSNCLAXSNIon Coupled Plasma/Optical Emission Spectrophotometry
Magnesium                                         mg/g
    Magnesium concentrations in stool water
    above the normal levels of 0.7-1.2 mg/mL 
    have been indicative of surreptitious abuse 
    of magnesium containing laxatives.

    NMS Labs calculated normal:
    Approximately 0.5-10 mg/g
    (Based on the reported range of magnesium 
    eliminated per day in stool and the range 
    of stool mass per day in adults.)

Phosphorus                                        mg/g
    Phosphorus concentrations in stool water        
    averaged 1.8 +/- 0.3 mg/mL (ranged from 
    0.3-4.2 mg/mL) following administration 
    of 105 mmol of sodium phosphate.

    NMS Labs calculated normal:
    Approximately 1.4-22 mg/g
    (Based on the reported range of phosphorus 
    eliminated per day in stool and the range of 
    stool mass per day in adults.)
MAGNESIUMMAGMGColorimetric
TitleDescriptorRangesUnits
Magnesiummg/dL
0-20 days1.9-4.6
21 days-12 months1.7-3.2
1-3 years2.2-3.2
4-18 years2.1-2.9
19+ years1.7-2.4
MALARIA EVALUATIONMALEVLMALEVLMicroscopic (thick and thin smears)
Malaria                       None Seen
Number of RBC's Scanned
Number of Parasitized Cells
Percent Parasitemia           0          %
Speciation
Reviewed by
MALARIA ANTIBODY IGGMALIGGMALIGGSemi-Quantitative Enzyme-Linked Immunosorbent Assay
Malaria Antibody, Total     0.00-1.00 IV
MAPLE LEAF SYCAMORE TREE IGEICTSYICTSYImmunoCap FEIA
TitleDescriptorRangesUnits
Maple Leaf Sycamore Tree IgELT 0.35kU/L
ALTERNATE AMPHETAMINE CONFIRMATION TESTING BY GC/MSPALTAPPALTAPGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
MDMApositive cutoff250ng/mL
MDApositive cutoff250ng/mL
MDEApositive cutoff250ng/mL
MELATONINMELQRMELQRQuantitative Radioimmunoassay
TitleDescriptorRangesUnits
Melatoninpg/mL
Adults
Daytime3.4-53.9
Nighttime7.1-89.5
MEPERIDINEMERMEPGC
TitleDescriptorRangesUnits
MeperidineExpected analgesic range0.1-0.6mcg/mL
NormeperidineUp to 0.5mcg/mL
This test is for clinical use only.
MEPERIDINE BY GC/MSMSMEPMSMEPGC/MS
TitleDescriptorRangesUnits
MeperidinePositive cutoff100ng/mL
NormeperidinePositive cutoff100ng/mL
MEPERIDINE SCREEN (REFLEX)MEPUMEPUEIA/Confirmation by GC/MS
TitleDescriptorRangesUnits
MeperidinePositive cutoff200ng/mL
MEPHOBARBITALMEBARALMEPHOBQuantitative Gas Chromatography-Mass Spectrometry
TitleDescriptorRangesUnits
Mephobarbitalug/mL
Therapeutic (Adult) dose 200-600 mg/d1-7
ToxicGT 15
CARISOPRODOL AND MEPROBAMATE MEPROBAMATECARMEPGC/MS
TitleDescriptorRangesUnits
MeprobamateTherapeutic5-20ug/mL
ToxicGT 40
CarisoprodolTherapeuticLT 8ug/mL
Toxic8 or more
MERCURY, WHOLE BLOODMERCMERCQuantitative Atomic Absorption/Quantitative Inductively Coupled Plasma-Mass Spectrometry
Mercury, Blood    0-10    ug/L
 This test measures total mercury,
 whereas the reference interval
 relates to inorganic mercury
 concentrations. Dietary and non-
 occupational exposure to organic
 mercury species may contribute to
 an elevated total mercury result.
MERCURY, SERUM/PLASMA HGQTHGQTICP/MS
TitleDescriptorRangesUnits
Mercury, Serum, QuantitativeNormalUp to 6mcg/mL
METHADONE (EDDP) PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPMETCPMETCGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
Methadone Metab (EDDP)positive cutoff300ng/mL
METHADONE & METABOLITE, SERUM/PLASMAMETMBNMETMBNGC/MS
TitleDescriptorRangesUnits
MethadoneUsual narcotic stabilization range50-1000ng/mL
EDDPng/mL
METHAQUALONEMETHAMETHAGC/MS
TitleDescriptorRangesUnits
Methaqualonemcg/mL
Reported blood levels associated with
Erratic driving2-12
Mild toxicity2-16
UnconsciousnessGT 8
METHSUXIMIDE (CELONTIN) AND NORMETHSUXIMIDECELONTINMSUXGC
TitleDescriptorRangesUnits
Methsuximideug/mL
TherapeuticLT 1
Normethsuximideug/mL
Therapeutic10-40
Totalug/mL
Therapeutic10-40
ToxicGT 60
METHYLMALONIC ACID (MMA) QUANTITATION, URINEURMMAURMMALiquid Chromatography-Tandem Mass Spectrometry LCMSMS, Enzymatic (IDMS Traceable)
Methylmalonic Acid (Urine)                                   umol/L   
Methylmalonic Acid [Calculated]     0.0-3.6                  mmol/moLCRT   
                     
Creatinine, Urine (Random)          No Normals Established   mg/dl   
Creatinine, Urine (24 Hour)         
  Creatinine, Ur                    g/24h
  M                                 0.8-2.0                  mg/dl   
  F                                 0.6-1.8                  mg/dl
METHYLPHENIDATE AND METABOLITE, URINERIT-URITAURHigh Performance Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Methylphenidate, Urineng/mL
Adult100-900 ng/mL in the 8 hours following a 25 mg oral dose to adults
Concentration as high as 3300 ng/mL have been reported in the 6 hour urine of children following a 10 mg dose.
Methylphenidate Metabolite, Urineng/mL
Concentrations as high as 64000 ng/mL have been reported in the 6 hour urine in children following a 10 mg dose.
MEXILETINEMEXIMEXIQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Mexiletineug/mL
Therapeutic Range1.0-2.0
Toxic LevelGT 2.0
MICROSOMAL ANTIBODY LIVER/KIDNEYMICROLKLKMIFA
TitleDescriptorRangesUnits
Microsomal Ab Liver/KidneyNegativeLT 1:20Titer
MICROSPORIDIA STAIN BY MODIFIED TRICHROME MICROSPORIDIAMCSPRMicrosporidia Stain by Modified Trichrome
Microsporidia Source
Microsporidia Stain          Negative
MITOCHONDRIAL ANTIBODIESMAMAIFA
Mitochondrial Ab
 Negative  LT 1:20
MITOCHONDRIAL M2 ANTIBODY, IGGMM2ABMM2ABELISA
Mitochondrial M2 Antibody, IgG    Units
 20.0 or less      Negative
 20.1-24.0         Equivocal
 25.0 or more      Positive
MOLINDONE, SERUM/PLASMAMOBANMOBHigh Performance Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Moban (Molindone)Steady state plasma levels from patient doses of 100 to 400 mg/day39-874 with high interpatient variabilityng/mL
MONONUCLEOSIS TESTMONMONOHA
Mono Test      Negative
MORICIZINEMORMORHPLC
TitleDescriptorRangesUnits
Moricizineug/mL
Steady state trough (with 200 mg dose 3 times/dose)0.02-0.18
Peak (1-3 hrs following single 500 mg oral dose)0.48-1.54
MYELOPROLIFERATIVE LEUKEMIA VIRUS ONCOGENE (MPL) W515 MUTATION ANALYSISMPL515MPL515Polymerase Chain Reaction
TitleDescriptorRangesUnits
MPL W515 Mutation AnalysisNot detected
MRSA NASAL SCREEN BY PCRMRSPCAMRSPCRPolymerase Chain Reaction
MRSA PCR Result
MRSA PCR Status
HNPCC LYNCH SYN (MSH2) SQUENCEMSH2AMSH2APCR
MSH2 Specimen
MSH2 Full Gene Analysis
MTHFR C677T AND A1298CMTINVMTINVPCR-eSensor
MTHFR Result      
 Negative for C677T and A1298C mutations.
 A negative result does not rule out other
 causes for hyperhomocysteinemia, coronary
 artery disease or venous thrombosis.
MTHFR Comment
 Patient DNA is assayed for the C677T and
 A1298C mutations by polymerase chain reactions
 (PCR) and eSensor technology. The product of PCR
 is detected on the GenMark XT-8 system. Patients
 receiving genetics testing should consider genetic
 counseling. Counseling of potentially affected
 family members may also be warranted.
MTHFR Comment
 This test is FDA approved and is intended for
 in vitro diagnostic use. This test is performed
 pursuant to an agreement with Roche Molecular
 Systems, Inc.
MUCOPOLYSACCHARIDES, QUANTITATIVE, URINEMPQTUAMPQTUASpectrophotometry
TitleDescriptorRangesUnits
Mucopolysaccharides, Urinemg/mmolCRT
0-5 mo14.6-47.8
6-11 mo3.7-35.5
1-2 yrs5.4-30.8
3-6 yrs5.2-30.8
7-13 yrs2.4-10.2
14 yrs+0.0-7.1
MUMPS VIRUS ANTIBODY, IGGMUMPSGMUMPSGEIA
TitleDescriptorRangesUnits
Mumps Virus Antibody, IgGOD
Negative - No significant level of detectable mumps virus Ab. 0.90 or less
Equivocal - Repeat testing in 10- 14 days may be helpful.0.91-1.09
Positive - IgG Ab to mumps virus detected, which may indicate a current or previous exposure/immunization to mumps virus. Positive IgG Ab levels in the absence of current clinical symptoms may indicate immunity.1.10 or more
MUMPS VIRUS ANTIBODY, IGMMUMPSMMUMPSMSemi-Quantitative Enzyme-Linked Immunosorbent Assay
Mumps Virus Antibody, IgM     IV
 0.79 or less    Negative-No significant
 level of detectable IgM Ab to Mumps 
 Virus.
 0.80-1.20       Equivocal-Borderline
 levels of IgM Ab to Mumps virus.
 Repeat testing in 10-14 days may be
 helpful.
 1.21 or greater Positive-Presence of
 IgM Ab to Mumps virus detected.
 However, low levels of IgM antibodies
 may occasionally persist for more than
 12 months post-infection or immuni-
 zation.
MYCOPHENOLIC ACIDMCPAMCPAHPLC
Mycophenolic Acid 1.0-5.0               ug/mL
 MPA does not have well established
 or therapeutic ranges. Dosing of 2 g/day gives
 trough values of 1.0-3.5 ug/mL while
 3 g/day gives values up to 5.0 ug/mL.
 Trough levels between 2.0-4.0 ug/mL
 have been suggested to maximize
 efficacy and minimize adverse effects.
MYCOPLASMA PNEUMONIAE ANTIBODY, IGG & IGMMPABGMMPABGMEIA
Mycoplasma Pneumoniae Antibody,  IgG                                U/L
  LT 0.100       Negative     No detectable IgG antibody, suggests no prior exposure to 
                              Mycoplasma pneumoniae.  Result does not rule out recent 
                              exposure.         
  0.100-0.320    Equivocal    Borderline antibody result. Testing of a 2nd specimen in
                              4 to 6 weeks suggested.      
  GT 0.320       Positive     Indicates recent or past exposure with Mycoplasma 
                              pneumoniae.      
Mycoplasma Pneumoniae Antibody, IgM                                 U/L
  LT 0.770       Negative     No clinically significant amount 
                              of Mycoplasma pneumoniae IgM antibody detected.        
  0.770-0.950    Low Positive Mycoplasma pneumoniae IgM
                              antibody presumptively detected. Testing of 
                              a 2nd specimen in 1 to 2 weeks suggested.      
  GT 0.950       Positive     A significant amount of Mycoplasma 
                              pneumoniae specific IgM antibody detected.   
                              Low levels of IgM antibodies may persist for
                              more than 12 months post-infection.
MYCOPLASMA PNEUMONIAE ANTIBODY, IGGMPABGMPABGEIA
Mycoplasma Pneumoniae Antibody,  IgG                                U/L
 LT 0.100         Negative    No detectable IgG antibody, suggests no prior exposure to 
                              Mycoplasma pneumoniae.  Result does not rule out recent 
                              exposure.         
 0.100-0.320      Equivocal   Borderline antibody result. Testing of a 2nd specimen in
                              4 to 6 weeks suggested.      
 GT 0.320         Positive    Indicates recent or past exposure with Mycoplasma 
                              pneumoniae.
MYCOPLASMA PNEUMONIAE ANTIBODY, IGMMPABMMPABMEIA
Mycoplasma Pneumoniae Antibody, IgM     U/L
 < 0.770      Negative      No clinically significant amount 
                            of Mycoplasma pneumoniae IgM antibody detected.        
 0.770-0.950  Low Positive  Mycoplasma pneumoniae IgM
                            antibody presumptively detected. Testing of 
                            a 2nd specimen in 1 to 2 weeks suggested.      
 > 0.950      Positive      A significant amount of Mycoplasma 
                            pneumoniae specific IgM antibody detected.   
                            Low levels of IgM antibodies may persist for
                            more than 12 months post-infection.
MYELOPEROXIDASE ANTIBODYMPOMPOEIA
Myeloperoxidase Antibody     Units
 Negative          LT 20
 Weak to Mod Pos   20-30
 Positive          GT 30
PEROXIDASE STAINSS.PERCSMPOCytochemical Stain
Myeloperoxidase Source
Myeloperoxidase Stain       Negative
Myeloperoxidase Interp    
Myeloperoxidase Reviewed By
ANTI-MYOCARDIAL ANTIBODY, IGG WITH REFLEX TO TITERABMYOABMYOSemi-Quantitative Indirect Fluorescent Antibody
Myocardial Ab, IgG Screen   LT 1:20              
Myocardial Ab, IgG Titer    LT 1:20
MYOGLOBINMYOGLOBINMYOChemiluminescence Assay
Myoglobin       
   M      109 or less      ng/mL   
   F      69 or less       ng/mL
MYOGLOBIN, URINEMYOGLOBIN-UMGNPURElectrochemiluminescent Immunoassay
Myoglobin, Urine         mg/L 
 Negative   0-1   
 1-15 mg/L Associated with vigorous
 exercise, myocardial infarction,
 mild muscle injury, and other
 conditions. GT 15 mg/L at risk of
 acute renal failure. Usual results
 less than 1 mg/L.
PROCAINAMIDE & NAPAPROCNAPROCNAFPI
N-acetyl-Procainamide 6.0-20.0 ug/mL
                      Toxic 35.1 or more
(NAPA)
Procainamide          4.0-10.0 ug/mL
                      Toxic 12.1 or greater
N-METHYLHISTAMINE, URINENMHUNMHULiquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)/Enzymatic Colorimetric Assay
TitleDescriptorRangesUnits
N-Methylhistamine, Urine0-5 years120-510mcg/g
6-16 years70-330
> 16 years30-200
N-TELOPEPTIDES, CROSS-LINKED, SERUMNTXSERNTXSERELISA
N-Telopeptide, Cross-Linked, Serum  nM BCE
F Premenopausal adult 6.2-19.0
M 25+ years 5.4-24.2
The target value for treated post-
menopausal adult females is the
same as the premenopausal reference
interval.
BCE=Bone Collagen Equivalent
NAPROXENNAPNAPHPLC
Naproxen ug/mL 
30-90  Anti-inflammatory or analesgic range
NARCOLEPSY PANELNARCNARCPCR
Narcolepsy HLA DNA Panel
 Separate Report to Follow
EOSINOPHILS, BODY SECRETIONSNASALEOSBODMicroscopic
Nasal Smear, Eosinophils   /100 WBC
 None seen to rare
NEFAZODONE, QUANTITATIONNEFAZQNEFAZQHPLC
TitleDescriptorRangesUnits
Nefazodonemcg/mL
Steady-state peak levels (at approximately 1.2 hours post-dose) following a daily regimen
50 mg bid0.08-0.39
100 mg bid0.46-1.2
200 mg bid1.6-3.9
OCCULT BLOOD, STOOLOBLDSHOBLDSHColorimetric
Negative
Positive
NEISSERIA GONORRHOEAE ANTIBODYGON-ABGONABComplement Fixation
TitleDescriptorRangesUnits
Neisseria Gonorrhoeae Ab, CFTiterLT 1:8
Interpretive CriteriaAntibody not detectedLT 1:8
Antibody detected1:8 or greater
Titers GT or equal to 1:8 suggest either gonococcal infection or asymptomatic colonization. Antibodies recognizing Neisseria gonorrhoeae are apparently unprotective, since reinfection frequently occurs.
NEUTROPHIL ANTIBODY, FLOW CYTOMETRYNEUTABNEUTABFlow Cytometry
Neutrophil Antibody           None Detected

The flow cytometric analysis of granulocyte antibodies is designed as a screening test
to detect antibody reacting with random donor granulocytes.  The assay will not
distinguish antibodies directed against neutrophil specific antigens from those directed
against HLA antigens.  Differences in donor neutrophil antigen characteristics may
result in some interassay variabliliy.
NEUTROPHIL OXIDATIVE BURST ASSAYNEUOXBNEUOXBFlow Cytometry
Neutrophil Oxidative Burst Assay
 See separate report
DIFFERENTIAL, BAL RFLXBALDIFBALDIFMicroscopic
TitleDescriptorRangesUnits
Neutrophils
Smoker0-1%
Non-smokerup to 3
Lymphocytes6-8%
Variant Lymphocytes%
Macrophages/Monocytes%
Phagocytic Monocytes%
Eosinophils0-1%
Basophils0-1%
Squamous EpithelialCells%
Columnar EpithelialCells%
Others%
Fungus
Bacteria
Bal Note
NIACIN (VITAMIN B3)NIACINIACIHigh Performance Liquid Chromatography
TitleDescriptorRangesUnits
Niacinug/mL
10+ years
Normal0.50-8.45
LowLT 0.50
HighGT 8.45
LT 10 years
Normal0.50-8.91
LowLT 0.50
HighGT 8.91
NICOTINE & METABOLITE, SERUM/PLASMANICMSPNICMSPQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
NicotineUnexposedLT 2ng/mL
PassiveLT 2
AbstinentLT 2
Active30-50
CotinineUnexposedLT 2ng/mL
PassiveLT 8
AbstinentLT 2
Active200-800
3-OH-CotinineUnexposedLT 2ng/mL
PassiveLT 2
AbstinentLT 2
Active100-500
Unexposed = Non tobacco user
Passive = Passive Exposure
Abstinent = Abstinent user for more than 2 weeks
Active = Active tobacco use
The absence of expected drug(s) and or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be GT or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the lab.
NMP 22NMP22NMP22EIA
NMP22     0.0-10.0 U/mL
 The NMP22 assay is intended as an aid
 in the management of patients with
 transitional cell carcinoma of the 
 urinary tract (TCC/UT). It is used
 after surgical treatment to identify
 patients with residual or rapidly
 recurring TCC/UT.
FUNGUS STAIN ONLYFSMFSMMicroscopy
No fungal elements seen
Budding yeast seen
Budding yeast with pseudohyphae seen
Hyphal elements seen
WET MOUNT VAGINAL PREPWMSHWMSHMicroscopy
No Trichomonas or Trichomonas seen
No Yeast or Yeast seen
No Clue Cells or Clue Cells seen
NOROVIRUS GROUP 1 & 2 RT-PCRNOROPCNOROPCRT-PCR
Norovirus 1 by RT-PCR             Not detected
Norovirus 2 by RT-PCR             Not detected
                                  A result of not detected does not rule out the presence 
                                  of PCR inhibitors in the patient specimen or norovirus nucleic 
                                  acid in concentrations below the level of detection of the 
                                  assay. This test is performed pursuant to an agreement with 
                                  Roche Molecular Systems, Inc.
PROPOXYPHENE PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPPROCPPROCGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
NorpropoxyphenPositive Cutoff300ng/mL
NORTRIPTYLINENORNORTHPLC
TitleDescriptorRangesUnits
Nortriptylineng/mL
Therapeutic50-150
ToxicGT 499
NUCLEOPHOSMIN (NPM1) MUTATION ANALYSIS BY PCR AND FRAGMENT ANALYSISNPMMUTNPMMUTPCR / Fragment Analysis
NPM1 Result
PROBRAIN NATRIURETIC PEPTIDE, NTPBNPARPBNPARElectrochemiluminescent Immunoassay
TitleDescriptorRangesUnits
NT-ProBNP Natriuretic Peptidepg/mL
0-74 yearsLT 125
75+ yearsLT 450
GUAIAC TEST FOR OCCULT BLOODOC.BLDOCBLDColorimetric
Occult Blood      Negative
OCCULT BLOOD, GASTRICOBGAOBGAQualitative Colorimetry
Occult Blood, Gastric Fluid      Negative
Gastric Fluid pH                 1-7
OLANZAPINEOLANZOLANZQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Olanzapineng/mL
Therapeutic range20-80
ToxicNot well established
OPIATES, SER/PLA RFLXOPISCOOPISCOEnzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Opiatesng/mL
6-Monoacetylmorphine, Freeng/mL
Coedine, FreeTherapeutic range30-120ng/mL
Dihydrocodeine/Hydrocodol, FreeUsual therapeutic range50-100ng/mL
Hydrocodone, FreeFollowing a single 10 mg doseUp to 39ng/mL
Hydromorphone, FreePeak plasma concentrations ranged from 18-27ng/mL (mean 22 ng/mL) one hour after a 4 mg oral dose.ng/mL
Morphine, FreeUsual range following therapeutic doses10-70ng/mL
Oxycodone, FreePeak plasma concentrations 1 hr after a single immediate-release tablet preparation containing 5 mg Oxycodone9-38ng/mL
Peak plasma concentrations within 2.5 hours after 10 mg of an immediate release preparation of Oxycodone13-46ng/mL
Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled release Oxycodone preparation39-100ng/mL
Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.
Oxymorphone, Freeng/mL
Oxycodoneng/mL
CULTURE IV CATHETER TIPCCATHCCATHCulture - Semiquantitative
Organism name with colony count
OSMOLALITYOSMOLALOSMFreezing Point Depression
Osmolality   275-295    mOsm/kg
OSMOLALITY, FECALFECOSAFECOSAQuantitative Freezing Point
TitleDescriptorRangesUnits
Osmolality, FecalmOsm/kg
0-16 years271-296
17 + years280-303
PAIN MANAGEMENT VALIDITY TESTING PMV1PMV1
Oxidants             ug/mL
pH
Creatinine           mg/dL
Specific Gravity
OXIDIZED LDLOXLDLOXLDLEnzyme-Linked Immunosorbent Assay
TitleDescriptorRangesUnits
Oxidized LDLU/L
Low Risk< 60
Moderate Risk60-69
High Risk> = 70
P0 ANTIBODIES BY WESTERN BLOTP0WBIMP0WBIMWestern Blot
P0 (Protein 0)    Negative
PANCREATIC ELASTASE, FECALPANEFPANEFELISA
TitleDescriptorRangesUnits
Pancreatic Elastase, Fecalug/g
Normal201 or greater
Moderate to mild pancreatic insufficiency100-200
Severe exocrine insufficiency99 or less
PANCREATIC POLYPEPTIDEPAN POLYPANPEPRIA/Extraction
TitleDescriptorRangesUnits
Pancreatic Polypeptidepg/mL
LT 3 yearsNot established
3-9 years519 or less
10-13 years361 or less
14-17 years297 or less
18-29 years480 or less
30-39 years70-400
40-49 years70-430
50-62 years100-780
GT 62 yearsNot established
LIQUID-BASED PAP ONLYPAPLQPAPLQLiquid-based vial
Pap Result
CONVENTIONAL SLIDE, PAP ONLYPAPSMRPAPSMRSlide
Pap result
ANTI-PARIETAL CELL ANTIBODY, TOTAL, IGA, IGG & IGMPARIETAL CELL ABAPCAIFA
Parietal Cell Ab, Total(IgA, IgG, IgM)
 Negative LT 1:20
PARVOVIRUS B19 ANTIBODY, IGG & IGMPRVOGMPRVOGMEIA
TitleDescriptorRangesUnits
Parvovirus B19 Ab, IgGIV
PositiveGT 1.09
Equivocal0.91-1.09
NegativeLT 0.91
Parvovirus B19 Ab, IgMIV
PositiveGT 1.09
Equivocal0.91-1.09
NegativeLT 0.91
PARVOVIRUS B19 ANTIBODY, IGGPARVOGPARVOGEIA
TitleDescriptorRangesUnits
Parvovirus B19 Ab, IgGIV
PositiveGT 1.09
Equivocal0.91-1.09
NegativeLT 0.91
PARVOVIRUS B19 ANTIBODY, IGMPARVOMPARVOMEIA
TitleDescriptorRangesUnits
Parvovirus B19 Ab, IgMIV
PositiveGT 1.09
Equivocal0.91-1.09
NegativeLT 0.91
PEMPHIGUS PANELPEMPABPEMPABEnzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody
Pemphigus Ab Panel
PENTOBARBITALPENTOPENTOQuantitative Gas Chromatography-Mass Spectrometry
TitleDescriptorRangesUnits
Pentobarbitalug/mL
Therapeutic RangeSedation: 1-5
Intracranial Pressure (ICP) Therapy: 25-35
Coma: 10-50
Toxic LevelGT 10
PERPHENAZINEPERPERPHQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Perphenazine (Tinlafar)ng/mL
Therapeutic0.6-2.4
ToxicGT 12
PH, FLUIDPHFLDPHFLpH meter or dipstick
pH, Fluid                  
 Serous fluid    6.8-7.6   
 Synovial fluid  Parallels serum
PHENCYCLIDINE PAIN MANAGEMENT CONFIRMATION TESTING BY GC/MSPPCPPPCPGas Chromatography Mass Spectrometry
TitleDescriptorRangesUnits
Phencyclidinepositive cutoff25ng/mL
PHENOBARBITALPHBPHBLA
Phenobarbital            ug/mL
 Therapeutic 15.0-40.0
 Toxic       GT 50.0
PRIMIDONEPRMPRPHLA & Enzymatic
TitleDescriptorRangesUnits
Phenobarbitalug/mL
Therapeutic15.0-40.0
ToxicGT 50.0
Primidoneug/mL
Therapeutic5.0-12.0
ToxicGT 15.0
PHENYLALANINE (QUANTITATIVE)PHEN-QPHENQuantitative Liquid Chromatography/Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Phenylalanineumol/L
0-30 days30-100
1 month-11 months30-90
1+ years30-80
PHENYTOINDILDILLA
Phenytoin                ug/mL
 Therapeutic  10.0-20.0
 Toxic        GT 25.0
PHOSPHORUSPHOPHOSColorimetric
Phosphorus               mg/dL
 0-10 days      4.2-9.6
 10 days-24 mo  4.2-7.2
 24 mo-12 yrs   4.2-5.9
 12-60 yrs      2.3-4.8
 60 yrs+  M     2.1-3.9
 60 yrs+  F     2.6-4.4
HEMOGLOBIN, PLASMA QUANTHGB.PLASMAPHGBQTSpectrophotometry
TitleDescriptorRangesUnits
Plasma Hgbquantitative0-10mg/dL
90% of population LT 10 mg/dL, 10% of population LT 20 mg/dL. Reference values are difficult to define, since hemoglobin concentration depends heavily on the care by which the sample was obtained and processed.
DIRECT PLATELET ANTIBODIES, IGG & IGMDIRPLTDIRPLTFlow Cytometry
Platelet Ab, Direct IgG  Negative
Platelet Ab, Direct IgM  Negative
Interpretation
PLATELET ANTIGEN GENOTYPING (HPA-1)PLTAGTPLTAGTPCR
Platelet Antigen Genotyping (HPA-1)
Platelet Antigen Genotyping (HPA-1), Interpretation
PLATELET ASPIRIN TESTPLTASAPLTASAVerifyNow Aspirin Test
Platelet Aspirin Test          ARU (Aspirin Reaction Units)

  < 550 ARU = Aspirin effect present.  Results can be affected by NSAID interference, 
  P2Y12 Inhibitors, GPIIb/IIIa inhibitors, inherited platelet disorders, low HCT or 
  low PLT counts.  

  > or = 550 ARU = Aspirin effect absent
PLATELET COUNTPLTPLTCNTAutomated
TitleDescriptorRangesUnits
Platelet CountK/uL
0-3 days250-450
3-9 days200-400
9-30 days250-450
1-6 months300-750
6 months-2 years250-600
2-8 years250-550
8-12 years200-450
12-18 years150-450
18+ years150-400
PML/RARA T (15;17), QNT (RT-PCR)PMLRPMLRRT-PCR
PML Result
PML Quantitative result
                  		This assay detects and quantifies
			PML-RARa transcript level resulting
			from a t(15;17) fusion mutation in	
			acute promyelocytic leukemia (APL).
			This assay detects all three gene	
			fusion patterns: type A (short, S-
			form, bcr-3), Type B (long, L-form,	
			bcr-1), and Type B variant	
			(variable, V-form, bcr-2).	
			Limit of detection: 1 in 10,000 cells.
			Results of this test must always be
			interpreted in the context of	
			morphologic and other relevant	
			data, and should not be used alone
			for a diagnosis of malignancy.                
STREP PNEUMONIAE, IGG SEROTYPE PNEUABPNEUABMultiplex Bead Assay
Pneumococcal Serotype 1, IgG
Pneumococcal Serotype 3, IgG
Pneumococcal Serotype 4, IgG
Pneumococcal Serotype 5, IgG
Pneumococcal Serotype 6B, IgG
Pneumococcal Serotype 7F, IgG
Pneumococcal Serotype 8, IgG
Pneumococcal Serotype 9N, IgG
Pneumococcal Serotype 9V, IgG
Pneumococcal Serotype 12F, IgG
Pneumococcal Serotype 14, IgG
Pneumococcal Serotype 18C, IgG
Pneumococcal Serotype 19F, IgG
Pneumococcal Serotype 23F, IgG
Pneumococcal Serotype Interpretation
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PANEL (PNH PANEL)PNHPANPNHPANFlow Cytometry
PNH Panel Result
PCBS PANEL, SERUM/PLASMAPCBSPCBSGas Chromatography
TitleDescriptorRangesUnits
Polychlorinated Biphenylsppb
Based on Aroclor 1260
General populationUp to 30
Average6
POLYMYOSITIS (PM-SCL) ABPOLYMYPOLYMYImmunodiffusion
TitleDescriptorRangesUnits
Polymyositis (PM-SCL) Antibody
Negative
Interpretive Criteria
Antibody not detectedNegative
Antibody detectedPositive
PORPHOBILINOGEN DEAMINASE, RBCURO-1-SYNPBGDFluorometric/Enzymatic
TitleDescriptorRangesUnits
Porphobilinogen Deaminase, RBCAdults2.10-4.30mU/g hgb
PORPHYRINS, COMPREHENSIVE + PBG, URINE 24HRPQNUPQNUHPLC with Fluorometric Detection/LC-MS/MS
TitleDescriptorRangesUnits
Porphyrins, QN, U
Collection Duration24h
Urine Volume1000mL
Uroporphyrin, Octa4< = 30nmol/24 h
Heptacarboxylporphyrins< 1 < = 9nmol/24 h
Hexacarboxylporphyrins< 1 < = 8nmol/24 h
Pentacarboxylporphyrins1< = 10 nmol/24 h
Coproporphyrin, Tetra71 < = 168nmol/24 h
Porphobilinogen1< = 2.2mcmol/24 h
InterpretationNormal porphyrins profile
POTASSIUMPOTKISE
Potassium         mmol/L
 0-30 days        3.9-6.9
 1-12 mo          3.6-6.8
 1-5 yrs          3.2-5.7
 5-10 yrs         3.4-5.4
 10 yrs+          3.5-5.3
POTASSIUM, FLUIDPOTFLDKFLISE
Potassium, Fluid            mmol/L
 CSF            70% of plasma level
 Gastric        About 10  
 Other fluid    No reference range established.
 Method not validated for body fluid. 
 Clinical correlation necessary.
POTASSIUM, FECALSTLKSTLKQuantitative Ion-Selective Electrode
Potassium, Stool    mmol/L
 Not established
PW/AS METHYLATION ANALYSISPWASMAPWASMACapillary Electrophoresis, Polymerase Chain Reaction (PCR)
Prader-Willi DNA Methylation Analysis
HCG, URINE, QUALITATIVE, BETAPRGPRGUEIA
Pregnancy Test           mIU/mL
 Negative   LT 25              
 Positive   25 or greater
The following comment will be appended to all
negative pregnancy results.
Levels of hCG greater than 300,000 mIU/mL (about
4-12 weeks gestation) may cause false-
negative results. Consider quantitative serum hCG 
test to confirm negative screening result if
clinical picture suggests pregnancy.
PAIN MANAGEMENT PROMPT FOR PRESCRIBED DRUGS PMM1PMM1
Prescribed Drug 1
Prescribed Drug 2
Prescribed Drug 3
Prescribed Drug 4
Prescribed Drug 5
Prescribed Drug 6
Prescribed Drug 7
Prescribed Drug 8
Prescribed Drug 10
PROGESTERONEPROGESPROGESICMA
Progesterone                  ng/mL
 M                0.28-1.22 
 F   
  Follicular      0.15-1.40
  Luteal          3.34-25.56
  Mid-luteal      4.44-28.03
  Post-menopausal 0.00-0.73
  Pregnancy 
   1st trimester  11.22-90.00
   2nd trimester  25.55-89.40
   3rd trimester  48.40-422.50
    Women using oral contraceptives
    have suppressed progesterone
    levels. Minimum detectable
    concentration is 0.15 ng/mL.
PROINSULINPRONAPRONAQuantitative Chemiluminescent Immunoassay
TitleDescriptorRangesUnits
Proinsulinpmol/L
0-17 yearsNot established
18+ years< 0.9
MACROPROLACTINMAPRLAMAPRLAICMA
Prolactin              ng/mL
 M 1-9 yrs     2.1-17.7
   10 yrs+     2.1-17.7
 F 1-9 yrs     2.1-17.7
   10 yrs+     2.8-26.0
Prolactin,             ng/mL
 Monomeric
 M 1-9 yrs     2.1-13.3
   10 yrs+     2.1-13.3
 F 1-9 yrs     2.1-13.3
   10 yrs+     2.8-19.5
Prolactin %, 
 Monomeric
PROLACTINPROLACPRLICMA
Prolactin     ng/mL                           
 M  1.6-18.8
 F  1.4-24.2
PROPAFENONEPROPAFENONEPROPAFQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Propafenoneug/mL
Therapeutic Range0.50-2.00
Toxic LevelGT 2.00
PROPOXYPHENE/METAB, SER RFLXPROOXYPROOXYLiquid Chromatography-Tandem Mass
Propoxyphene & Metabolite
     Drugs covered: propoxyphene and norpropoxyphene
Positive cutoff:                                   10       ng/mL

Average serum concentrations on daily regimen of 65 mg, three times per day,
drawn 2 hours after last dosage:
     Propoxyphene                                  420      ng/mL
     Norpropoxyphene  (25-50% analgesic activity)  1450     ng/mL
PROSTATE SPECIFIC ANTIGENPSAPSAICMA
Prostate Specific Antigen  0.00-4.00   ng/mL
PROSTATE SPECIFIC ANTIGEN, POST PROSTATECTOMYPSAPRPSAPRICMA
Prostate Specific Antigen,     
 Post Prostatectomy  LT 0.05     ng/mL
 After radical prostatectomy, a PSA
 value of less than 0.05 ng/mL indicates
 no detectable residual disease. The  
 minimum detectable concentration is
 0.01 ng/mL.
PROTEIN C, ACTIVITYPROCFACTPCClotting Assay
TitleDescriptorRangesUnits
Protein C Activity1 day31-35%
3 days31-45
1 month-1 year36-108
1-5 years65-117
6-10 years83-109
11-16 years76-98
16+ years70-145
PROTEIN, CSFPRO-CTPSFColorimetric
TitleDescriptorRangesUnits
Protein, CSFmg/dL
LT 1 day40-120
1-30 days20-80
1 month-adult15-45
PROTEIN, FLUIDPRO-FLDTPFLColorimetric
TitleDescriptorRangesUnits
Protein, Fluidg/dL
Exudate3.0 or greater
TransudateLT 3.0
SynovialLT 3.0
Method not validated for body fluid.
Clinical correlation necessary.
PROTEIN, TOTALPROTPColorimetric (Biuret)
Protein, Total   g/dL
 0-12 mo         4.3-6.9
 1-3 yrs         5.2-7.4
 3-6 yrs         5.6-7.7
 6-10 yrs        6.5-8.3
 10-18 yrs       6.1-8.0
 18-60 yrs       6.2-8.2
 60 yrs+         6.1-7.8
SPEP, SERUMELPPELPAgarose Gel ELP (high resolution)
TitleDescriptorRangesUnits
Protein, Total0-12 months4.3-6.9g/dL
1-3 years5.2-7.4
3-6 years5.6-7.7
6-10 years6.5-8.3
10-18 years6.1-8.0
18-60 years6.2-8.2
60+ years6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
Alpha-10.1-0.4g/dL
Alpha-20.5-1.1g/dL
Beta-10.4-0.8g/dL
Beta-20.2-0.5g/dL
Gamma 0.6-1.5g/dL
Albumin45.0-80.0%
Alpha-11.0-6.0%
Alpha-26.0-17.0%
Beta-15.0-13.0%
Beta-22.0-8.0%
Gamma7.5-24.0%
Interpretation
Monoclonal Peak
If Positive
Monoclonal Proteing/dL
Monoclonal Protein %%
Monoclonal Protein (2)g/dL
Monoclonal Protein (2)%%
SPEP, SERUM RFLXPELPIFPELPIFAgarose Gel ELP (high resolution)
TitleDescriptorRangesUnits
Protein, Total0-12 months4.3-6.9g/dL
1-3 years5.2-7.4
3-6 years5.6-7.7
6-10 years6.5-8.3
10-18 years6.1-8.0
18-60 years6.3-8.0
60+ years6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
Alpha-10.1-0.4g/dL
Alpha-20.5-1.1g/dL
Beta-10.4-0.8g/dL
Beta-20.2-0.5g/dL
Gamma0.6-1.5g/dL
Albumin45.0-80.0%
Alpha-11.0-6.0%
Alpha-26.0-17.0%
Beta-15.0-13.0%
Beta-22.0-8.0%
Gamma7.5-24.0%
Monoclonal Peak
If Positive
Monoclonal Proteing/dL
Monoclonal Protein %%
Monoclonal Protein (2)g/dL
Monoclonal Protein (2)%%
Interpretation
Immunofixation Interpretation
MONOCLONAL PROTEINMOPRMOPRImmunofixation/High Resolution (IEP), Nephelometry (IGGAM), Agarose Gel ELP/High Resolution (PELP)
TitleDescriptorRangesUnits
Protein, Totalg/dL
0-12 months4.3-6.9
1-3 years5.2-7.4
3-6 years5.6-7.7
6-10 years6.5-8.3
10-18 years6.1-8.0
18-60 years6.3-8.0
60+ years6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
Alpha-10.1-0.4g/dL
Alpha-20.5-1.1g/dL
Beta-10.4-0.8g/dL
Beta-20.2-0.5g/dL
Gamma0.6-1.5g/dL
Albumin45.0-80.0%
Alpha-11.0-6.0%
Alpha-26.0-17.0%
Beta-15.0-13.0%
Beta-22.0-8.0%
Gamma7.5-24.0%
Interpretation
Monoclonal Peak
If Positive
Monoclonal Proteing/dL
Monoclonal Protein %%
Monoclonal Protein (2)g/dL
Monoclonal Protein (2)%%
Immunofixation Interpretation
IgAmg/dL
0-30 days1-7
1 month1-56
2 months3-49
3 months5-48
4 months4-76
5 months8-87
6 months8-70
7-8 months12-93
9-11 months17-87
1 year15-110
2 years15-128
3 years23-164
4 years26-474
5-7 years35-210
8-9 years47-245
10+ years71-397
IgGmg/dL
0-30 days603-1523
1 months238-860
2 months195-570
3 months166-551
4 months185-530
5 months163-772
6 months204-668
7-8 months206-857
9-11 months279-1014
1 year327-1150
2 years402-997
3 years417-1077
4 years438-1173
5-7 years600-1214
8-9 years576-1490
10+ years758-1612
IgMmg/dL
0-30 days0-25
1 month20-87
2 months17-105
3 months24-89
4 months27-101
5 months33-108
6 months35-102
7-8 months34-126
9-11 months41-149
1 year43-172
2 years48-168
3 years47-199
4 years43-195
5-7 years48-207
8-9 years51-241
10+ years63-276
IMMUNOFIXATION, SERUMIEPIEPImmunofixation ELP/High Resolution
TitleDescriptorRangesUnits
Protein, Totalg/dL
0-12 months4.3-6.9
1-3 years5.2-7.4
3-6 years5.6-7.7
6-10 years6.5-8.3
10-18 years6.1-8.0
18-60 years6.3-8.0
60+ years6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 years3.9-5.6
14-18 years3.3-4.7
18-60 years3.5-5.0
60-90 years3.3-4.8
90+ years3.0-4.7
Alpha-10.1-0.4g/dL
Alpha-20.5-1.1g/dL
Beta-10.4-0.8g/dL
Beta-20.2-0.5g/dL
Gamma0.6-1.5g/dL
Albumin45.0-80.0%
Alpha-11.0-6.0%
Alpha-26.0-17.0%
Beta-15.0-13.0%
Beta-22.0-8.0%
Gamma7.5-24.0%
Interpretation
Monoclonal Peak
If Positive
Monoclonal Proteing/dL
Monoclonal Protein %%
Monoclonal Protein (2)g/dL
Monoclonal Protein (2)%%
Immunofixation Interpretation
PROTEINASE 3 ANTIBODYPR3ABPR3ABEIA
Proteinase 3 Antibody     Units
 Negative            LT 20
 Weak to Mod Pos     20-30
 Positive            GT 30
PROTIMEPTPTElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reported
INR1 day1.2-1.3
3 days1.1-1.3
1 month-1 year0.9-1.2
1-5 years0.9-1.1
6-10 years0.9-1.1
11-16 years1.0-1.2
16+ years0.9-1.1
Usual oral anticoagulation range2.0-3.0
High level oral anticoagulation range2.5-3.5
COAGULATION BATTERYCOAG-BATCOAGB
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
INR1 day1.2-1.3
3 days1.1-1.3
1 month-1 year0.9-1.2
1-5 years0.9-1.1
6-10 years0.9-1.1
11-16 years1.0-1.2
16+ years0.9-1.1
Usual oral anticoagulation range2.0-3.0
High level oral anticoagulation range2.5-3.5
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
PTT Population Mean31sec
Platelet CountK/uL
0-3 days250-450
3-9 days200-400
9-30 days250-450
1-6 months300-750
6 months-2 years250-600
2-8 years250-550
8-12 years200-450
12-18 years150-450
18+ years150-400
Interpretation
Reviewed by
MENORRHAGIA EVALUATION RFLXMENEVLMENEVLElectromechanical, Immuno-turbidimetric, Platelet Aggregation
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
INR0.9-1.2
Usual oral anticoagulation range2.0-3.0
High level oral anticoagulation range2.5-3.5
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
PT 1/1 Mixsec
PT Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
von Willebrand FactorGT 40%
von Willebrand Factor Antigen50-165%
Factor VIII Coagulant Activity1 day111-170%
3 days88-142
1 month-1 year57-75
1-5 years38-96
6-10 years55-94
11-16 years62-103
16+ years55-150
Factor XI1 day7-28%
3 days23-54
1 month-1 year60-86
1-5 years63-112
6-10 years63-112
11-16 years63-96
16+ years65-135
DIC SCREEN RFLXDICBDICElectromechanical, Immuno-turbidimetric Microscopy
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
INR1 day1.2-1.3
3 days1.1-1.3
1 month-1 year0.9-1.2
1-5 years0.9-1.1
6-10 years0.9-1.1
11-16 years1.0-1.2
16+ years0.9-1.1
Usual oral anitcoagulation range2.0-3.0
High-level oral anticoagulation range2.5-3.5
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti Factor Xa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
Thrombin Time Patient15.6-20.0sec
Thrombin Time Control15.6-20.0sec
Thrombin Time PT/CT Mixsec
Thrombin Time PT/SO4 Mixsec
D-dimer, QuantitativeLT 0.50ug/mL FEU
Platelet Count0-3 days250-450K/uL
3-9 days200-400
9-30 days250-450
1-6 months300-750
6 months-2 years250-600
2-8 years250-550
8-12 years200-450
12-18 years150-450
18+ years150-400
RBC Morphology
DIC Comment
FACTOR IX INHIB, QUANT RFLXF09INHF09INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti Factor Xa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor IX1 day31-36%
3 days45-53
1 month-1 year44-67
1-5 years45-70
6-10 years49-80
11-16 years65-119
16+ years60-140
Factor 9 InhibitorsNegative Inhibitor Units
FACTOR X INHIB, QUANT RFLXF10INHF10INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti Factor Xa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor X1 day41-60%
3 days41-67
1 month-1 year68-108
1-5 years64-111
6-10 years60-111
11-16 years47-108
16+ years85-152
Factor 10 InhibitorsNegative Inhibitor Units
FACTOR XII INHIB, QUANT RFLXF12INHF12INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti Factor Xa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
PT Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor XII1 day43-80%
3 days19-70
1 month-1 year29-98
1-5 years50-98
6-10 years50-99
11-16 years50-85
16+ years50-150
Factor 12 InhibitorsNegative Inhibitor Units
FACTOR V INHIB, QUANT RFLXF05INHF05INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor V1 day57-83%
3 days83-124
1 month-1 year84-113
1-5 years60-102
6-10 years50-113
11-16 years60-113
16+ years70-122
Factor 5 InhibitorsNegative Inhibitor Units
FACTOR II INHIB, QUANT RFLXF02INHF02INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor II1 day46-66%
3 days56-69
1 month-1 year69-98
1-5 years78-103
6-10 years75-104
11-16 years68-102
16+ years87-131
Factor 2 InhibitorsNegative Inhibitor Units
FACTOR VII INHIB, QUANT RFLXF07INHF07INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor VII1 day57-80%
3 days74-98
1 month-1 year79-137
1-5 years79-137
6-10 years77-143
11-16 years76-183
16+ years67-182
Factor 7 InhibitorsNegative Inhibitor Units
FACTOR XI INHIB, QUANT RFLXF11INHF11INHElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime Population MeanNo longer reportedsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
Protime 1/1 Mixsec
Protime Control Plasmasec
PTT 1/1 Mixsec
PTT Control Plasmasec
Factor XI1 day7-28%
3 days23-54
1 month-1 year60-86
1-5 years63-112
6-10 years63-112
11-16 years63-96
16+ years65-135
Factor 11 InhibitorsNegative Inhibitor Units
PROTIME MIXING STUDYPTMXSPTMXSElectromechanical
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
Protime, Patient/Control Mixsec
A PT mix that is not within 3 seconds of the control plasma may suggest an inhibitor. This can also occur in the presence of anticoagulant inhibitor drugs such as heparin or direct thrombin inhibitors.
Protime, Control Plamsasec
BLEEDING DIATHESIS PNL RFLXBLDPNLBLDPNLElectromechanical Clot Detection, Urea Solubility, Immuno-turbidimetric, Platelet Aggregation
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
PT, Pt/Clt Mix
A protime that is not within 3 sec of the control plasma may suggest an inhibitor
PT, Ctl Plasma
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
APTT, Pt/Ctl Mix
A PTT mix is not within 5 seconds of the control plasma usually suggests an inhibitor. This can also occur in the presence of anticoagulant inhibitor drugs such as heparin or direct thrombin inhibitors.
APTT Ctl Plasmasec
APTT, Pt Post Incubationsec
Heparinase aPTT26-38sec
TT, Pt15.6-20.0sec
TT, Control15.6-20.0sec
TT, Pt/Ctl Mixsec
TT, Pt/PSO4 Mixsec
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
Reptilase, Pt14.8-21.2sec
Reptilase, Ctl14.8-21.2sec
Reptilase, Pt/Ctl Mixsec
Factor XIIINo clot dissolution
D-Dimer, QuantLT 0.50ug/mL FEU
Factor VIII Coagulant Activity1 day111-170%
3 days88-142
1 month-1 year57-75
1-5 years38-96
6-10 years55-94
11-16 years62-103
16+ years55-150
von Willebrand FactorGT 40sec
Activity
von Willebrand Factor Antigen50-165%
Factor II1 day46-66%
3 days56-69
1 month-1 year69-98
1-5 years78-103
6-10 years75-104
11-16 years68-102
16+ years87-131
Factor V1 day57-83%
3 days83-124
1 month-1 year84-113
1-5 years60-102
6-10 years50-113
11-16 years60-113
16+ years70-122
Factor X1 day41-60%
3 days41-67
1 month-1 year68-108
1-5 years64-111
6-10 years60-111
11-16 years47-108
16+ years85-152
Factor VII1 day57-80%
3 days74-98
1 month-1 year79-137
1-5 years79-137
6-10 years77-143
11-16 years76-183
16+ years67-182
Factor IX1 day31-36%
3 days45-53
1 month-1 year44-67
1-5 years45-70
6-10 years49-80
11-16 years65-119
16+ years60-140
Factor XI1 day7-28%
3 days23-54
1 month-1 year60-86
1-5 years63-112
6-10 years63-112
11-16 years63-96
16+ years65-135
Hexagonal Phospholipid NeutralizationNegative< = 9.1sec
Positive> = 9.2
dRVVT31.8-45.7sec
dRVVT Mix Ratio0.0-1.2
Factor VIII Inhibitor, QntNegativeBethesda Units
Factor II InhibitorNegativeBethesda Units
Factor V InhibitorNegativeBethesda Units
Factor X InhibitorNegativeBethesda Units
Factor VIII InhibitorNegativeBethesda Units
Factor IX InhibitorNegativeBethesda Units
Factor XI InhibitorNegativeBethesda Units
Interpretation
Reviewed by
LUPUS ANTICOAGULANT SCREEN RFLXACTLPACTLPElectromechanical (clot based)
TitleDescriptorRangesUnits
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
PT, PT/NL Mixsec
Thrombin T,Pt15.6-20.0sec
TT, Pt/Ps Mixsec
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
aPTT, Controlsec
aPTT, PT Ct Mixsec
HPNTNegative< = 9.1sec
Positive> = 9.2
dRVVT31.8-45.7sec
dRVVT mix ratio0.0-1.2
dRVVT confirm ratio< 1.2
PROTRIPTYLINEPROTPROTRILC-MS
TitleDescriptorRangesUnits
Protriptylineng/mL
Therapeutic70-240
ToxicGT 400
MENS HORMONE HEALTH PANELMHOPANMHOPAN
PSA   
DHEAS   
EDIOL   
ANDRMS   
PROGES   
TESAMS
PSEUDOCHOLINESTERASE, DIBUCAINE INHIBITIONPSEUPSEUEnzymatic
Pseudocholinesterase  2900-7100    U/L     
Dibucaine             GT 75        %
Phenotype
PROLONGED APTT EVAL RFLXPRLPTTPRLPTTElectromechanical Clot Detection
TitleDescriptorRangesUnits
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
Heparinase aPTT26-38sec
aPTT, Controlsec
aPTT, Pt/Clt Mixsec
Protime1 day15.0-16.1sec
3 days14.1-16.1
1 month-1 year12.0-15.1
1-5 years12.6-14.2
6-10 years12.2-14.8
11-16 years13.3-15.8
16+ years12.0-14.2
TT, Patient15.6-20.0
TT, Pt/PSO4 Mix
HPNTLT 9.2
dRVVT31.8-45.7
dRVVT Mix0.0-1.2
dRVVT Confirm RatioLT 1.2
Factor VIII Coagulant Activity1 day111-170%
3 days88-142
1 month-1 year57-75
1-5 years38-96
6-10 years55-94
11-16 years62-103
16+ years55-150
Factor VIII Inhibitor QuantitativeNegative
von Willebrand Factor Antigen50-165%
von Willebrand Factor ActivityGT 40
Factor IX1 day31-36%
3 days45-53
1 month-1 year44-67
1-5 years45-70
6-10 years49-80
11-16 years65-119
16+ years60-140
Factor XI1 day7-28%
3 days23-54
1 month-1 year60-86
1-5 years63-112
6-10 years63-112
11-16 years63-96
16+ years65-135
Factor XII1 day43-80%
3 days19-70
1 month-1 year29-98
1-5 years50-98
6-10 years50-99
11-16 years50-85
16+ years50-150
Interpretation
Reviewed By
PTT MIXING STUDYPTTMXSPTTMXSElectromechanical
TitleDescriptorRangesUnits
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT, Patient/Control Mixsec
A PTT mix that is not within 5 seconds of the control plasma usually suggests an inhibitor. This can also occur in the presence of anticoagulant inhibitor drugs such as heparin or direct thrombin inhibitors.
PTT, Control Plasmasec
PTT, Patient Post Incubatesec
PTTPTTPTTElectromechanical
TitleDescriptorRangesUnits
PTT1 day31-42sec
3 days27-40
1 month-1 year32-44
1-5 years31-41
6-10 years29-41
11-16 years31-43
16+ years26-36
PTT, Population Mean31sec
Deep venous thrombosis or pulmonary embolism therapeutic heparin levels of 0.3-0.7 Units/mL anti FactorXa usually correspond to an aPTT of 65-99 seconds. Acute cardiac syndrome therapeutic range based on heparin levels of 0.2 to 0.5 usually correspond to an aPTT of 57 to 76 seconds. Pediatric guidelines suggested heparin levels of 0.35-0.7 usually correspond to an aPTT of 69 to 99 seconds.
QUETIAPINE, SERUMQUETQTQUETQTLC-MS/MS
Quetiapine, Serum                ng/mL
 Steady-state peak (1.0-1.5) hours
 plasma levels following a tid daily
 regimen.
 Dose (mg/day)    Mean Max Conc (ng/mL)
     225                286
     450                598
     750                828
RABIES ANTIBODY, IGG (VACCINE RESPONSE)RABIGGRABIGGSemi-Quantitative Enzyme-Linked Immunosorbent Assay
Rabies Ab IgG (Vaccine Response)         EU/mL
 0.50 or greater: Represents adequate
 protection against rabies virus 
 following vaccination. This test is
 only intended for vaccine response,
 not for diagnosis of infection.
                                    
IMMUNE COMPLEX PROFILE IIM-COM IIMCOMFC/ELISA
Raji Cell Assay   LT 33      ugE/mL             
C1Q Binding      
 LT 4 ugE/mL is considered negative for
 circulation complement binding immune
 complexes.
COMP METABOLIC PANELCMPACMPAColorimetric, Enzymatic, ISE, Hexokinase, Enzymatic (IDMS Traceable)
TitleDescriptorRangesUnits
Ranges as they appear on report:
Glucose0-2 days premature30-80mg/dL
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
ADA diagnostic comments:
Glucose0-2 days premature30-80mg/dL
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
Pregnant65-94
ADA Diagnostic Categories for non-pregnant adults:Impaired fasting glucose100-125mg/dL
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
BUN8-25mg/dL
CreatinineM0.70-1.30mg/dL
F0.50-1.00
BUN/Creatinine Ratio11.0-35.0
Calcium8.5-10.2mg/dL
Total Protein0-12 mo4.3-6.9g/dL
1-3 yrs5.2-7.4
3-6 yrs5.6-7.7
6-10 yrs6.5-8.3
10-18 yrs6.1-8.0
18-60 yrs6.2-8.2
60+ yrs6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 yrs3.9-5.6
14-18 yrs3.3-4.7
18-60 yrs3.5-5.0
60-90 yrs3.3-4.8
90+ yrs3.0-4.7
Bilirubin, Total0-30 daysLT 11.7mg/dL
1 mo-18 yrsLT 2.0
18-60 yrs0.1-1.5
60-90 yrs0.2-1.1
90+ yrs0.2-0.9
Alkaline Phosphatase0-6 yrs72-307U/L
6-9 yrs133-340
M 9-15 yrs103-429
M 15-18 yrs49-210
F 9-13 yrs99-453
F 13-15 yrs53-186
F 15-18 yrs38-110
18+ yrs35-115
ALT (SGPT)10-65U/L
AST(SGOT)0-6 yrs20-60U/L
6-10 yrs20-40
10-18 yrs14-40
18+ yrs10-45
Sodium135-145mmol/L
Potassium0-30 days3.9-6.9mmol/L
1-12 mo3.6-6.8
1-5 yrs3.2-5.7
5-10 yrs3.4-5.4
10+ yrs3.5-5.3
Chloride99-109mmol/L
C020-10 days13-22mmol/L
11 days-4 yrs20-28
5+ yrs22-31
Anion Gap5-16
COMP METABOLIC PANEL W/GFRCMPDCMPDColorimetric, Enzymatic, ISE, Hexokinase, Enzymatic (IDMS Traceable)
TitleDescriptorRangesUnits
Ranges as they appear on report:
Glucose0-2 days premature30-80mg/dL
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
ADA diagnostic comments:
Glucose0-2 days premature30-80mg/dL
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
Pregnant65-94
ADA Diagnostic Categories for non-pregnant adults:Impaired fasting glucose100-125mg/dL
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
BUN8-25mg/dL
CreatinineM0.70-1.30mg/dL
F0.50-1.00
BUN/Creatinine Ratio11.0-35.0
Calcium8.5-10.2mg/dL
Total Protein0-12 mo4.3-6.9g/dL
1-3 yrs5.2-7.4
3-6 yrs5.6-7.7
6-10 yrs6.5-8.3
10-18 yrs6.1-8.0
18-60 yrs6.2-8.2
60+ yrs6.1-7.8
Albumin0-4 days2.9-4.6g/dL
4 days-14 yrs3.9-5.6
14-18 yrs3.3-4.7
18-60 yrs3.5-5.0
60-90 yrs3.3-4.8
90+ yrs3.0-4.7
Bilirubin, Total0-30 daysLT 11.7mg/dL
1 mo-18 yrsLT 2.0
18-60 yrs0.1-1.5
60-90 yrs0.2-1.1
90+ yrs0.2-0.9
Alkaline Phosphatase0-6 yrs72-307U/L
6-9 yrs133-340
M 9-15 yrs103-429
M 15-18 yrs49-210
F 9-13 yrs99-453
F 13-15 yrs53-186
F 15-18 yrs38-110
18+ yrs35-115
ALT (SGPT)10-65U/L
AST(SGOT)0-6 yrs20-60U/L
6-10 yrs20-40
10-18 yrs14-40
18+ yrs10-45
Sodium135-145mmol/L
Potassium0-30 days3.9-6.9mmol/L
1-12 mo3.6-6.8
1-5 yrs3.2-5.7
5-10 yrs3.4-5.4
10+ yrs3.5-5.3
Chloride99-109mmol/L
C020-10 days13-22mmol/L
11 days-4 yrs20-28
5+ yrs22-31
Anion Gap5-16
Estimated GlomerularmL/min/1.73m2
Filtration RateChronic kidney disease, if found over a 3 month periodLT 60
Kidney failureLT 15
For African Americans, multiply the calculated GFR by 1.21.
GLUCOSE, RANDOMGLURANGLURANHexokinase
TitleDescriptorRangesUnits
Ranges as they appear on report
Glucose, Randommg/dL
0-2 days premature30-80
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
ADA diagnostic comments
Glucosemg/dL
0-2 days premature30-80
0-2 days full-term40-90
2 days-1 month60-105
Adult65-99
Pregnant65-94
ADA Diagnostic Categories for nonpregnant adults
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose of 200 mg/dL or greater in a symptomatic patient indicates diabetes if the abnormality is confirmed on a subsequent day. Confirmation by a fasting glucose is preferred.
GLUCOSE, SPECIFIC TIMEDGLU.SPECIFICGLUSPHexokinase
TitleDescriptorRangesUnits
Ranges as they appear on report
Glucosemg/dL
0-2 days premature30-80
0-2 days full term40-90
2 days to 1 month60-105
Adults65-99
ADA diagnostic comments
Glucosemg/dL
0-2 days premature30-80
0-2 days full-term40-90
2 days-1 month60-105
Adult65-99
Pregnant65-94
ADA Diagnostic Categories for nonpregnant adults
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or greater indicates diabetes if the abnormality is confirmed on a subsequent day.
A random glucose result of GT 200 mg/dL indicates diabetes if the abnormality is confirmed on a subsequent day.
RASPBERRY IGEICRAARICRAARImmunocap
TitleDescriptorRangesUnits
Raspberry IgEkU/L
No significant level detected< 0.10
Clinical relevance undetermined0.10-0.34
Low0.35-0.70
Moderate0.71-3.50
High3.51-17.50
Very high> or = 17.51
RED CELL COUNTRBCRBCCNTAutomated
RBC                          M/uL
 0-3 days         4.00-6.60
 3-7 days         3.90-6.30
 7-14 days        3.60-6.20
 14-30 days       3.00-5.40
 30-60 days       2.70-4.90
 2-6 mo           3.10-4.50
 6-24 mo          3.70-5.30
 2-6 yrs          3.90-5.30
 6-12 yrs         4.00-5.20
 12-18 yrs  M     4.50-5.30
 18 yrs+    M     4.20-5.70
 12-18 yrs  F     4.10-5.10
 18 yrs+    F     3.70-5.10
RBC MORPHOLOGYRMORPHRMORPHMicroscopy
RBC Morphology
RED BLOOD CELL OSMOTIC FRAGILITY, INCUBATEDFRAGIFRAGISpectrophotometric
RBC Osmotic Fragility, Incubated, Interp
RBC Osmotic Fragility, Incubated, Reviewed By
RENIN, PLASMARENRENPERRIA
TitleDescriptorRangesUnits
Renin with normal sodium intakeng/mL/h
Adult
Random ambulatory0.8-2.5
Random non-ambulatory1.5-5.2
Child, supine with normal sodium intake
1-7 days15-114
7 days-12 months18-120
12 months-3 years13-36
3-5 years7.5-21.1
5-10 years3.8-19.2
10-15 years3.8-10.7
RENIN ACTIVITYRENARURENARUQuantitative Radioimmunoassay
TitleDescriptorRangesUnits
Renin, Normal Sodium Dietng/mL/hr
AdultSupine 0.2-1.6
Upright0.5-4.0
Children Supine1-12 months2.4-37.0
13 months-3 years1.7-11.2
4-5 years1.0-6.5
6-10 years0.5-5.9
11-15 years0.5-3.3
Newborn 1-7 days2.0-35.0
Cord Blood 4.0-32.0
Children Upright0-3 yearsnot available
4-5 years15 or less
6-10 years17 or less
11-15 years16 or less
REPTILASE (REFLEX)REPTLSREPTLSElectromechanical
Reptilase, Patient    14.8-21.2    sec
Reptilase, Control    14.8-21.2    sec
Reptilase, Pat/Ctl Mix             sec
HIV 1 GENOTYPINGHIVGT2HIVGT2PCR/CLIP® Sequencing
Resistance Associated RT Mutations
Zidovudine (AZT)
Didanosine (DDL)
Lamivudine (3TC)/Emtricitabine
Stavudine(D4T)
Abacavir (ABC)
Tenofovir (TDF)
Nevirapine (NVP)
Efavirenz
Etravirine (ETR)
Rilpivirine(RPV)
Resistance Associated PR Mutations
Saquinavir + Ritonavir (SQV/R)
Indinavir (IDV)
IDV/R
Nelfinavir (NFV)
Fosamprenavir/(FPV)
FPV/R
Lopinavir + Ritonavir (LPV/R)
Atazanavir (ATV)
Atazanavir + Ritonavir
Tipranavir + Ritonavir (TPV/R)
Darunavir + Ritonavir

Comment
 All HIV 1 Genotype results must be interpreted in the context of both
 clinical and laboratory findings. This information is protected by various
 state laws to client location &, in such cases, cannot be further disclosed 
 without the patient's specific written consent, or as otherwise permitted by law.
MYCOBACTERIUM TUBERCULOSIS COMPLEX, PCR, RESPIRATORYMTPCRRMTPCRRRT-PCR
Respiratory Source
MTB Complex, PCR         Not detected
                         This test is performed pursuant
                         to a license agreement with Roche
                         Molecular Systems, Inc.
RESPIRATORY SYNCYTIAL VIRUS ANTIBODY, IGG & IGMRSVGMRSVGMELISA
Respiratory Syncytial Virus Ab, IgG          IV
0.89 or less Negative-no significant
level of RSV IgG antibody detected.
0.90-1.10 Equivocal-questionable
presence of RSV IgG antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgG antibody
to RSV detected, which may
suggest current or recent infection.
Respiratory Syncytial Virus Ab, IgM IV
0.89 or less Negative-no significant
level of RSV IgM antibody detected.
0.90-1.10 Equivocal-questionable
presence of RSV IgM antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to RSV detected, which may
suggest current or recent infection.
RETICULIN ANTIBODY, TOTAL, IGA, IGG & IGMRETICULIN.ABRETABIFA
Reticulin Ab, Total A,G,M  
 Negative    LT 1:20
RETICULOCYTE COUNT, AUTOMATEDRETCARETCAAutomated-New Methylene Blue
Reticulocyte Count            % 
 0-2 days      3.0-7.0
 3-6 days      1.0-3.0
 7 days-1 mo   0.0-1.0 
 2 mo-4 yrs    1.0-2.0
 5+ yrs        0.4-2.7
Reticulocytes,                 K/uL
 Absolute  
 5+ yrs        16-123  
Immature       
 Reticulocyte
 Fraction      
 1+ yrs        0.17-0.43
RETICULOCYTE COUNT, AUTOMATED WITHOUT IRFRETCAWRETCAWAutomated-New Methylene Blue
Reticulocyte Count            % 
 0-2 days      3.0-7.0
 3-6 days      1.0-3.0
 7 days-1 mo   0.0-1.0 
 2 mo-4 yrs    1.0-2.0
 5+ yrs        0.4-2.7
Reticulocytes,                 K/uL
 Absolute  
 5+ yrs        16-123
RETICULOCYTE COUNT, MANUALRETICMRETICMMicroscopic
Reticulocytes               %
 0-2 days         3.0-7.0
 3-6 days         1.0-3.0
 7 days-1 mo      0.0-1.0
 2 mo-4 yrs       1.0-2.0
 5+ yrs           0.9-3.5
Reticulocytes, Absolute     K/uL
 5+ yrs           20-150
Reticulocytes, Corrected   
 no longer reported
RETINOL BINDING PROTEINRETBPRETBPQuantitative Nephelometry
TitleDescriptorRangesUnits
Retinol Binding Protein3.0-6.0mg/dL
RETINOL & RETINYL PALMITATEVTARRPVTARRPTandem Mass Spectrometry
TitleDescriptorRangesUnits
Retinol0-30 days0.18-0.50mg/L
1 month-12 years0.20-0.50
13-17 years0.26-0.70
18+ years0.30-1.20
Retinyl Palmitate0.0-0.1mg/L
RETT SYNDROME MUTATION ANAYRETTSRETTSDirect Sequencing, Polymerase Chain Reaction Amplification
RETT DNA Analysis
CLINICAL HEM INTERP COMPREHENSIVECHICOMCHICOM
Reviewed material
Interpretation
Reviewed by
Comment
CLINICAL HEM INTERP LIMITEDCHILIMCHILIM
Reviewed material
Interpretation
Reviewed by
Comment
RH FACTORRHM2RHHemagglutination
RH
RHEUMATOID FACTOR (IGA, IGG, IGM)RHFAGMRHFAGMEnzyme Linked Immunosorbent Immunoassay
TitleDescriptorRangesUnits
Rheumatoid Factor IgGNegativeLT or = 6U
Rheumatoid Factor IgANegativeLT or = 6U
Rheumatoid Factor IgMNegativeLT or = 6U
RIBOSOMAL P AUTOANTIBODY, IGGRIBPMPRIBPMPMultiplex luminex
TitleDescriptorRangesUnits
Ribosomal P Autoantibody, IgGNegativeLT 1.0AI
Positive1.0 or more
RISPERIDONERISRISHPLC/LC/MS/MS
TitleDescriptorRangesUnits
Risperidoneng/mL
9-Hydroxyrisperidoneng/mL
Risperidone and 9-Hydroxyrisperidone are approximately equieffective; therefore, the sum of their concentration is pertinent.
Risperidone and 9-Hydroxyrisperidoneng/mL
Mean steady-state plasma levels of the total active moiety following daily regimens2 mg/day14ng/mL
6 mg/day45ng/mL
10 mg/day73ng/mL
16 mg/day110ng/mL
RNA POLYMERASE III ANTIBODY, IGGRNAPAARNAPAASemi-Quant ELISA
RNA Polymerase 3 Antibody, IgG    19 Units or less:    Negative
                                  20-39 Units:         Weak Positive
                                  40-80 Units:         Moderate Positive
                                  81 Units or greater: Strong Positive            

Elevated RNA polymerase III IgG antibodies are found primarily in a subset of
systemic sclerosis (SSc) patients who are typically negative for anti-centromere
and anti-Scl-70 antibodies, and which may be predictive of increased risk for skin
involvement and hypertensive renal failure associated with the diffuse cutaneous
form of scleroderma.
RNP AUTOANTIBODY, IGGRNPMPRNPMPMultiplex luminex
TitleDescriptorRangesUnits
RNP Autoantibody, IgGNegativeLT 1.0AI
Positive1.0 or more
ROTAVIRUSROTEIAROTEIAEnzyme Immunoassay
Rotavirus Antigen      Not Detected
RAPID PLASMA REAGIN (RPR) (REFLEX)RPRRPRFLOC
RPR   Nonreactive
RAPID PLASMA REAGIN CONFIRMATION PROFILERPRCRPRCFlocculation, EIA
RPR Titer                       LT 1:1
Treponema pallidum Ab by EIA    Negative
RUBELLA AB, IGGRUBELLARUBEGICMA
TitleDescriptorRangesUnits
Rubella Ab, IgGPresumed Immune10 or greaterIU/mL
Equivocal5-9
Presumed Non-ImmuneLT 5
Result flagging will be based on presumed immune status
RUBELLA AB, IGM [ARUP]RUBMARRUBMARChemiluminescent Immunoassay
TitleDescriptorRangesUnits
Rubella Ab, IgMNegative0.89 IV or lessIV
No significant level of detectable Rubella IgM antibody
Equivocal0.90-1.09IV
Repeat testing in 10-14 days may be helpful
Positive1.10 IV or more
IgM Ab to Rubella detected which may indicate a current or recent infection or immunization. Testing immediately post-exposure is of no value without a later convalescent specimen. While the presence of IgM Abs suggest current or recent infection, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.
RUBELLA AB, IGMRUBEMRUBEMEIA
TitleDescriptorRangesUnits
Rubella Ab, IgMIndex
Negative - Indicates absence of a current or recent (within previous 6 to 8 weeks) infectionLT 0.9
This does not preclude the possibility of infection within the previous 7 days.
Indeterminate - The presence of IgM Ab is equivocal0.9-1.1
Testing of a fresh specimen may aid in determining the presence or absence of infection.
Positive - Indicates Rubella infection or vaccination within the previous 3 monthsGT 1.1
(Low levels of IgM Ab may occasionally persist for more than 12 months post infection.)
RUBEOLA AB, IGMRUBEOLA.IGMRUBEOMSemi-Quantitative Enzyme-linked immunosorbent assay
TitleDescriptorRangesUnits
Rubeola Ab, IgMNegative0.79 or lessAU
No significant level of Ab to measles(Rubeola) virus detected
Equivocal0.80-1.20
Repeat testing in 10-14 days may be helpful
Positive1.21 or more
IgM Ab to measles (Rubeola) virus detected. Suggestive of current or recent infection or immunization. However, low levels of IgM Abs may occasionally persist for more than 12 months post-infection or immunization.
RUBEOLA AB, IGGRUBEOLARUBOGEIA
TitleDescriptorRangesUnits
Rubeola IgGISR
Negative - No significant level of IgG Ab to Rubeola virus detected. Patient may be susceptible to infection.LT 0.91
Indeterminate - Rubeola virus IgG Ab are equivocal. Cannot determine the patient's immune status by this method.0.91-1.09
Positive - Significant level of IgG Ab to Rubeola virus detected. Indicates current or previous infection or prior immunization.GT 1.09
RUBEOLA/MUMPS/RUBELLA ABS, IGGMMRGMMRGEIA and ICMA
TitleDescriptorRangesUnits
Rubeola IgGISR
Negative - No significant level of IgG Ab to Rubeola virus detected. Patient may be susceptible to infection.LT 0.91
Indeterminate - Rubeola virus IgG Ab are equivocal. Cannot determine the patient's immune status by this method.0.91-1.09
Positive - Significant level of IgG Ab to Rubeola virus detected. Indicates current or previous infection.GT 1.09
Mumps Virus Antibody, IgGIV
Negative - No significant level of detectable mumps virus Ab.0.90 or less
Equivocal - Repeat testing in 10- 14 days may be helpful.0.91-1.09
Positive-IgG Ab to mumps virus detected, which may indicate a current or previous exposure/immunization to mumps virus. Positive IgG Ab levels in the absence of current clinical symptoms may indicate immunity.1.10 or more
Rubella Ab, IgGIU/mL
Presumed Immune10 or greater
Equivocal5-9
Presumed Non-ImmuneLT 5
Result flagging will be based on presumed immune status
S. CEREVISIAE AB, IGG, IGAASCAGASCAGEIA
TitleDescriptorRangesUnits
S. cerevisiae IgGNegative20.0 or lessUnits
Equivocal20.1-24.9
Positive25.0 or more
S. cerevisiae, IgANegative20.0 or lessUnits
Equivocal20.1-24.9
Positive25.0 or more
INFLAMMATORY BOWEL DISEASE DIFFERENTIATION PANELIBDPIBDPELISA, IFA
S. cerevisiae, IgG                Units
 20.0 or less     Negative
 20.1-24.9        Equivocal
 25.0 or more     Positive
S. cerevisiae, IgA                Units     
 20.0 or less     Negative
 21.0-24.9        Equivocal
 25.0 or more     Positive
ANCA, Atypical Pattern
 < 1:20           Not significant
SALICYLATESSALSALEnzyme Immunoassay
TitleDescriptorRangesUnits
Salicylatesug/mL
Analgesia20-100
Anti-inflammatory100-300
ToxicGT 300
Salicylatesmg/dL
Analgesia2.0-10.0
Anti-inflammatory10.0-30.0
ToxicGT 30.0
Individuals on chronic administration may be asymptomatic at levels up to
500 ug/mL.
SCHISTOSOMA AB, IGGSCHABSCHABFluorescent Microsphere Immunoassay
TitleDescriptorRangesUnits
Schistosoma Antibody IgG
Antibody not detectedLT 1.00
Antibody detected1.00 or more
This assay utilizes the microsomal fraction of adult S. mansoni worms (MAMA) as antigen, and is thus highly specific (99%) and sensitive (96%) for detection of infection caused by S. mansoni. Although the assay is also highly specific for infections caused by other Schistosoma species (S.japonicum, S.haematobium, S.mekongi), its sensitivity for these infections is lower (55%). Antibody levels do not correlate with intensity of infection.
SCL 70 AUTOANTIBODY, IGGSCLMPSCLMPMultiplex luminex
TitleDescriptorRangesUnits
SCL-70 Auto-antibody, IgGNegativeLT 1.0AI
Positive1.0 or more
SEQUENTIAL SCREEN W/NT, SPEC 1SEQN1SEQN1ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
2nd Sample Draw Date Earliest
2nd Sample Draw Date Latest
Gestational Age
Maternal Age at Term
Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
Chorionicity
Nuchal Translucency
Nuchal Translucency, Twin B
Crown Rump Length
Crown Rump Length, Twin B
Sonographer Code/Name
DS Screen Result
DS Risk Interpretation
DS Risk(At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
Note
Screening Status
NT MoM
NT MoM, Twin B
PAPP-A MoM, 1st Trimester
hCG MoM, 1st Trimester
PAPP-A, 1st Trimesterng/mL
hCG, 1st TrimesterIU/mL
Comment
1ST TRIMESTER SCREEN W/NTFTSNTFTSNTICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Gestational Age
Maternal Age at Term
Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
Chorionicity
Nuchal Translucency
Nuchal Translucency, Twin B
Crown Rump Length
Crown Rump Length, Twin B
Sonographer Code/Name
DS Screen Result
DS Risk Interpretation
DS Risk (At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
Note
Screening Status
NT MoM
NT MoM, Twin B
PAPP-A MoM, 1st Trimester
hCG MoM, 1st Trimester
PAPP-A, 1st Trimesterng/mL
hCG, 1st TrimesterIU/mL
Comment
PRENATAL RISK QUAD SCREENMSS4MSS4ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Gestational Age
Maternal Age at Term
Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
DS Screen Result
DS Risk Interpretation
DS Risk (At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
OSB Screen Result
OSB Risk Interpretation
OSB Patient Risk
OSB Population Risk
Family Hx of OSB
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
SLOS Screen Result
SLOS Risk Interpretation
SLOS Risk
Note
Screening Status
AFP MoM
Unconjugated Estriol MoM
HCG MoM
Inhibin A MoM
AFPng/mL
Estriol, Unconjugatedng/mL
hCGIU/mL
Dimeric Inhibin Apg/mL
AFP, MATERNAL SERUMMSS1MSS1ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Gestational Age
Maternal Age at Term
Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
OSB Screen Result
OSB Risk Interpretation
OSB Patient Risk
OSB Population Risk
Family Hx of OSB
Note
Screening Status
AFP MoM
AFPng/mL
SEQUENTIAL SCREEN W/NT, SPEC 2SEQN2SEQN2ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Maternal Age at Term
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
Date of Specimen 2
Gestational Age, Spec 2
Weight, Spec 2
Date of Specimen 1
Gestational Age
Weight
Chorionicity
Nuchal Translucency
Nuchal Translucency, Twin B
Crown Rump Length
Crown Rump Length, Twin B
Sonographer Code/Name
DS Screen Result
DS Risk Interpretation
DS Risk (At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
OSB Screen Result
OSB Risk Interpretation
OSB Patient Risk
OSB Population Risk
Family Hx of OSB
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
SLOS Screen Result
SLOS Risk Interpretation
SLOS Risk
Note
Screening Status
NT MoM
NT MoM, Twin B
PAPP-A MoM, 1st Trimester
hCG MoM, 1st Trimester
AFP MoM
Unconjugated Estriol MoM
HCG MoM
Inhibin A MoM
PAPP-A, 1st Trimesterng/mL
hCG, 1st TrimesterIU/mL
AFPng/mL
Estriol, Unconjugatedng/mL
hCGIU/mL
Dimeric Inhibin Apg/mL
Comment
INTEGRATED SCREEN W/NT, SPEC 2ITGN2ITGN2ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Maternal Age at Term
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
Date of Specimen 2
Gestational Age, Spec 2
Weight, Spec 2
Date of Specimen 1
Gestational Age
Weight
Chorionicity
Nuchal Translucency
Nuchal Translucency, Twin B
Crown Rump Length
Crown Rump Length, Twin B
Sonographer Code/Name
DS Screen Result
DS Risk Interpretation
DS Risk(At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
OSB Screen Result
OSB Risk Interpretation
OSB Patient Risk
OSB Population Risk
Family Hx of OSB
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
SLOS Screen Result
SLOS Risk Interpretation
SLOS Risk
Note
Screening Status
NT MoM
NT MoM, Twin B
PAPP-A MoM, 1st Trimester
AFP MoM
Unconjugated Estriol MoM
HCG MoM
Inhibin A MoM
PAPP-A, 1st Trimesterng/mL
AFPng/mL
Estriol, Unconjugatedng/mL
hCGIU/mL
Dimeric Inhibin Apg/mL
Comment
INTEGRATED SCREEN, SPEC 2ITG2ITG2ICMA
TitleDescriptorRangesUnits
Screen ResultNegativeNEG
Maternal Age at Term
Race
Diabetic
IVF Donor Birthdate
Gestation
Estimated Due Date
Para
Gravida
Date of Specimen 2
Gestational Age, Spec 2
Weight, Spec 2
Date of Specimen 1
Gestational Age
Weight
DS Screen Result
DS Risk Interpretation
DS Risk (At Mid-Trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
Family Hx of Down Syndrome
OSB Screen Result
OSB Risk Interpretation
OSB Patient Risk
OSB Population Risk
Family Hx of OSB
Trisomy 18 Screen Result
T18 Risk Interpretation
T18 Patient Risk
SLOS Screen Result
SLOS Risk Interpretation
SLOS Risk
Note
Screening Status
PAPP-A MoM, 1st Trimester
AFP MoM
Unconjugated Estriol MoM
HCG MoM
Inhibin A MoM
PAPP-A, 1st Trimesterng/mL
AFPng/mL
Estriol, Unconjugatedng/mL
hCGIU/mL
Dimeric Inhibin Apg/mL
Comment
ACE POLYMORPHISM INSERT/DELETEACEPACEPFluorescent Polymerase Chain Reaction, Capillary Electrophoresis
See laboratory report
HLA B GENOTYPEHLABGTHLABGTPolymerase Chain Reaction/Fluorescence Monitoring
See separate attachment
APO E MUTATION DETECT FOR CVRAPOECRAPOECRPolymerase Chain Reaction/Fluorescence Monitoring
See separate attachment
GALECTIN-3, SERUMGAS3GAS3Quantitative Enzyme Immunoassay
See Separate Attachment
FISH ASSAY, 1p/19q DELETIONS AND REARRANGEMENTS IN GLIOMA, 1P/1Q, 19P/19Q, FFPEGLIOFIGLIOFIFISH
See separate report
COMPLEMENT ACTIVITY, (AH50)CAAP50CAAP50Semi-Quantitative Radial Immunodiffusion
See Separate Report
PROCOLLAGEN TYPE I INTACT N-TERMINAL PROPEPTIDEPRTNPPRTNPQuantitative Radioimmunoassay
See Separate Report
PLASMINOGEN ACTIVATOR INHIBITOR 1PAI1PAI1Bioimmunoassay
See Seperate Report
SEMEN EXAMINATIONSEMNSEMN
TitleDescriptorRangesUnits
Semen ExamAppearanceOpalescent
ViscosityNormal
Sperm ConcentrationGT 19M/mL
Volume1.5-5.0mL
Total Sperm NumberGT 39M
LiquefactionLiquified
MotilityGT 39% Normal
Activity GradeGT 2+
MorphologyGT 29% Normal forms
LeukocytesAbsent
CommentsSperm morphology classification based on WHO 4th edition.
Reviewed by
SERTRALINEZOLOFTSERTQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Sertralineng/mL
Therapeutic RangeNot well established
ToxicGT 300
Interpretive Data: Sertraline doses ranging from 50-200 mg/d produce serum concentration ranging from 30-200 ng/mL. Dosing above 200 mg/d is associated with increased adverse effects and decreased efficacy. Adverse effects may include dry mouth, headache, dizziness, somnolence, nausea and diarrhea.
SEX HORMONE BINDING GLOBULINSHBGLSHBGLICMA
TitleDescriptorRangesUnits
Sex hormone Binding Globulinnmol/L
Male1-30 days13-85
31-364 days70-250
1-3 years50-180
4-6 years45-175
7-9 years28-190
10-12 years23-160
13-15 years13-140
16-17 years10-60
18+ years11-80
Tanner Stage I26-286
Tanner Stage II22-169
Tanner Stage III13-104
Tanner Stage IV11-60
Tanner Stage V11-71
Female1-30 days14-60
31-364 days60-215
1-3 years 60-190
4-6 years 55-170
7-9 years 35-170
10-12 years17-155
13-15 years11-120
16-17 years19-145
18+ years30-135
Tanner Stage I30-173
Tanner Stage II16-127
Tanner Stage III12-98
Tanner Stage IV14-151
Tanner Stage V23-165
SILICON, SERUM OR PLASMASILISSILISICP/MS
TitleDescriptorRangesUnits
SiliconGenerallyLT 0.05mg/dL
Silicon concentrations are influenced by diet, especially vegetable intake.
SILVER, URINE RANDOMSILVER.USILURICP/MS
TitleDescriptorRangesUnits
Silver, UrineNormalLT 1ug/L
SM AUTOANTIBODY, IGGSMMPSMMPMultiplex luminex
TitleDescriptorRangesUnits
SM Autoantibody, IgGNegativeLT 1.0AI
Positive1.0 or more
EXTRACTABLE NUCLEAR AUTOABSENAMPENAMPMultiplex luminex
TitleDescriptorRangesUnits
SM AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
RNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SMRNP AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SMALL DENSE LDLSDLDLSDLDLImmunoturbidimetric
TitleDescriptorRangesUnits
Small Dense LDLLow Risk< 41U/L
Moderate RiskN/A
High Risk> 40
SMA CARRIER SCREENSMACTSMACTAllele Specific Real-Time Polymerase Chain Reaction (PCR), ddCt Method
SMN1
SMN2
Interpretation
SMA DIAGNOSTIC TESTSMADSSMADSAllele Specific Real-Time Polymerase Chain Reaction, ddCt Method
SMN1
SMN2
Interpretation
CHROMOSOME MICROARRAY TESTINGSNPMASNPMAWhole Genomic Microarray (CNV and SNP oligo array)
SNP Microarray
ELECTROLYTES PANELEPEPISE, Colorimetric
TitleDescriptorRangesUnits
Sodium135-145mmol/L
Potassium0-30 days3.9-6.9mmol/L
1-12 months3.6-6.8
1-5 years3.2-5.7
5-10 years3.4-5.4
10+ years3.5-5.3
Chloride98-109mmol/L
CO20-10 days13-22mmol/L
11 days-4 years20-28
5+ years22-31
Anion Gap5-1mmol/L
SODIUM AND POTASSIUMNA/KNAKISE
TitleDescriptorRangesUnits
Sodium135-145mmol/L
Potassium0-30 days3.9-6.9mmol/L
1-12 mo3.6-6.8
1-5 yrs3.2-5.7
5-10 yrs3.4-5.4
10 yrs+3.5-5.3
APT (DOWNEY TEST)APTAPTVisual Hemolysis
Source
APT
BETA STREP GROUP B PCR RFLXBSBPCRBSBPCRPolymerase Chain Reaction
Source
Beta Strep Group B PCR Result
Beta Strep Group B PCR Status
IRON STAINFESTNFESTNCytochemical Stain
Source
Bone Marrow, Iron
Red Cell, Iron
CLOSTRIDIUM DIFFICILE (PCR)CDTPCRCDTPCRPolymerase Chain Reaction
Source
C. difficile Toxin B gene Result Negative for Clostridium difficile Toxin B gene by PCR                           
C. difficile Toxin B gene Status
C. IMMITIS ID (DNA PROBE)COCIPRCOCIPRNucleic Acid Probe
Source
Coccidioides Immitis ID by DNA Probe
COLONY COUNT, DIALYSATECCDICCDICulture
Source
Culture, Fluid
Report Status
COLONY COUNT, DIALYSIS WATERCCDWCCDWCulture
Source
Culture, Fluid
Report Status
DNA CONTENT/CELL CYC ANAL, MISCDNAMICDYAMICQuantitative Flow Cytometry
Source
DNA Content
S-Phase Interpretation
DNA Index, Misc
EBV (PCR) EBVPCEBVPCPCR
Source
EBV Result by PCR        Not Detected
EBV PCR Comment          A result of Not Detected does not rule out the
 presence of PCR inhibitors in the patient specimen or EBV concentrations
 below the level of detection of this assay.
 This test is performed pursuant to the agreement with Roche Molecular 
 Systems.
FAT STAIN (OIL RED O)FAT.STOROSTNCytochemical Stain
Source
Fat Stain Interpretation
Fat Stain Reviewed by
FECAL FAT QUALITATIVESTL-FATFATMicroscopic
Source
Fat, Stool            Negative
Fat, Stool, Status
KLEIHAUER BETKE (STAT ONLY)KBKBSAcid Elution
Source
Fetal Cells               %                              
 Newborn    61.00-88.50
 1 mo       45.70-67.30
 2 mo       29.40-60.80
 3 mo       14.80-55.90
 4 mo       9.40-28.50
 5 mo       2.30-22.40
 6-11 mo    2.30-13.00
 12 mo      1.30-5.00
 13+ mo     0.00-0.90
NEISSERIA MENINGITIDIS ANTIGEN DETECTION (B 7 ECOLI K1)NMADNMADLA
Source
Group B/E. Coli K1 AG Detection    Not detected
HELICOBACTOR PYLORI SCREENHELICO.SCRHPSCulture
Source
Helico pylori Screen
Helico pylori Screen, Status
HPV GENOTYPE 16/18HPVGTYHPVGTYReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source
HPV Genotype 16
HPV Genotype 18
HPV Genotype 16 Comment
HPV Genotype 18 Comment
Comment
Comment
HPV HIGH RISK RFLXHPVWGTHPVWGTReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source
HPV High Risk DNA
HPV Genotype 16
HPV Genotype 18
HPV High Risk Other
HPV High Risk DNA Comment
HPV Genotype 16 Comment
HPV Genotype 18 Comment
HPV High Risk Other Comment
Comment
ID CULTURE AFB RFLXAFB.IDAFBIDCulture
Source
ID AFB Result
ID AFB Status
ID FUNGUS (MOLD) RFLXFUNGIDFUNGIDCulture
Source
ID Fungus (Mold) Result
ID Fungus (Mold) Status
ID ORGANISM, URINE RFLXCORGURCORGURCulture
Source
ID Organism Urine Result
ID Organism Urine Status
ID ORGANISM W/SUSCEPT RFLXCIDSCIDSCulture, Susceptibility
Source
ID Organism with Susceptibility Result
ID Organism with Susceptibility Status
ID ORG, URINE W/SUSCEPT RFLXCURIDSCURIDSCulture
Source
ID Organism, Urine with Susceptibility Result
ID Organism, Urine with Susceptibility Status
KOH WET MOUNTKOHKOHPRPMicroscopic
Source
KOH Preparation
LACTATE DEHYDROGENASE TOTAL, CSFLDFLALDFLAQuantitative Enzymatic
Source
Lactic Dehydrogenase Total, Body Fluid         U/L
LEGIONELLA FA STAINLEGION.FALEGSMIndirect Fluorescent Antibody
Source
Legionella FA Stain           Negative
Legionella FA Stain, Status
LEUKOCYTE ALKALINE PHOSPHATASE STAINSS.LAPLAPCytochemical Stain
Source
Leukocycte Alkaline Phosphatase Stain  13-70
LAP Interpretation
Reviewed by
NEISSERIA MENINGITIDIS ANTIGEN DETECTION (A/Y & C/W135)NMAYCWNMAYCWLA
Source
N. meningitidis Group C/W135   Not detected
N. meningitidis Group A/Y      Not detected
ID ORGANISM RFLXORG.IDCORGCulture
Source
Organism ID
Organism, Status
ORGANISM SENSITIVITY, EACH ORGANISMSUSCSUSCDisk Diffusion, Automated MIC, or Antibiotic Gradient
Source
Organism Sens          Negative
Organism Sens, Status
LIQUID-BASED PAP; REFLEX HPV IF ASCUS AND REFLEX TO 16/18 GENOTYPE IF HPV POSPAPACRPAPACRReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source
Pap Result
HPV High Risk DNA
HPV Genotype 16
HPV Genotype 18
HPV High Risk Other
HPV High Risk DNA Comment
HPV Genotype 16 Comment
HPV Genotype 18 Comment
HPV High Risk Other Comment
Comment
LIQUID-BASED PAP AND HPV; REFLEX TO 16/18 GENOTYPE IF PAP NEG AND HPV POSPAP30PAP30Liquid-based vial
Source
Pap Result
HPV High Risk DNA
HPV Genotype 16
HPV Genotype 18
HPV High Risk Other
HPV High Risk DNA Comment
HPV Genotype 16 Comment
HPV Genotype 18 Comment
HPV High Risk Other Comment
Comment
LIQUID-BASED PAP; REFLEX HPV IF ASCUSPAPACPAPACReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source
Pap Result
HPV High Risk DNA
HPV High Risk DNA Comment
Comment
LIQUID-BASED PAP AND HPVPAPHPVPAPHPVReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source
Pap Result
HPV High Risk DNA
HPV High Risk DNA Comment
Comment
PARASITE IDENTIFICATION, MACROSCOPICPARIDPARIDMacroscopic Inspection
Source
Parasite ID
Parasite ID Status
PINWORM PREPARATIONPINWPINMicroscopy
Source
Pinworm Prep           Negative
Pinworm Prep, Status
PNEUMOCYSTIS FA STAINPNEUMO.FAPNESMIndirect Fluorescent Antibody
Source
Pneumocystis FA Stain        Negative
Pneumocystis FA Stain, Status
RESPIRATORY SYNCYTIAL VIRUS, STAT ONLY STRSVSTRSVICT Assay
Source
Respiratory Syncytial Virus Screen  Negative
Report Status
IMMUNOPHENOTYPING ONE ANTIBODYIP1ABIP1ABFlow Cytometry
Source
Result
Note
IMMUNOPHENOTYPING TWO ANTIBODIESIP2ABIP2ABFlow Cytometry
Source
Result
Note
CD57CD57ABCD57ABFlow Cytometry
Source
Result
Note
RHEUMATOID FACTOR, BODY FLUIDRAFLARAFLAQuantitative Immunoturbidimetry
Source
Rheumatoid Factor, Body Fluid    A reference interval has not been established    IU/mL
                                 for body fluid specimens.
TARTRATE RESISTANT ACID PHOSSS.TRAPTRAPCytochemical Stain; TRAP Stain
Source
Tartrate Resistant Acid Phosphatase Stain
TRAP Interpretation
Reviewed by
VIRAL CULTURE RFLXVIRCULVIRCULIsolation in Tissue Culture
Source
Viral Culture               Negative
Viral Culture, Status
INFLUENZA A & B VIRUS ANTIGEN BY DFA, REFLEX TO VIRAL CULTUREFLUDFAFLUDFADFA reflex to culture
Source
Viral Culture and DFA Stain    Negative for Influenza A & B
                               No virus isolated
Report Status
VZV/HSV AG (DFA) RFLXVZHSFAVZHSFADFA reflex to Viral Culture
Source
VZV & HSV Antigen by DFA Result
Report Status
ID YEAST RFLXYIDYIDCulture
Source
Yeast ID Result
Yeast ID Status
CHLAMYDIA TRACHOMATIS CULTURECHLAMCHLAMIsolation in Tissue Culture
Source 
C Trachomatis Culture         Negative
C Trachomatis Culture, Status
PNEUMOCYSTIS JIROVECII, QUALITATIVE REAL-TIME PCRPJPCRPJPCRReal-Time Polymerase Chain Reaction
Source   
P jirovecii DNA QL PCR        Not Detected
LEGIONELLA DNA, QUALITATIVE REAL-TIME PCRLEGDNALEGDNAReal-Time Polymerase Chain Reaction
Source          
Legionella Species          Not Detected   
Legionella Pneumophila      Not Detected   
HPV HIGH RISKHPVHRDHPVHRDReal-Time PCR - The Cobas HPV test is based on two major processes: (1) automated specimen preparation to simultaneously extract HPV and cellular DNA, (2) PCR amplification22 of target DNA sequences using both HPV and B-globin specific complementary primer pairs and real-time detection of cleaved fluorescent labeled HPV and B-globin specific oligonucleotide detection probes.
Source               
HPV High Risk DNA     
HPV High Risk DNA Comment
Comment
MYCOPLASMA PNEUMONIAE DNA BY PCRMPPCRMPPCRReal-Time PCR
Source                
M. pneumoniae DNA by PCR     Not Detected
LYMPHOCYTE SUBSETSTBNKTBNKFlow Cytometry
Source                  
WBC                                          K/uL                  
                  0 days       9.0-30.0                  
                  1-7 days     5.0-21.0                  
                  7-30 days    5.0-19.5                  
                  1-12 mo      6.0-17.5                  
                  1-2 yrs      5.0-15.5                  
                  2-4 yrs      6.0-15.5                  
                  4-6 yrs      5.0-13.5                  
                  6-10 yrs     4.5-13.5                  
                  10-14 yrs    5.0-11.0                  
                  14-18 yrs    4.5-11.0                  
                  18 yrs+      3.8-11.0                   
Lymphocytes       Newborn      9.0-46.0      %                           
                  1-3 days     16.0-46.0                                                        
                  4-7 days     26.0-56.0                                                        
                  8-14 days    33.0-63.0                                                        
                  15-60 days   41.0-71.0                                                        
                  2-11 mo      46.0-76.0                                                        
                  1-4 yrs      35.0-76.0                                                        
                  5-12 yrs     23.0-57.0                                                        
                  13-18 yrs    20.0-50.0                                                        
                  19+ yrs      15.0-48.0                                                        
Lymphs, Abs       Newborn      2.00-11.00    K/uL                  
                  1-3 days     2.00-11.50                  
                  4-7 days     2.00-17.00                  
                  8-14 days    2.00-17.00                  
                  15-60 days   2.50-16.50                  
                  2-11 mo      4.00-13.50                  
                  1-4 yrs      2.00-10.50                  
                  5-12 yrs     1.50-7.00                  
                  13-18 yrs    1.20-5.20                  
                  19+ yrs      1.00-3.90                  
CD3               0-3 yrs      55.0-82.0     %                           
                  4+ yrs       53.0-91.0                                                        
CD3 Absolute      0-5 mo       3500-5000     /uL                         
                  6-11 mo      3400-4600                                                        
                  12-17 mo     3200-3900                                                        
                  18-29 mo     2800-3500                                                        
                  30 mo-35 mo  1900-3100                                                        
                  3 yrs        1000-3900                                                        
                  4+ yrs       560-3000                                                         
CD4               0-5 mo       50.0-57.0     %                           
                  6-11 mo      49.0-55.0                                                        
                  12-17 mo     46.0-51.0                                                        
                  18-23 mo     42.0-48.0                                                        
                  24-29 mo     38.0-46.0                                                        
                  30-35 mo     33.0-44.0                                                        
                  3 yrs        27.0-57.0                                                        
                  4+ yrs       30.0-65.0                                                        
CD4 Absolute      0-5 mo       2800-3900     /uL                         
                  6-11 mo      2600-3500                                                        
                  12-17 mo     2300-2900                                                        
                  18-23 mo     1900-2500                                                        
                  24-29 mo     1500-2200                                                        
                  30-35 mo     1200-2000                                                        
                  3 yrs        560-2700                                                         
                  4+ yrs       490-1400                                                         
CD8               0-2 yrs      8.0-31.0      %                           
                  3 yrs        14.0-34.0                                                        
                  4+ yrs       12.0-38.0                                                        
CD8 Absolute      0-2 yrs      350-2500                                                                                  
                  4+ yrs       225-900                                                          
CD19              0-2 yrs      11.0-45.0     %                           
                  3 yrs        9.0-29.0                                                         
                  4+ yrs       3.0-21.0                                                         
CD19 Absolute     0-2 yrs      430-3300      /uL                         
                  3 yrs        200-1300                                                         
                  4+ yrs       80-450                                                           
CD56+16                                      %
CD56+16 Absolute                  /uL
CD4/CD8 Ratio     0-2 yrs      1.17-6.22     to 1.0                      
                  3 yrs        0.98-3.24                                                        
                  4+ yrs       1.00-3.00                                                                                                                     
Note                                                                                            
Note
ADENOVIRUS DNA, QUANT (RT-PCR)ADQPCRADQPCRRT-PCR
TitleDescriptorRangesUnits
Source
Adenovirus DNA Quant RT-PCRNot detectedLT 500copies/mL
This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test. This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.
HELPER SUPPRESSOR HSSUBHSSUBFlow Cytometry
TitleDescriptorRangesUnits
Source
WBC0 days9.0-30.0K/uL
1-7 days5.0-21.0
7-30 days5.0-19.5
1-12 months6.0-17.5
1-2 years5.0-15.5
2-4 years6.0-15.5
4-6 years5.0-13.5
6-10 years4.5-13.5
10-14 years5.0-11.0
14-18 years4.5-11.0
18+ years3.8-11.0
LymphocyteNewborn9.0-46.0%
1-3 days16.0-46.0
4-7 days26.0-56.0
8-14 days33.0-63.0
15-60 days41.0-71.0
2-11 months46.0-76.0
1-4 years35.0-76.0
5-12 years23.0-57.0
13-18 years20.0-50.0
19+ years15.0-48.0
Lymphs, AbsNewborn2.00-11.00K/uL
1-3 days2.00-11.50
4-7 days2.00-17.00
8-14 days2.00-17.00
15-60 days2.50-16.50
2-11 months4.00-13.50
1-4 years2.00-10.50
5-12 years1.50-7.00
13-18 years1.20-5.20
19+ years1.00-3.90
CD40-5 months50.0-57.0%
6-11 months49.0-55.0
12-17 months46.0-51.0
24-29 months38.0-46.0
30-35 months33.0-44.0
3 years27.0-57.0
CD4 Abs0-5 months2800-3900/uL
6-11 months2600-3500
12-17 months2300-2900
18-23 months1900-2500
24-29 months1500-2200
30-35 months1200-2000
3 years560-2700
4+ years490-1400
CD80-3 years8.0-31.0%
3-4 years14.0-34.0
4+ years12.0-38.0
CD8 Abs0-3 years350-2500/uL
3-4 years330-1400
4+ years225-900
CD4/CD8 Ratioto 1.0
0-3 years1.17-6.22
3-4 years0.98-3.24
4+ years1.00-3.00
Note
Note
CD19 CD19SCD19SFlow Cytometry
TitleDescriptorRangesUnits
Source
WBCK/uL
0 days9.0-30.0
1-7 days5.0-21.0
7-30 days5.0-19.5
1-12 months6.0-17.5
1-2 years5.0-15.0
2-4 years6.0-15.5
4-6 years5.0-13.5
6-10 years4.5-13.5
10-14 years5.0-11.0
14-18 years4.5-11.0
18+ years3.8-11.0
Lymphocytes%
Newborn9.0-46.0
1-3 days16.0-46.0
4-7 days26.0-56.0
8-14 days33.0-63.0
15-60 days41.0-71.0
2-11 months46.0-76.0
1-4 years35.0-76.0
5-12 years23.0-57.0
13-18 years20.0-50.0
19+ years15.0-48.0
Lymphs, AbsK/uL
Newborn2.00-11.00
1-3 days2.00-11.50
4-7 days2.00-17.00
8-14 days2.00-17.00
15-60 days2.50-16.50
2-11 months4.00-13.50
1-4 years2.00-10.50
5-12 years1.50-7.00
13-18 years1.20-5.20
19+ years1.00-3.90
CD19%
0-2 years11.0-45.0
3 years9.0-29.0
4+ years3.0-21.0
CD19 Abs/uL
0-2 years430-3300
3 years200-1300
4+ years80-450
Note
Note
CD3CD3CD3Flow Cytometry
TitleDescriptorRangesUnits
Source
WBCK/uL
0 days9.0-30.0
1-7 days5.0-21.0
7-30 days5.0-19.5
1-12 months6.0-17.5
1-2 years5.0-15.5
2-4 years6.0-15.5
4-6 years5.0-13.5
6-10 years4.5-13.5
10-14 years5.0-11.0
14-18 years4.5-11.0
18+ years3.8-11.0
Lymphocytes%
Newborn9.0-46.0
1-3 days16.0-46.0
4-7 days26.0-56.0
8-14 days33.0-63.0
15-60 days41.0-71.0
2-11 months46.0-76.0
1-4 years35.0-76.0
5-12 years23.0-57.0
13-18 years20.0-50.0
19+ years15.0-48.0
Lymphs, AbsK/uL
Newborn2.00-11.00
1-3 days2.00-11.50
4-7 days2.00-17.00
8-14 days2.00-17.00
15-60 days2.50-16.50
2-11 months4.00-13.50
1-4 years2.00-10.50
5-12 years1.50-7.00
13-18 years1.20-5.20
19+ years1.00-3.90
CD3%
0-3 years55.0-82.0
4+ years53.0-91.0
CD3 Abs/uL
0-5 months3500-5000
6-11 months3400-4600
12-17 months3200-3900
18-29 months2800-3500
30-35 months1900-3100
3 years1000-3900
4+ years560-3000
Note
Note
CD4 CD4CD4Flow Cytometry
TitleDescriptorRangesUnits
Source
WBCK/uL
0 days9.0-30.0
1-7 days5.0-21.0
7-30 days5.0-19.5
1-12 months6.0-17.5
1-2 years5.0-15.5
2-4 years6.0-15.5
4-6 years5.0-13.5
6-10 years4.5-13.5
10-14 years5.0-11.0
14-18 years4.5-11.0
18+ years3.8-11.0
Lymphocytes%
Newborn9.0-46.0
1-3 days16.0-46.0
4-7 days26.0-56.0
8-14 days33.0-63.0
15-60 days41.0-71.0
2-11 months46.0-76.0
1-4 years35.0-76.0
5-12 years23.0-57.0
13-18 years20.0-50.0
19+ years15.0-48.0
Lymphs, AbsK/uL
Newborn2.00-11.00
1-3 days2.00-11.50
4-7 days2.00-17.00
8-14 days2.00-17.00
15-60 days2.50-16.50
2-11 months4.00-13.50
1-4 years2.00-10.50
5-12 years1.50-7.00
13-18 years1.20-5.20
19+ years1.00-3.90
CD4%
0-5 months50.0-57.0
6-11 months49.0-55.0
12-17 months46.0-51.0
24-29 months38.0-46.0
30-35 months33.0-44.0
3 years27.0-57.0
CD4 Abs/uL
0-5 months2800-3900
6-11 months2600-3500
12-17 months2300-2900
18-23 months1900-2500
24-29 months1500-2200
30-35 months1200-2000
3 years560-2700
4+ years490-1400
Note
Note
CT/CG, RNA, DONOR (TMA)DCTNGDCTNGTranscription-Mediated Amplification (TMA)
TitleDescriptorRangesUnits
Source
Donor C. trachomatis, TMANot detected
Donor N. gonorrhoeae, TMANot detected
This test is for eligibility determination of donors of blood components and human cells, tissues, and cellular and tissue based products (HCT/Ps). This test is not intended to be used for routine clinical or routine diagnostic evaluation.
ALPHA GLOBIN GENE ANALYSISALGGAALGGAPCR. MLPA and Luminex
Specimen
Specimen ID
Source
Order date
Method
Result
Interpretation
Amendment
Reviewed by
Release date
PANCREATITIS IP SEQUENCINGPANCISPANCISPolymerase Chain Reaction/Sequencing
Specimen   
CFTR Sequencing   
PRSS1 Sequencing   
SPINK1 Sequencing   
Pancreatitis, Idiopathic Interpretation
SJOGRENS ABSSJOMPSJOMPMultiplex luminex
TitleDescriptorRangesUnits
SSA (RO) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
SSB (LA) AutoantibodyNegativeLT 1.0AI
Positive1.0 or more
VORICONAZOLE LEVEL (HPLC)VORIFVORIFHigh Performance Liquid Chromatography
TitleDescriptorRangesUnits
Steady state trough levels are achieved within 1 day when an IV loading dose is used and after approximately 5 days of oral or IV therapy without a loading dose.


Targeted blood levelsProphylaxistrough > 0.5mcg/mL
Therapytrough > 1.0 to 2.0mcg/mL
Safetytrough < 5.5mcg/mL


Serum trough levels less than or equal to 1 mcg/mL are reported to be associated with lack of therapeutic response and serum trough levels > 5.5 mcg/mL have been reported to be associated with reversible neurological adverse events and hepatotoxicity.


Co-administration of drugs that metabolically induce or inhibit CYP2C19, or other conditions that affect CYP2C19 may alter voriconazole metabolism.
STREPTOCOCCAL DNASE B ABSTREPTODNASEBQuantitative Nephelometry
TitleDescriptorRangesUnits
Streptococcal Ab-Dnase BU/mL
0-6 yearsLT 250
7-17 yearsLT 310
18+ yearsLT 260
STREP PNEUMONIAE AG, URINE SPNUAGSPNUAGICT Assay
TitleDescriptorRangesUnits
Streptococcus pneumoniae Antigen, UrineNegative
A negative S. pneumoniae urinary antigen test result does not exclude infection with S. pneumoniae. Clinical correlation is recommended.
False-positives may occur because of cross-reactivity with other members
of the S. mitis group. Clinical correlation is recommended.
STRIATED MUSCLE AB, IGG RFLXSTRABSTRABSemi-Quantitative Indirect Fluorescent Antibody
TitleDescriptorRangesUnits
Striated Muscle Ab, IgG ScreenNo antibody detectedLT 1:40
Striated Muscle Ab, IgG Titer
SULFONAMIDES (SULFAS)SULFASULFAQuantitative Colorimetric
TitleDescriptorRangesUnits
Sulfonamidesmg/dL
Therapeutic5.0-15.0
ToxicGT 20.0
This test is designed to measure sulfamethoxazole and sulfisoxazole.
Peak sulfonamide (total) blood levels of 5-15 mg/dL may be considered effective for most infections, concentrations of 12-15 mg/dL being optimal for serious infections. Sulfonamide levels should not exceed 20 mg/dL.
SYNTHETIC CANNABINOIDS SCREEN RFLXSYNCANSYNCANEIA
TitleDescriptorRangesUnits
Synthetic Cannabinoids20ng/mL
AM-2201 (Parent)Positive Cutoffng/mL
AM-2201 MetabolitesPositive Cutoffng/mL
JWH-018 (Parent)Positive Cutoffng/mL
JWH-018 and/or JWH-073 MetPositive Cutoffng/mL
JWH-073 (Parent)Positive Cutoffng/mL
JWH-081 (Parent)Positive Cutoffng/mL
JWH-081 MetabolitesPositive Cutoffng/mL
JWH-250 (Parent)Positive Cutoffng/mL
JWH-250 MetabolitesPositive Cutoffng/mL
RCS-4 (Parent)Positive Cutoffng/mL
RCS-4 MetabolitesPositive Cutoffng/mL
AMINO ACIDS QNT, PLASMAAA.QUANTAAQHPLC
TitleDescriptorRangesUnits
Taurineumol/L
LT 1 month30-180
1 month-6 years30-133
6+ years30-110
Aspartic Acidumol/L
LT 1 month0-25
1 month-6 years0-20
6+ years0-20
OH-Prolineumol/L
LT 1 month0-80
1 month-6 years0-50
6+ years0-30
Threonineumol/L
LT 1 month55-320
1 month-6 years45-205
6+ years60-200
Serineumol/L
LT 1 month60-240
1 month-6 years60-200
6+ years60-170
Asparagineumol/L
LT 1 month15-90
1 month-6 years25-90
6+ years20-80
Glutamic Acidumol/L
LT 1 month20-135
1 month-6 years15-100
6+ years10-80
Glutamineumol/L
LT 1 month300-900
1 month-6 years325-825
6+ years375-825
Prolineumol/L
LT 1 month75-400
1 month-6 years60-360
6+ years80-360
Glycineumol/L
LT 1 month150-375
1 month-6 years105-385
6+ years130-400
Alanineumol/L
LT 1 month145-480
1 month-6 years145-495
6+ years150-560
Citrullineumol/L
LT 1 month6-33
1 month-6 years6-40
6+ years10-52
Valineumol/L
LT 1 month70-300
1 month-6 years75-350
6+ years120-300
Cystineumol/L
LT 1 month15-55
1 month-6 years15-50
6+ years 15-55
Methionineumol/L
LT 1 month15-50
1 month-6 years10-45
6+ years10-40
Isoleucineumol/L
LT 1 month20-90
1 month-6 years27-120
6+ years30-110
Leucineumol/L
LT 1 month50-193
1 month-6 years45-160
6+ years60-200
Tyrosineumol/L
LT 1 month35-135
1 month-6 years30-127
6+ years15-115
Phenylalanineumol/L
LT 1 month30-90
1 month-6 years30-91
6+ years36-87
Ornithineumol/L
LT 1 month25-185
1 month-6 years22-115
6+ years25-105
Lysineumol/L
LT 1 month65-275
1 month-6 years60-240
6+ years108-233
Histidineumol/L
LT 1 month45-135
1 month-6 years45-118
6+ years55-110
Arginineumol/L
LT 1 month20-125
1 month-8 years30-130
6+ years30-130
Amino Acids Interpretation
TESTOS, FREE (FEMALE/CHILD)TESFRTESFRLiquid Chromatography-Tandem Mass Spectrometry LCMSMS
TitleDescriptorRangesUnits
Testosterone, Free (Calculated)pg/mL
Female1-6 yearsLT 0.6
7-9 years0.6-1.8
10-11 years0.1-3.5
12-13 years0.9-6.8
14-15 years1.2-7.5
16-17 years1.2-9.9
18-30 years0.8-7.4
31-40 years1.3-9.2
41-51 years1.1-5.8
Postmenopausal0.6-3.8
Tanner Stage ILT 2.2
Tanner Stage II0.4-4.5
Tanner Stage III1.3-7.5
Tanner Stage IV1.1-15.5
Tanner Stage V0.8-9.2
Testosterone, Free (Calculated)pg/mL
Male1-6 yearsLT 0.6
7-9 years0.1-0.9
10-11 years0.1-6.3
12-13 years0.5-98.0
14-15 years3-138.0
16-17 years38.0-173.0
18+ years47-244
Tanner Stage I3.7 or less
Tanner Stage II0.3-21
Tanner Stage III1.0-98.0
Tanner Stage IV35.0-169.0
Tanner Stage V41.0-239.0
TESTOS, TOT (LCMSMS), FREE, SHBGTESTEDTESTEDEquilibrium Dialysis/Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Testosterone, Free, Serumng/mL
Male16+ years9-30
Female16+ years0.3-1.9
Testosterone, Total, Serumng/mL
Male0-5 months75-400
6 months-9 yearsLT 7-20
10-11 yearsLT 7-130
12-13 yearsLT 7-800
14 yearsLT 7-1200
15-16 years100-1200
17-18 years300-1200
19+ years240-950
Tanner Stage ILT 7-20
Tanner Stage II8-66
Tanner Stage III26-800
Tanner Stage IV85-1200
Tanner Stage V300-950
Female0-5 months20-80
6 months-9 yearsLT 7-20
10-11 yearsLT 7-44
12-16 yearsLT 7-75
17-18 years20-75
19+ years8-60
Tanner Stage ILT 7-20
Tanner Stage IILT 7-47
Tanner Stage III17-75
Tanner Stage IV20-75
Tanner Stage V12-60
TESTOS, TOT (FEMALE/CHILD)TESFCTESFCLiquid Chromatography-Tandem Mass Spectrometry LCMSMS
TitleDescriptorRangesUnits
Testosterone, Total (Female/Child)ng/dL
MalePremature 26-28 weeks49-104
Premature 31-59 weeks31-164
Newborn62-332
1-5 months14-363 (See Interpretive Comment)
6-24 months 0-37
2-3 years2-15
4-5 years2-19
6-7 years2-13
8-9 years2-8
10-11 years2-47
12-13 years6-620
14-15 years27-486
16-17 years154-735
18-39 years332-896
40-59 years291-739
60+ years291-598
Tanner Stage I0-16
Tanner Stage II2-124
Tanner Stage III6-632
Tanner Stage IV136-709
Tanner Stage V161-650
*Interpretive CommentLevels decrease rapidly the first week to 17-50 ng/dL and then increase to 50-332 ng/dL between 20-60 days. Levels then decline to prepubertal range levels of 2-8 ng/dL by seven months.
FemalePremature 26-28 weeks4-13
Premature 31-59 weeks4-18
Newborn17-53
1-5 months0-20 (See Interpretive Comment)
6-24 months0-9
2-3 years2-20
4-5 years2-30
6-7 years2-7
8-9 years2-11
10-11 years2-35
12-13 years5-53
14-15 years7-41
16-17 years7-52
18-30 years9-49
31-40 years9-46
41-51 years7-46
Postmenopausal5-21
Tanner Stage I1-13
Tanner Stage II3-32
Tanner Stage III8-50
Tanner Stage IV7-52
Tanner Stage V8-50
*Interpretive CommentLevels decrease during the first month to less than 8 ng/dL and remain at this level until puberty.
TESTOSTERONE, TOTAL (LCMSMS)TESTAMTESTAMLiquid Chromatography-Tandem Mass Spectrometry LCMSMS
TitleDescriptorRangesUnits
Testosterone, Totalng/dL
MalePremature 26-28 weeks49-104
Premature 31-59 weeks31-164
Newborn62-332
1-5 month14-363 (See Interpretive Comment)
6-24 month0-37
2-3 years2-15
4-5 years2-19
6-7 years2-13
8-9 years2-8
10-11 years2-47
12-13 years6-620
14-15 years27-486
16-17 years154-735
18-39 years332-896
40-59 years291-739
60+ years291-598
Tanner Stage I0-16
Tanner Stage II2-124
Tanner Stage III6-632
Tanner Stage IV136-709
Tanner Stage V161-650
*Interpretive CommentLevels decrease rapidly the first week to 17-50 ng/dL and then increase to 50-332 ng/dL between 20-60 days. Levels then decline to prepubertal range levels of 2-8 ng/dL by seven months.
FemalePremature 26-28 weeks4-13
Premature 31-59 weeks4-18
Newborn17-53
1-5 months0-20 (See Interpretive Comment)
6-24 months0-9
2-3 years2-20
4-5 years2-30
6-7 years2-7
8-9 years2-11
10-11 years2-35
12-13 years5-53
14-15 years7-41
16-17 years7-52
18-30 years9-49
31-40 years9-46
41-51 years7-46
Postmenopausal5-21
Tanner Stage I1-13
Tanner Stage II3-32
Tanner Stage III8-50
Tanner Stage IV7-52
Tanner Stage V8-50
*Interpretive CommentLevels decrease during the first month to less than 8 ng/dL and remain at this level until puberty.
THEOPHYLLINETHEOTHEOEnzyme Immunoassay
TitleDescriptorRangesUnits
TheophyllineTherapeutic10.0-20.0ug/mL
ToxicGT 20.0
THIOCYANATE, SERUMTHIOSTHIOSQuantitative Colorimetry
TitleDescriptorRangesUnits
Thiocyanateug/mL
Nonsmoker1-4
Smoker3-12
Toxic> 50
Values seen with Nitroprusside therapy6-29
THIOTHIXENENAVANETHIOTHQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleDescriptorRangesUnits
Thiothixeneng/mL
Therapeutic Range1.0-15.0
ToxicNot well established
THROMBIN TIME/FIBRINOGEN RFLXTTFIBTTFIBElectromechanical
TitleDescriptorRangesUnits
Thrombin Time Patient15.6-20.0sec
Thrombin Time Control15.6-20.0sec
Thrombin Time PT/CT Mixsec
Thrombin Time PT/PSO4 Mixsec
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
THROMBIN TIME RFLXTTIMETTIMEElectromechanical
TitleDescriptorRangesUnits
Thrombin Time Patient15.6-20.0sec
Thrombin Time Control15.6-20.0sec
Thrombin Time PT/CT Mixsec
Thrombin Time PT/PSO4 Mixsec
Fibrinogen1 day213-364mg/dL
3 days314-391
1 month-1 year91-373
1-5 years180-391
6-10 years221-399
11-16 years235-422
16+ years211-419
CYTOGENETICS, TISSUE CULTURE, AMNIOTIC FLUIDAFTCCytogenetics
Tissue Culture, Amniotic Fluid
 Separate Report to Follow
CYTOGENETICS, TISSUE CULTURE, SOLID TISSUESTITCCytogenetics
Tissue Culture, Solid Tissue
 Separate Report to Follow
CELIAC PANEL EXTENDEDCELPEXCELPEXEIA/Nephelometry
TitleDescriptorRangesUnits
Tissue Transglutaminase Ab, IgANegativeLT 4.0U/mL
Weak Positive4.0-10.0
PositiveGT 10.0
Tissue Transglutaminase Ab, IgGNegativeLT 6.0U/mL
Weak Positive6.0-9.0
PositiveGT 9.0
TTG antibody, especially IgA, is sensitive and specific for untreated celiac disease. Levels can decrease significantly in response to a gluten-free diet. The IgG assay is used mainly to detect celiac patients who are IgA-deficient.
Gliadin Ab, IgANegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
This test is performed using a deamidated gliadin peptide (DGP) assay.
Gliadin Ab, IgGNegativeLT 20Units
Weak to Mod Pos20-30
PositiveGT 30
This test is performed using a deamidated gliadin peptide (DGP) assay.
IgA0-30 days1-7mg/dL
1 mo1-56
2 mo3-49
3 mo5-48
4 mo4-76
5 mo8-87
6 mo8-70
7-8 mo12-93
9-11 mo17-87
1 yr15-110
2 yrs15-128
3 yrs23-164
4 yrs26-474
5-7 yrs35-210
8-9 yrs47-245
10+ yrs71-397
CELIAC PANEL BASICCELPANCELPANEIA
TitleDescriptorRangesUnits
Tissue Transglutaminase Ab, IgANegativeLT 4.0U/mL
Weak Positive4.0-10.0
PositiveGT 10.0
Tissue Transglutaminase Ab, IgGNegativeLT 6.0U/mL
Weak Positive6.0-9.0
PositiveGT 9.0
TTG antibody, especially IgA, is sensitive and specific for untreated celiac disease. Levels can decrease significantly in response to a gluten-free diet. The IgG assay is used mainly to detect celiac patients who are IgA-deficient.
AMINO ACIDS, URINEAAU.QUANTAAURQHigh Performance Liquid Chromatography
Title
Amino Acids, Urine (Quantitative)
Separate Report to Follow
HLA DQB GENOTYPINGHLADQBHLADQBPCR/Sequence specific Oligo probe
Title
Class II locus DQB, Allele 1
Class II locus DQB, Allele 2
HLA-DQ Oligotyping Interp
The presence of a disease associated HLA combination does not establish a diagnosis. If less than 2 alleles are reported for a locus, the patient is likely homozygous. Rare diagnostic errors can occur due to primer or probe site mutations. This test is not sufficient for comprehensive HLA evaluation for clinical hematopoietic stem cell transplantation. Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
FACTOR V LEIDEN MUTATIONFVMUTFVLMUTPCR
Title
Factor V Leiden, Method
Factor V Leiden, Result
Factor V Leiden, Interpretation
Factor V Leiden, Comment
Factor V Leiden, Comment
This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
This test is performed by real-time PCR using the Roche LightCycler instrument. The product of PCR is detected by fluorescence produced when a specific pair of probes, each labeled with a fluorophore, binds to the PCR product in close proximity.
PROTHROMBIN 20210 MUTATIONPRMUTPROMUTPCR
Title
Prothrombin 20210, Method
Prothrombin 20210, Result
Prothrombin 20210, Interpretation
Prothrombin 20210, Comment
Prothrombin 20210, Comment
This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
This test is performed by real-time PCR using the Roche LightCycler instrument. The product of PCR is detected by fluorescence produced when a specific pair of probes, each labeled with a fluorophore, binds to the PCR product in close proximity.
STOOL PHSTL.PHSTPHpH Indicator
Title
Source
Stool pH
Stool pH, Status
STONE ANALYSIS WITH IMAGESTONASTONAIR (FTIR), Gravimetric
Title
Specimen Source
Nidus
Component 1
Component 2
Stone Weight
N-TELOPEPTIDES, CROSS-LINKED, URINENTXNTXEIA
TitleGenderRangesUnits
NTXnmol BCE/mmolCr
Male3-63
Female5-65
This range represents normal bone metabolism in a population of healthy pre-menopausal women. For postmenopausal women, the following risk factors apply for a decrease in bone mineral density if not treated with hormone replacement therapy.
NTX ValueRelative Risk
18-381.4
39-512.5
52-673.8
68-18817.3
Post-menopausal women with baseline NTX values greater than 38 have been shown to experience the greatest improvement in spinal bone mass after one year on hormone replacement therapy.
TRYPSIN-LIKE IMMUNOREACTIVITYTRYPSNTRYPRIA
TitleRangesUnits
Trypsin-like Immunoreactivity10-57ng/mL
Trypsinogen expected values for:
Chronic pancreatitisLT 47.0
Acute pancreatitis92.0-850.0
Total Pancreatectomy1.4 or less
CHLORPROMAZINETHORCHLORPQuantitative Liquid Chromatography-Tandem Mass Spectrometry
TitleAge RangeDescriptorRangesUnits
Chlorpromazine (Thorazine)0-11 yrsTherapeutic30-80ng/mL
ToxicGT 200
12+ yrsTherapeutic50-300
ToxicGT 500
INFLUENZA A SUBTYPING RT-PCR FLATYPFLATYPReal-Time PCR
TitleDescription
2009 H1N1Not Detected
Seasonal H1Not Detected
Seasonal H3Not Detected
A result of Not Detected does not rule out the possibility of influenza infection and should not be used as the sole basis for treatment or management decisions.
B. BURGDORFERI (LYME) (WB)LYMCONLYMEWBWestern Blot
TitleDescription
B. burgdorferi AB by WB, IgG Negative
B. burgdorferi AB by WB, IgM Negative
Interp for Lyme IgG by WBPositive: Presence of any of 5 bands of 18, 23, 28, 30, 39, 41, 45, 58, 66 or 93 kDa.
Negative-Any pattern that fails to meet the positive criteria.
Interp for Lyme IgM by WBPositive: Presence of any 2 bands of 23, 39 or 41 kDa. If antibodies to the 37 kDa antigen are present it is considered to be an additional criteria band.
Negative-Any pattern which fails to meet the positive criteria.
LEGIONELLA PNEUMOPHILA ANTIGEN, URINELEGUAGLEGUAGELISA
TitleDescription
Legionella Antigen, UrineNegative
This assay detects Legionella pneumophila serogroup one (1) antigen. A negative test result does not rule out the possibility of Legionella infection due to other subgroups or species of Legionella. Positive-presumptive positive for Legionella pneumophila serogroup 1 antigen in urine, suggesting current or past infection. Culture is recommended to confirm infection.
CMV, QUANT (RT-PCR)CMVQRTCMVQRTReal-time PCR
TitleDescriptionRange
CMV Source
CMV DNA Quant PCR, IU/mLNot Detected137 to 9,100,000/IU/mL
CMV DNA Quant PCR, Copies/mLNot Detected151 to 10,010,000 Copies/mL
CMV DNA Quant PCR, Log Copies/mLNot Detected2.2 to 7.0 Log Copies/mL
B. BURGDORFERI SCREEN RFLXLYMERLYMEREIA/WB
TitleDescriptionRange
Lyme (B. burgdorferi) Antibody, IgG/IgMNegative: No antibodies to B.burgdorferi detected.LT 0.91
Per CDC guidelines, if EIA test is negative, Western Blot should not be performed.
Equivocal0.91-1.09
Positive: Antibodies to B.burgdorferi detected.GT 1.09
B. burgdorferi AB by WB, IgGNegative
B. burgdorferi AB by WB, IgMNegative
Interp for Lyme IgG by WBPositive: Presence of any of 5 bands of 18, 23, 28, 30, 39, 41, 45, 58, 66 or 93 kDa.
Negative: Any pattern that fails to meet the positive criteria.
Interp for Lyme IgM by WBPositive: Presence of any 2 bands of 23, 39 or 41 kDa. If antibodies to the 37 kDa antigen are present, it is considered to be an additional criteria band.
Negative: Any pattern which fails to meet the positive criteria.
COLORADO TICK FEVER ABCOL.TICKCOTICKIFA
TitleDescriptionRanges
Colorado Tick Fever IgG AntibodyLT 1:16
Interpretive criteriaAntibody not detectedLT 1:16
Antibody detected1:16 or greater
A four-fold or greater change in IgG titer between acute and convalescent sera is indicative of recent or current infection.
PARVOVIRUS B19 ANTIBODY PANEL, ELISA/PCRB19ABPB19ABPELISA and RT-PCR
TitleDescriptionRanges
Parvovirus, IgGAntibody not detectedLT 0.90
Parvovirus, IgMAntibody not detectedLT 0.90
Interpretation
Parvovirus B19 DNA, Qualitative PCRNot detected
PCA3 PROSTATE CANCER BIOMARKERPCATMAPCATMATranscription-mediated Amplification
TitleDescriptionRanges
PCA3 by TMAResult
Score0-24
RENIN, SAMPLE 1REN.S1RN1RIA
TitleDescriptionRangesUnits
Renin, #1
Renin with normal sodium intakeng/mL/h
Adult
Random ambulatory0.8-2.5
Random non-ambulatory1.5-5.2
Child, supine with normal sodium intake
1-7 days15-114
7 days-12 months18-120
12 months-3 years13-36
3-5 years7.5-21.1
5-10 years3.8-19.2
10-15 years3.8-10.7
Renin, Site 1
ANTIBODY SCRN, NON-CMATCH RFLXABSMABSHemagglutination
TitleDescriptor
Antibody ScreenNegative
CULTURE B. PERTUSSIS RFLXCBPERTCBPERTCulture
TitleDescriptor
B. pertussis ResultNegative
B. pertussis Status
RH-COMPLETE CDECOMPRHCOMPRHSlide/Tube Agglutination
TitleDescriptor
Complete RHSeparate Report to Follow
CRYOFIBRINOGENCRFBCRFBPrecipitation
TitleDescriptor
Cryofibrinogen, 24 hoursNegative
Cryofibrinogen, 48 hoursNegative
Cryofibrinogen, 72 hoursNegative
Cryofibrinogen, 7 daysNegative
CRYOGLOBULIN/CRYOFIBRINOGENCRGCRFCRGCRFPrecipitation
TitleDescriptor
Cryoglobulin, 24 hoursNegative
Cryoglobulin, 48 hoursNegative
Cryoglobulin, 72 hoursNegative
Cryoglobulin, 7 daysNegative
Cryofibrinogen, 24 hoursNegative
Cryofibrinogen, 48 hoursNegative
Cryofibrinogen, 72 hoursNegative
Cryofibrinogen, 7 daysNegative
CRYOGLOBULINCRYOCRYOPrecipitation
TitleDescriptor
Cryoglobulin, 24 hoursNegative
Cryoglobulin, 48 hoursNegative
Cryoglobulin, 72 hoursNegative
Cryoglobulin, 7 daysNegative
CULTURE B STREP (A) SCR RFLXCBSASCBSASCulture
TitleDescriptor
Culture, Beta Strep A ScreenNegative
Beta Strep A Screen, Status
CULTURE B STREP (B) SCR RFLXCBSBSCBSBSCulture
TitleDescriptor
Culture, Beta Strep B ScreenNegative
Beta Strep B Screen, Status
CULTURE STOOL (NO SMR) RFLXCSTLSTCSTLSTCulture and Enzyme Immunoassay
TitleDescriptor
Culture, Stool, ReportNegative
Culture, Stool, Status
HLA B27 RFLXHLA B27HLAB27Flow Cytometry
TitleDescriptor
HLA-B27Negative
PLATELET P2Y12 FUNCTIONP2Y12P2Y12VerifyNow Platelet Aggregation for P2Y12
TitleDescriptor
Platelet Function P2Y12PRU
PRU baseline reference range is 194-418. Post Drug Results: Lower PRU levels are associated with expected antiplatelet effect. Values may be below the stated reference range above. The post-drug values reported in the VerifyNow P2Y12 Test package insert are 18-435 PRU. Surgical bleeding has been associated with PRU < 178. Thrombotic events have been associated with PRU > 230.
CULTURE AFB (NO SMEAR) RFLXCAFBNSCAFBNSCulture
TitleDescriptor
Source
Culture, AFBNegative
Culture, Status
CULTURE AFB RFLXAFBCAFBCulture
TitleDescriptor
Source
Culture, AFBNegative
Culture, Status
CULTURE FUNGUS BLOOD RFLXCBFCBFCulture
TitleDescriptor
Source
Culture, Blood FungusNegative
Culture, Blood Fungus, Status
CULTURE BLOOD RFLXBLOODCBLDBacT/ALERT 3D continuous monitoring automated system
TitleDescriptor
Source
Culture, BloodNegative
Culture, Blood, Status
CULTURE LEGIONELLA RFLXLEGIONCLEGCulture
TitleDescriptor
Source
Culture, LegionellaNegative
Culture, Legionella, Status
CULTURE, MRSA SCREEN RFLXCMRSACMRSACulture
TitleDescriptor
Source
Culture, Methicillin Resistant Staph aureusNegative
Culture, Methicillin Resistant Staph aureus, Status
CULTURE RESPIRATORY CF RFLXCRCFCRCFCulture
TitleDescriptor
Source
Culture, Respiratory, Cystic FibrosisNegative
Culture, Respiratory, Cystic Fibrosis Status
CULTURE URINE (NO SMEAR) RFLXCURNNSCURNNSCulture
TitleDescriptor
Source
Culture, UrineNegative
Culture, Urine, Status
CULTURE VRE SCREEN RFLXCVRECVRECulture
TitleDescriptor
Source
Culture, Vancomycin Resistant Enterococcus, ResultNegative
Culture, Vancomycin Resistant Enterococcus, Status
CULTURE FUNGUS RFLXFUNGCFCCulture
TitleDescriptor
Source
Fungus Stain
Culture, FungusNegative
Culture, Fungus, Status
CULTURE EAR RFLXCULT.EARCEARCulture
TitleDescriptor
Source
Gram Stain
Culture, EarNegative
Culture, Ear, Status
CULTURE EYE RFLXCULT.EYECEYECulture
TitleDescriptor
Source
Gram Stain
Culture, EyeNegative
Culture, Eye, Status
CULTURE BODY FLUID RFLXCULT.FLDCFLOrganism Isolation
TitleDescriptor
Source
Gram Stain
Culture, FluidNegative
Culture, Fluid, Status
CULTURE GENITAL RFLXGENCGENCulture
TitleDescriptor
Source
Gram Stain
Culture, GenitalNegative
Culture, Genital, Status
CULTURE GC SCRN RFLXCGCCGCCulture
TitleDescriptor
Source
Gram Stain
Culture, Neisseria gonorrhoeaeNegative
Culture, Neisseria gonorrhoeae, Status
CULTURE TISSUE RFLXCULT.TISSUECTISCulture
TitleDescriptor
Source
Gram Stain
Culture, TissueNegative
Culture, Tissue, Status
JC VIRUSJCVRPCJCVRPCReal-Time PCR
TitleDescriptor
Source
JC Virus by PCRNot detected
CULTURE YERSINIA SCRN RFLXYERS.SCRCYERCulture
TitleDescriptor
Source
Yersinia ScreenNegative
Yersinia Screen, Status
ADRENAL AB SCREEN RFLXADNLABADNLABImmunofluorescence Assay (IFA)
TitleDescriptor
Adrenal AbNegative in normal individuals
Adrenal Ab Titer
CYTOGENETICS, CHROMOSOME ANALYSIS, BONE MARROW, ASPIRATE/BONE COREBMCYTOBMCYTOCytogenetics
TitleDescriptor
Chromosome Analysis, Bone Marrow
Separate Report to Follow
BETA HCG, QUANTHCG-QUANTBHCGQICMA
TitleDescriptorRangesUnits
HCG-Quant Beta Subunit
Non-pregnant femalesLT 5mIU/mL
Minimum detectable concentration of HCG is 2.0 mIU/mL.
**Representative Reference Intervals**
After FertilizationAfter LMPmIU/mL
2 Weeks4 Weeks5-450
3 Weeks5 Weeks50-7000
4 Weeks6 Weeks1000-50000
5-12 Weeks7-14 Weeks5000-290000
13-24 Weeks15-26 Weeks4000-250000
25-38 Weeks27-41 Weeks3000-100000
HCG values in early normal pregnancy double every 48 hours.
PEMPHIGOID PANELPAPEBPAPEBEnzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody
TitleDescriptorRange
Basement Membrane Zone AntibodiesPositiveTiter > 1:10
BorderlineTiter 1:10
NegativeTiter < 1:10
IgG BP 180 AntibodiesPositive(H)Greater than or equal to 9 units
NegativeLess than 9 units
IgG BP 230 AntibodiesPositive(H)Greater than or equal to 9 units
NegativeLess than 9 units
IGF BINDING PROTEIN-3IGFB3IGFB3RIA in dilute serum
TitleDescriptorRangeMeanUnits
IGF Binding Protein-3mg/L
Premature0-1 month0.3-1.40.9
2-3 months0.9-2.31.6
4-5 months0.4-2.21.5
6-11 months1.0-2.31.5
Fullterm0-1 month0.4-1.70.9
2-3 months0.5-2.11.3
4-5 months0.6-2.41.4
6-11 months0.5-2.41.4
12 months-4 years0.8-3.02.1
5-6 years1.5-3.42.4
7-8 years2.1-4.23.0
9-11 years2.0-4.83.3
12-13 years2.1-6.23.8
14-15 years2.2-5.94.2
16-18 years2.5-4.83.8
19-30 years2.0-4.23.0
31-70 years1.9-3.62.7
PAROXETINE, SERUM/PLASMAPAROXETINEPAROXLC-MS/MS
TitleDescriptorRangeUnits
Paroxetine (Paxil)ng/mL
Paroxetine trough steady-state plasma levels in adult patients have great inter-individual variability.
The following steady-state trough plasma data for paroxetine is reported as mean +/- 1 SD:
20 mg/day: 49 +/- 26 ng/mL
30 mg/day: 86 +/- 61 ng/mL
40 mg/day: 129 +/- 86 ng/mL
50 mg/day: 117 +/- 90 ng/mL
ANCA SCREEN (IFA) ANCASRANCASRIFA
TitleDescriptorRanges
ANCA Titer, IFANegativeLT 1:20
ANCA Pattern
ANCA, ATYPICALANCAAANCAAIFA
TitleDescriptorRanges
ANCA, AtypicalANCA, Atypical Pattern< 1:20 Not significant
ASPERGILLUS ABS PANELASPABPASPABPCF/ID
TitleDescriptorRanges
Aspergillus Ab, CFNo antibody detectedLT 1:8
A serum titer of LT 1:8 is expected. Higher titers tend to be a stronger indication of diseaSe and its severity. Cross reactions with dimorphic fungi are uncommon, but not unusual within the genus Aspergillus. Negative test does not exclude infection, especially in immunocompromised patients. Best use of test is with paried sera taken three weeks apart to detect a rise in titer against a single antigen.
Aspergillus Ab, IDNone detected
In general immunodiffusion measures IgG and a positive result may suggest active or recent infection. The test is positive in about 90% of sera from patients with aspergilloma and 50-70% of patients with allergic bronchopulmonary aspergillosis. A negative test (none detected) does not exclude aspergillosis.
BABESIA MICROTI AB, IGG, IGMBABMICBABMICSemi-Quantitative Indirect Fluorescent Antibody
TitleDescriptorRanges
Babesia microti, IgGNegativeLT 1:16
No significant level of detectable Babesia IgG antibodies.
Equivocal1:16
Repeat testing in 10-14 days may be helpful.
PositiveGT 1:16
IgG Ab to Babesia detected, which may indicate a current or previous infection.
Babesia microti IgMNegativeLT 1:20
No significant level of detectable Babesia IgM antibodies.
Equivocal1:20
Repeat testing in 10-14 days may be helpful.
PositiveGT 1:20
IgM Ab to Babesia detected, which may indicate a current or recent infection.
Babesia Interpretation
BAL, OIL RED O STAINBAL.OROBALOROCytochemical Stain
TitleDescriptorRanges
BAL, Oil Red O
Normal0-50
Equivocal51-100
Indicates aspirationGT 100
BAL, IRON STAINBAL.IRNBALFECytochemical Stain
TitleDescriptorRanges
BAL-Iron
Low0-20
Moderate21-100
ElevatedGT 100
BAL PROFILE RFLXBALPRBALPRMicroscopic, Cytochemical Stains
TitleDescriptorRanges
BAL-Volume
BAL-Color
BAL-Clarity